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 ABSTRACT 
 
De Novo Asymmetric Syntheses of Bioactive Natural Products 
and Carbohydrate Motifs 
 
Yalan Xing 
 
De novo asymmetric syntheses of daumone I-1 and the fluorescent analog have 
been described.  This route took advantage of the Noyori asymmetric hydrogenation of 
acetyl furan and alkynyl ketone, the Pd-catalyzed glycosylation and various post-
glycosylation transformations to finish the total synthesis of Daumone I-1, which 
provided materials for mechanism of action studies.  
In an effort to mimics natures use of rare sugars in the synthesis of biologically 
important natural products (e.g., the carbohydrate portion of Daumone I-1), the 
O’Doherty group has been interested in developing new methods for practical and 
stereoselective synthesis. As part of these efforts, a concise synthesis of benzyl α-6-
deoxy-altro-pyranoside and benzyl-ascarylo-pyranoside has been developed. The 
synthesis relied upon a Pd-catalyzed glycosylation reaction, a highly diastereoselecitve 
epoxidation and ring opening. 
An enantioselective synthesis of cladospolide B, C and (ent)-cladospolide D has 
been achieved. This synthesis not only provided access to these antimicrobial natural 
products but also corrected the structural assignment of cladospolide D by means of a 
de novo synthesis and kinetic/thermodynamic alkene isomerization. The synthesis 
coupled the Noyori reduction of alkynyl ketone and the alkyl zipper reaction with the 
conversion to and asymmetric oxidation of dienoates to enable the successful synthesis 
of cladospolides B-D. 
A de novo asymmetric total synthesis of aspergilliges has been investigated. The 
challenge of our route is using a novel palladium-catalyzed addition of a vinyl group to 
install the key trans-pyran ring system. To date, an intermediate which is five steps 
away from a formal synthesis of aspergillide C has been prepared by Pd-catalyzed C-
glycosylation and Julia olefination.  Noyori reductions of furyl and propargyl ketone, 
alkyne zipper reaction and Au-catalyzed alkyne hydration have been utilized. 
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 Chapter 1 
De Novo Asymmetric Synthesis of Pheromone Daumone I-1 
 
1.1. Introduction 
       Daumone, a family of small molecule pheromones, can control multiple behaviors in 
the nematode in Caenorhabditis elegans.1 Developmental arrest at the dauer stage and 
male mating behavior are the two basic C. elegans traits which are controlled by 
daumone pheromones. Under harsh growth condition, daumone could signal C. elegans 
to enter the dauer stage, an enduring and non-ageing stage of the nematode life cycle with 
distinctive adaptive features and extended life.2  At low concentrations, a synergistic 
mixture of daumone produced by hermaphrodites causes male-specific attraction.  
 
Figure 1.  Daumone 
 
   In 2005, Jeong et al. have first isolated, characterized and completed a total synthesis 
of daumone I-2,3 recently, another two daumone pheromones (I-1 and I-3) were isolated 
and characterized by the Clardy’s group.2  Because of the fascinating biological activity, 
we desired to access synthetic samples of daumone. 
Herein, I wish to present a de novo route of preparing daumone using our recently 
developed palladium catalyzed glycosylation reaction.4,5  This de novo route starts from 
1
 the non-chiral materials and uses asymmetric catalysis such as Noyori reduction to install 
the stereochemistry of daumone.  Our strategies allowed us to not only access the natural 
products but also synthesize many daumone analogs which could be studied for the 
biological activities.  
 
1.2. Previous Approach to Daumone I-2 
In our group, former student Haibing Guo has developed a de novo asymmetric route5 
for daumone I-2 and provided the synthetic sample of I-2 for the mechanism of action 
study in the Noel labs at The Salk Institute.6 After the biological activity study, daumone 
I-2 was not as active as people thought before. Thus, based on Haibing’s synthesis, I 
finished the total synthesis of daumone I-1 as well as its fluorescent analog. The 
mechanism of action study showed that daumone I-1 is the most active daumone 
component in terms of the dauer activity.  
 
2
 Scheme 1. Retrosynthetic analysis of Daumone I-1 and I-2 
 
 As we can see from the retrosynthetic analysis (Scheme 1),   both daumone I-1 and 
daumone I-2 could be established from diol I-4, which could be stereoselectively derived 
by a palladium-catalyzed glycosylation of the pyranone I-5 and alcohol I-6 and several 
post-glycosylation transformations. The Noyori reductions of acylfuran I-7 and propargyl 
ketone I-8 respectively could install the absolute stereochemistry of both I-5 and I-6.7 For 
the synthesis of daumone I-2, the TBS protecting group of common intermediate I-4 can 
be removed by TBAF, the resulting primary alcohol I-9 was oxidized by TEMPO 
condition to provide Daumone I-2. 
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Scheme 2. Synthesis of Daumone I-2 
 
1.3. De Novo Asymmetric Synthesis of Daumone I-1 
As a de novo route, we wish to introduce both of the absolute stereochemistry of furan 
alcohol I-10 and propargyl alcohol I-12 by Noyori reduction respectively (Scheme 3).8 
Furan alcohol I-10 was obtained from acylfuran I-7 using Noyori (S,S) catalyst in a very 
high enantiomeric excess (93% yield and > 96% ee). Noyori reduction of propargyl 
3
 ketone I-8 provided propargyl alcohol I-12 with high yield (81%) and enantiomeric 
purity (> 96% ee). Propargyl ketone I-8 was established from 4-pentynol I-11 by 
metalation of the TBS ether with n-BuLi and then quenching with acetaldehyde followed 
by oxidation with MnO2 (98%).  
 
Scheme 3.  Noyori reduction to install stereochemistry  
 
   With successful installation of the stereochemistry of I-10 and I-12, we next proceeded 
to couple I-5 and I-6 (Scheme 4) using palladium-catalyzed glycosylation reaction. 
Achmatowicz reaction (NBS in THF/H2O) of I-10 gave the ring-expanded pyranone 
product I-13 in good yield (91%).9 The mechanism of Achmatowicz reaction is shown in 
scheme 5. The hemiacetal of I-13 was then protected with (Boc)2O to obtain Boc-
protected pyranone I-5 in good  yield (78%) .  
4
  
 
Scheme 4.  Palladium-catalyzed glycosylation 
 
                       
Scheme 5.  Achmatowicz reaction 
 
  Propargyl alcohol I-12 was reduced (H2, 10% Pd/C) to generate the coupling partner 
alcohol I-6 (82%). The palladium-catalyzed glycosylation of pyranone I-5 and alcohol I-
6 by using 5% palladium (0) and 10% triphenylphosphine provided enone I-14 as a single 
diastereomer (94%).10 The mechanism of the glycosylation reaction is shown in scheme 6.  
First, the Pd--allyl specie was formed from the opposite face of the Boc group, and then 
5
 the alcohol nucleophile comes to attack the anomeric position from the top face to give 
the glycosylation product with the retention of stereochemistry.  
                          
Scheme 6. Palladium-catalyzed glycosylation 
 
As shown in scheme 7, enone I-14 was diastereoselectively epoxidized to give epoxy-
enone I-15 (81%) using hydrogen peroxide in the presence of a catalytic amount of base 
(10 mol % NaOH).11   Then we turned our efforts to the diastereoselectivly opening of the 
expoxide ring. We decided to use reductive hydration strategy. Epoxy-enone I-15 was 
diatereoselectviely reduced to provide the equatorial alcohol I-16 (93%) with NaBH4 (-78 
to -20 oC).  The epoxide I-16 was regioselectively and diastereoselectively opened with 
LiAlH4 to generate diol I-4 (88%) in a trans-diaxial way.12 Diol I-4 can also be achieved 
in a one-step reaction by treating I-15 with LiAlH4 at -78 oC followed by warming to 
room temperature (86%). 
6
                              
Scheme 7. Reductive hydration 
 
   With diol I-4 in hand, we next protected it with acetic anhydride to provide the acetate 
I-17 (85%), which was treated with aq. HCl to remove TBS group to give alcohol I-18 
(97%). The aldehyde I-19 was obtained from oxidation of alcohol I-18 with TEMPO in 
88% yield.  Wittig reaction of corresponding aldehyde I-19 installed ethyl ester I-20 in 
97% yield. Treatment of I-20 with LiOH in MeOH provided the acetyl deprotected 
methyl ester I-21 in 99% yield. Finally, hydrolysis of methyl ester I-21 with LiOH in 
THF/H2O generated daumone I-1 in 99% yield (Scheme 8).     
7
                 
Scheme 8.  Synthesis of Daumone I-1 
 
   As an effort to study the dauer activity of C. elegant, we also made the fluorescent 
daumone analog I-23. Simple peptide coupling linked fluorescent probe I-22 and 
daumone I-1 to provide fluorescent daumone analog I-23 which has been used for the 
mechanism of action study in The Salk Institute. 
8
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Scheme 9.  Synthesis of fluorescent Daumone. 
 
1.4. Conclusion: 
In conclusion, the de novo enantioselective total syntheses of daumone I-1 and its 
fluorescent analog have been accomplished. This approach takes advantage of our highy 
enantio- and diatereocontrolled palladium-catalyzed glycosylation reaction and Noyori 
reduction of two ketones. Daumone I-1, I-2 and the fluorescent analogs we accessed 
were utilized in the biological study of the dauer stage of C. elegans in The Salk Institute 
along with antihelmycin studies at USDA. These compounds have been used as probes to 
track the uptake and localization of dauer stage of C. elegans and the fluorescent probes 
have been shown to have activity in dauer formation.6 
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 Chapter 2 
 
De Novo Asymmetric Synthesis of -6-deoxy-altro-pyranoside 
and -3, 6-dideoxy-altro-pyranoside † 
 
2.1. Introduction 
Deoxysugars are a common structural motif in biologically active natural products.1 
The removal of the hydroxyl groups in sugars along with the use of unusual 
stereochemistry imparts resistance to most glycosidases and thus conveys improved 
metabolic stability.1 Examples of nature’s reliance of these structural motifs are seen in 
the use of -6-deoxy-altrose as the main constituent of bacterial lipopolysaccharides,2 as 
well as, the use of -2,6- and -3,6-dideoxy-altrose (i.e., -digitoxose and -ascarylose) 
in biologically active natural products, such as jadomycin B 3  and daumone, 4 
respectively.5 
                        
Scheme 1. De novo approach to carbohydrate 
                                                     
† Reproduced with permission from J. Org. Chem. 2009, 74, 5961-5966.  Copyright 2009, with 
permission from American Chemical Society 
11
 Over the last 10 years, there has been considerable effort made toward the synthesis of 
monosaccharides from achiral starting materials.6 In this regard, our group has developed 
a de novo asymmetric synthesis of carbohydrates using achiral acylfurans II-1 (Scheme 
1). 7  Our approach used a Noyori reduction, an Achmatowicz reaction and a Pd(0)-
catalyzed glycosylation (II-2 to II-3) to prepare pyranone intermediate II-3,7,8,9 which via 
post-glycosylation transformations were converted into corresponding carbohydrates (e.g., 
II-3 to II-4, II-5 and II-6).7,9 This method has allowed for the stereoselective synthesis of 
a variety of sugars, including rare sugars, aminosugars and even unnatural sugars.10 
These approaches primarily rely on the osmium catalyzed dihydroxylation reaction for 
the syn-addition of two hydroxyl groups across the C-2/C-3 pyran double bond, which 
has been used to prepare D- or L-sugars with manno-, gulo- and talo-stereochemistry.9,10 
A related dihydroxylation on the C-3/C-4 pyran double bond provided the sugars with 
galacto- and allo-stereochemistry.10, 11 By combining this approach with 
protection/inversion reactions, this route has also been used to access to the gluco-
stereoisomers.12 
 
2.2. Previous approaches to deoxysugars 
 
     In 2009, Lowary and co-workers reported the use of 2, 3-anhydrosugars as 
glycosylating agents for the preparation of 2-deoxypyranosides.5a  Glycosylation of a 
panel of alcohols with one of two 6-deoxy-2,3-anhydrosugar thioglycosides (II-7 and II-
8) afforded 2,6-dideoxy-2-thiotolyl glycoside products II-9 and II-11 in excellent yields 
with an exclusively syn relationship between the aglycon and the C-3 hydroxyl group. 
12
 Removal of the 2-thiotolyl group can be achieved via reaction with tri-n-butyltin hydride 
and AIBN to give the corresponding 2, 6-dideoxy pyranosides II-10 and II-12 (Scheme 
2). 
 
Scheme 2. Lowary’s approach to 2, 6-dideoxysugars.  
 
     The synthesis of glycosyl donors II-7 and II-8 is outline in Scheme 3. The preparation 
of II-7 started with the known benzylidene acetal protected 6-deoxy-D-mannopyranoside 
II-13. The Hanessian-Huller reaction to II-13 led to the formation of II-14 in 75% yield. 
After five steps transformations, II-14 was converted to glycosyl donor II-7.  The 
preparation of II-8 proved more challenging than II-7. They first synthesized 
thioglycoside II-15, which underwent five steps transformations to provide II-16. PMB 
protection followed by the removal of allyl group and reaction with sodium hydride led 
the formation of glycosyl donor II-8.  
 
Scheme 3. Lowary’s synthesis of glycosyl donors II-7 and II-8. 
13
 2.3.  De Novo Asymmetric Synthesis of -6-deoxy-altro-
pyranoside and -3,6-dideoxy-altro-pyranoside  
 
   As part of our efforts to expand upon this methodology, we have been investigating 
epoxidation/nucleophilic ring-opening reactions for the net anti-addition of hydroxyl 
groups across the C-2/C-3 pyran double bond. Herein I would like to introduce our 
successful application of this new post-glycosylation transformation for the de novo 
synthesis of two deoxysugar targets (i.e., benzyl pyranosides with -altro-
stereochemistry and its 3-deoxy (-ascarylose) congeners) (Figure 2). 
 
Figure 2.-6-Deoxy-altrose and -ascarylose  
 
2.3.1. Retrosynthetic Analysis  
Retrosynthetically, we envisioned both -6-deoxy-altro-pyranoside and -3, 6-
dideoxy-altro-pyranoside II-17 as being derived from the trans-diaxial opening of 
epoxide II-18 with either a formal hydroxy or hydride nucleophile, respectively (Scheme 
4). Epoxide II-18 could be prepared by epoxidation of pyran II-19, which in turn could 
be prepared by a ketone reduction of pyranone II-20.  Because our route began with the 
Noyori reduction of acylfuran, it is amenable to the synthesis of either D- or L-
enantiomers of these sugars.13 
14
  
Scheme 4. Retrosynthetic analysis 
 
 
2.3.2. De Novo Synthesis of -Boc-pyranone  
As we have previously reported,13b the Noyori reduction of acylfuran II-21, with 
formic acid/triethylamine as the hydride source, produced either enantiomer of furfuryl 
alcohol II-22 in 96% yield with high enantiomeric excess (> 96% ee).13 An Achmatowicz 
rearrangement transformed the furfuryl alcohol to pyranone in 91% yield.  The 
hemiacetal was then protected as t-butyl carbonate II-23 at low temperature in 78% yield 
with 3:1 ratio of α- and β-diastereomers (Scheme 5). 
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Scheme 5.  De Novo synthesis of -Boc-pyranone 
 
2.3.3. Synthesis of -6-deoxy-altro-pyranoside 
Our proposed synthesis of -6-deoxy-altro-pyranoside started with the attempted 
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 epoxidation of pyran II-19. Unfortunately, our efforts to epoxidize allylic alcohol II-19 
were not satisfactory.  As a result, we decided to reverse the reduction/oxidation 
sequence.  These efforts began with our Pd(0)-catalyzed glycosylation reaction to 
diastereoselectively install the anomeric benzyloxy group with complete -selectivity 
(Scheme 6). Similarly, treating pyranone II-20 with hydrogen peroxide in the presence of 
catalytic amount of base (10 mol % NaOH/H2O2) diastereoselectively installed the 
epoxide II-24 in 88% yield.4b In an equally diastereoselective fashion, the ketone II-24 
was reduced with NaBH4 (-78 to -20 °C) to form the equatorial alcohol II-18 in 85% 
yield.  
 
Scheme 6.  Synthesis of -6-deoxy-altro-pyranoside 
 
With the alcohol II-18 in hand, we turned our attention to the epoxide ring opening 
with acetic acid. After investigating the use of a variety of Lewis acids, we found 
Sc(OTf)3 gave the best results. In practice, treatment of epoxide II-18 with Sc(OTf)3 in 
HOAc afforded an inseparable mixture of acetates which presumably resulted from acid 
catalyzed ester migration of the initial epoxide ring opening product. This mixture was 
directly hydrolyzed with LiOH in aqueous THF producing -6-deoxy-altrose II-25 in 
69% yield. The stereochemistry of the ring opening was confirmed by analysis of the 
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 corresponding proton/proton coupling constants at C-2, C-3 and C-4 positions of II-25. 
2.3.4. Synthesis of α-ascarylo-pyranoside 
As we previously reported,4b epoxide II-18 was converted into the α-ascarylose sugar 
II-26 in 85% yield using LiAlH4 (Scheme 7). This same regioselective Lewis acid 
promoted ring opening reaction can also be used for 3-deoxy-sugars, which provides a 
less basic alternative to our previously reported LiAlH4 method.4b Simply switching the 
Lewis acid to MgBr2•Et2O promoted a regioselective opening to form bromide II-27. The 
axial bromide in II-27 was cleanly removed to give II-26 in 76% yield, using an AIBN 
promoted tris(trimethylsilyl)silane (TTMSS) radical reduction.  
 
Scheme 7.  Synthesis of α-ascarylo-pyranoside 
 
 
2.4. Conclusions 
In summary, a highly enantio- and diastereoselective procedure for the preparation of 
C-3 and C-6 deoxypyranosides has been developed.  Our approach to these sugars 
provides rapid and practical access to these rare and naturally occurring sugars, which 
should be of use for further natural product synthesis. Critical to the success of this 
synthesis was the use of the Pd(0)-catalyzed glycosylation and corresponding post-
glycosylation transformations. It is also worth noting that our method is structurally 
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 divergent in that it produces four different sugar congeners from the same advanced 
intermediate. We believe that this approach will be particularly useful for medicinal 
chemistry. Finally, by selecting either enantiomeric form of the Noyori catalyst (R, R) or 
(S, S), our strategy is also amenable to the synthesis of both D- or L-forms of these sugars.   
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 Chapter 3 
Structure Investigations of ent-Cladospolide D 
by De Novo Synthesis and Kinetic and 
Thermodynamic Isomerization† 
 
3.1. Introduction  
In an interesting synergistic relationship between parasite and host, the 
Cladosporium species produce secondary metabolites that can regulate the host 
plant’s growth.1  This growth regulation is believed to occur via the inhibition of 
gibberellin biosynthesis.1c Structurally these fugal products/plant pheromones are 
made up of a group of diastereoisomeric 12-membered macrolactone diols, which 
differ in stereochemistry at the C-4/C-5 diol and C-2/C-3 double bond 
stereochemistry (Figure 3).1 These stereochemical differences affect the biological 
activity. For instance, cladospolides A-C inhibit the shoot elongation in rice 
seedlings,1c whereas, cladospolides A and B have the opposite effect on the root 
growth of lettuce seedlings.1b  
 
                                                 
† Reproduced with permission from Synthesis. 2009, 17, 2847-2854. Copyright 2009, with 
permission from Thieme Stuttgart. Reproduced with permission from Org. Lett. . 2009, 11, 1107-1110. 
Copyright 2009, with permission from American Chemical Society.  
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Figure 3: The cladospolide A-D 
 
Because these three natural products, cladospolides A-C,2,3,4 are produced by the 
same and related organisms, it was initially suggested that they should share the C-11 
carbinol stereochemistry, which biosynthetically would be formed earliest in the fatty 
acid biosynthetic pathway.  The relative stereochemistry for the cladospolides A-C 
have been confirmed by several total syntheses, although it should be noted that 
questions remain around cladospolide B, where the different signs of rotation were 
found for the same absolute stereoisomer for synthetic cladospolide B by Banwell and 
us.2,3,4  
  
Figure 4 : (E/Z)-cladospolide D 
 
In contrast to the plant pheromone activity of cladospolide A-C, cladospolide D 
possesses antimicrobial activity with IC50 values of 0.1 and 29 g/mL against M. 
racemosus and P. oryzae, respectively.1d Until our work, the absolute and relative 
stereochemistry of cladospolide D had not been correctly determined.5 At issue was 
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 the stereochemical assignment of the C2/C3 double bond, which was solely based on 
a 13.5 Hz vicinal coupling constant for the purported trans-enoate carbon/carbon 
double bond.1d  
Using asymmetric synthesis of all the possible diastereomers and the comparison of 
optical rotation data, we assigned the absolute and relative stereochemistry for 
cladospolide D (Figure 4).3c This work resulted in a correction of the initially assigned 
C-2/C-3 double bond stereochemistry, which the first synthesis of cladospolide D, by 
Hou, initially confirmed the structure as E-isomer III-6.5 Unfortunately, this synthetic 
study missed a facile E/Z-double bond isomerization and thus they actually prepared 
the enantiomer of the Z-isomer, (ent)-cladospolide D III-4. Herein, I describe the full 
account of our synthetic studies toward the successful synthesis of cladospolide B/C 
and the (ent)-cladospolide D, which includes our study of the E/Z-double bond 
isomerization of cladospolides and their diastereomers. 
 
3.2. Previous Approaches to Cladospolides  
   In Hou’s synthesis of cladospolide D, they started from chiral starting material diol 
III-7 which was converted to allylic alcohol III-8 after four steps (Scheme 1). The 
cross-metathesis between the allylic alcohol III-8 and both enantiomerically pure (R)- 
and (S)-2-(6-heptenyl) acetates (III-9a and III-9b, respectively) provided III-10a and 
III-10b. The allylic alcohol of III-10 was protected as its TBDPS ether followed by 
Michael addition to give III-11a and III-11b respectively. Acid III-12 was achieved 
by five steps transformations from III-11.    
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Scheme 1. Total synthesis of cladospolide D by Hou 
 
    With III-12 in hand, they next preceded the Yamaguchi lactonization to generate 
lactone III-13 (Scheme 2). After deprotection of MEM group and oxidation with DMP, 
III-15 was prepared in good yield. Diastereomers III-16a and III-16b were 
established after removing the tert-butyldiphenyl silyl (TBDPS) groups by 
tetrabutylammonium fluoride (TBAF) or hydrogen fluoride/pyridine. They noticed 
that the diastereomer III-16b was only generated by HF-Py (46%). 
    After comparing the spectra data with the isolation paper, Hou claimed that the 
structure III-16b was the natural product cladospolide D. However, in their last 
deprotection of TBDPS step using HF-Py, they missed a facile double bond 
isomerization. Therefore, they actually prepared the natural product cladospolide D, 
but they mis-assigned the structure as E isomer III-16b.   
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Scheme 2. Lactonization to form cladospolide D by Hou 
   
 
3.3. De Novo Approach to Natural Products Cladospolides 
Our de novo synthesis linked the use of Noyori asymmetric hydrogenation of 
propargyl ketone, alkyne zipper reaction and Sharpless dihydroxylation together to 
construct natural products cladospolides B, C and (ent)-cladospolide D as well as all 
the possible isomers of cladospolide D.  
 
3.3.1. Retrosynthetic Analysis  
At the outset of this project, we had reservations regarding the assignment of double 
bond stereochemistry for purported cladospolide D (III-5).  Thus our retrosynthetic 
analysis envisioned that Z-cladospolide D (III-4) could be prepared from cladospolide 
B (III-2) or its bis-epimer III-17.  Similarly, E-cladospolide D (III-6) could be 
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 prepared from cladospolide C (III-3) or its bis-epimer III-18. In turn, cladospolides B, 
C (III-2, III-3) and their bis-epimers III-17 and III-18 could come from the 
lactonization reactions of diols III-19 and III-20.  Diols III-19 and III-20 could come 
from the diastereoselective and regioselective dihydroxylation6 and diene conjugation 
of ynone III-21,7 which could be prepared from commercially available 1-nonyne 
III-22 employing the Noyori asymmetric reduction/alkyne zipper isomerization 
(Scheme 3). 
 
Scheme 3. Retrosynthetic analysis 
 
3.3.2. Synthesis of diols 
Lithiation of commercially available 1-nonyne III-22 and alkylation with 
acetylaldehyde gave racemic propargylic alcohol (rac)- III-23 (69%, two steps) 
(Scheme 4).  Propargylic oxidation of (rac)-III-23 with MnO2 gave the ynone III-21. 
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 Exposure of ynone III-21 to our modified Noyori conditions provided an excellent 
yield (85%) of propargyl alcohol III-23 with high enantiomeric purity (> 96% ee). 
Exposure of III-23 to the KAPA reagent readily isomerized it to the terminal 
undecynol, which was protected as a TBS-ether (TBSCl/imid. in DMF) in good 
overall yield (82%) and with no loss of enantiomeric purity (> 96% ee).8  
            
Scheme 4. Synthesis of diol 
 
The mechanism of alkyne zipper reaction is shown in Scheme 5.9 KAPA reagent 
which refers to potassium 3-aminopropylamide is a readily prepared difunctional 
superbase. KAPA is prepared by quantitative reaction of KH with excess 
3-aminopropylamine. In this KAPA catalyzed alkyne zipper reaction, the triple bond 
from the middle of the carbon chain migrates to the end of the carbon chain because 
of the formation of stable acetylide ion.  
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Scheme 5. Mechanism of alkyne zipper reaction 
 
The terminal alkyne III-24 was carboxylated (n-BuLi/ClCO2Et, 83%) to give an 
ynoate, which by means of the Rychnovsky variant of the Trost ynoate to dienoate 
isomerization (Ph3P/PhOH) was cleanly converted into E,E-dienoate III-25 in good 
yields (90%) and stereoselectivity.7 Dienoate III-25 was subjected to Sharpless 
asymmetric dihydroxylation conditions (2% OsO4 and 4% (DHQD)2PHAL) to give 
diol III-19 in approximately 80% yield and as a single diastereomer.6 Similarly, 
dienoate III-25 was dihydroxylated with the pseudo-enantiomeric reagent (2% OsO4 
and 4% (DHQ)2PHAL) to give diol III-20 in approximately 80% yield and as a single 
diastereomer. The mechanism of Rychnovsky variant of the Trost ynoate to dienoate 
isomerization is outlined in scheme 6.  
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Scheme 6. Mechanism of ynoate to dienoate isomerization  
 
3.3.3. Synthesis of cladospolide B, C and isomers 
With all the sp3 stereocenters established for the cladospolides, we turned to the 
assembly of the macrocycle (Scheme 7). To our delight this occurred with a small 
amount of double bond isomerization.  Thus exposing diol III-19 to acid catalyzed 
acetonide formation/TBS deprotection conditions gave the desired seco-acid, which 
when exposed to the Yamaguchi lactonization conditions10 gave a 6:1 mixture of 
cladospolide C (III-3)  (36%) and its double bond isomer III-17 (6%), after TFA 
promoted acetonide deprotection. Following a virtually identical macrocyclization 
protocol, diol III-20 was converted into a similar mixture of cladospolide B (III-2) 
(6%) and its double bond isomer III-18 (34%). 
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Scheme 7. Synthesis of cladospolide B, C and isomers 
 
3.3.4. Synthesis of cladospolide D and diastereomers 
With the construction of the required four stereoisomeric macrolactone diols, we 
turned our attention to the synthesis and structural proof of cladospolide D. This began 
with the investigation of the selective oxidation of the allylic alcohol in cladospolide C 
(III-3) (Scheme 8). Unfortunately, several oxidants (e.g., MnO2 and Dess-Martin 
Periodinane) led to oxidative diol cleavage giving a dialdehyde product. In our 
grahamimycin A synthesis, we had previously found that the enone functionality could 
be installed by a stochiometric TEMPO oxidation of the allylic alcohol in colletodiol, 
without the need for selective protection.6c Unfortunately, when we applied these same 
conditions to the cladospolides, only products of double oxidation were obtained. Thus, 
when we exposed cladospolide C (III-3) and its C-4,5-bis-epimer III-18 to the catalytic 
TEMPO oxidation conditions (1 mol% 2,2,6,6-tetramethylpiperidinooxy/1 equiv 
trichloroisocyanuric acid),11 only diketone III-26 was observed. When only one equiv 
30
 of co-oxidant was used (1 mol% 2,2,6,6-tetramethylpiperidinooxy/0.33 equiv 
trichloroisocyanuric acid),  only low yields of III-26 and starting material were 
observed. Similarly, cladospolide B (III-2) and its C-4,5-bis-epimer III-17 reacted 
under the TEMPO oxidation conditions to give diketone III-27. Thus, we turned to a 
selective protection/oxidation/deprotection sequence. 
 
Scheme 8. Diol per-oxidation 
Because the absolute stereochemistry of cladospolide D was not known and we had 
our doubts about the assigned olefin geometry, we decided to perform the 
protection/oxidation/deprotection sequence on both cladospolide B (III-2) and C (III-3) 
as well as their 4,5-bis-epimers III-17 and III-18. Because of the exploratory nature of 
these studies, no effort was made to maximize the regioselectivity in the protection-step. 
Rather a regio-unselective TBS-protection was chosen for simplicity’s sake (i.e., no 
bis-protection was observed and the minor regioisomer could be recycled). This in turn 
helped with the assignment of the regioisomers. 
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Scheme 9. Synthesis of cladospolide D and diastereomers 
 
Thus exposure of cladospolide C (III-3) to the three-step TBS 
mono-protection/Dess-Martin oxidation/HF deprotection gave a 27% yield of enone 
III-28 (Scheme 9). Cladospolide B (III-2) and its 4,5-bis-epimer III-17 gave the 
corresponding enones III-31 and III-30, respectively, with similar yields for this 
three-step sequence. The low yield for these sequences was due to the poor 
regioselectivity (1:2 against) in the TBS-protection step. In contrast, when the 
4,5-bis-epimer III-18 was exposed to the same three-step sequence a higher yield of 
enone III-29 was obtained due to improved regioselectivity in the TBS-protection (2:1).  
Of the enones produced only III-31 had spectral data that matched cladospolide D,1d 
although the rotation was opposite in sign. The spectral data also matched the data 
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 reported by Hou for (ent)-cladospolide D, who reported its structure to be the E-isomer 
III-29. Therefore, we concluded that a hidden alkene isomerization reaction must have 
occurred during the Hou synthesis. 
 
3.3.5. Photo Isomerization of Double Bond 
Thus, we decided to investigate the isomerization of the olefin III-29. When enone 
III-29 was irradiated with UV-light (300 nm) with and without iodine, a 1:1 ratio of 
III-29 and (ent)-cladospolide D (III-31) was found along with a significant amount of 
photo-degradation products. While this isomerization explained the problem with 
Hou’s assignment of cladospolide D, the photochemical isomerization reaction was not 
clean enough to be consistent with his reported yield. Similarly byproducts were also 
observed, when we explored the photoisomerization of III-28 and III-30. However, 
much cleaner isomerization reactions were observed for the TBS-protected enones, 
III-32, III-33, III-34 and III-35 (Scheme 10).  
Thus when we irradiated D6-benzene solutions of pure III-32 and III-33 for 24 h 
with 300 nm light through a Pyrex filter, a photo-equilibrium (1:1.3, E/Z) was 
established with the Z-isomer III-33 being slightly favored. When we irradiated 
D6-benzene solutions of III-34 and III-35 under identical conditions a 
photo-equilibrium (1:2, E/Z) was established, which slightly favored the Z-isomer 
III-35 (Scheme 10). 
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Scheme 10. Photo equilibration 
 
Because the photo-isomerization give photo-equilibriums and not true Keq, we 
decided to isomerize the enones under iodine radical conditions. Thus we exposed pure 
D6-benzene solutions of III-32 and III-33 to a catalytic amount of I2 under thermal and 
photochemical conditions (Scheme 11). Under these conditions, both solutions rapidly 
(< 1 h) reached equilibrium (Keq = 1:4, E/Z) with the Z-isomer being more stable. When 
we turned to the E/Z-isomers of the natural cladospolide D diastereomer, we found a 
much greater difference in stability. When the same isomerization was preformed with 
pure solutions of III-34 and III-35 the equilibrium was reached much more quickly and 
the equilibrium achieved was in even greater preference for the Z-isomer III-35 (Keq > 
20, Z/E). Thus, we can conclude that the driving force and barrier to isomerization of 
the cladospolide D diastereomer III-35 is quite strong. 
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Scheme 11. Photochemical equilibrium 
 
For comparison, we decided to study the double bond isomerization between 
cladospolide C (III-3) and its 4,5-bis-epimer III-18 using the same equilibration 
condition (Scheme 12). This study showed that no strong thermodynamic preference 
for the Z-isomers could be found. For example, when cladospolide C (III-3) and its 
double bond isomer III-17 were isomerized under radical iodine conditions (24 h 
irradiation with I2), we found equal isomers of III-3 and III-17 (Keq = 1).  In contrast, 
we were not able to reach to full equilibirum for the isomerization of 
4,5-bis-epi-cladospolide C (III-18) to cladospolide B (III-2), but we could bracket the 
equilibrium constant to be between 0.3 and 6 (Scheme 12). Thus, we can conclude that 
the C-4 carbonyl in cladospolide D has a strong effect on the E/Z-stability. 
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Scheme 12. Photochemical equilibrium 
 
3.3.6. Improved approaches to cladospolide D 
With the knowledge of the structure of the desired target molecule, we next sought 
an improved synthesis (Scheme 13). These efforts lead to the discovery of the double 
bond isomerization found in the Hou’s synthesis. Thus we returned to the trans-diol 
III-18, which could be regioselectively protected to give III-36 in good yield. 
Dess-Martin oxidation of III-36 cleanly gave enone III-34. At this stage a 
photo-chemical isomerization of III-34 cleanly gave the previous prepared cis-isomer 
III-35 in near quantitative yield (> 95%). Interestingly, when III-34 was treated with 
the conditions used by Hou (HF/Py), instead of our preferred conditions (5 % 
HF/CH3CN), a clean double bond isomerization occurred to give III-35.  As before, 
TBS-deprotection with 5 % HF/CH3CN occurred to give -keto-enoate III-31. 
Synthetic III-31 material was spectroscopically (1H NMR, 13C NMR, IR and MS) 
identical with natural cladospolide D, although the optical rotation was opposite in 
sign ([]D –58 vs + 56 in MeOH). Thus structure III-31 must be the enantiomer of 
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 cladospolide D and the structure should be revised to structure III-4 as shown in 
Figure 1. 
 
Scheme 13. Improved approaches to cladospolide D 
 
3.4. Conclusions  
    In conclusion, a short and enantioselective synthesis of (ent)-cladospolide D has 
been developed, which clears up any ambiguities with its structural assignment.  
This structural proof involved the synthesis of all the possible stereoisomers of 
cladospolide D as well as to other members of this family of natural products, 
cladospolides B and C. This de novo asymmetric approach used two remote catalytic 
asymmetric reactions (Noyori reduction and Sharpless asymmetric dihydroxylation) 
to establish its asymmetry, therefore, this synthesis is also a formal synthesis of the 
natural stereoisomer of cladospolide D. This de novo route to the cladospolides 
compares favorably (i.e., less steps and greater overall efficiency) to the previous 
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 routes from chiral starting materials.  In addition, this route enabled the study of the 
C-2/3 alkene isomerization that was of central importance to the structural proof of 
cladospolide D.   
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 Chapter 4 
 De Novo Asymmetric Total Synthesis of 
Aspergillides 
 
4.1. Introduction  
   In 2007, Kusumi and coworkers had isolated three new 14-membered macrolides, 
aspergillides A (IV-1), B (IV-2), and C (IV-3) from marine-derived fungus Aspergillus 
ostianus strain 01F313 (Figure 5).1 The aspergillides contain interesting tri-substituted 
tetrahydro and dihydropyran rings. These compounds were found to exhibit significant 
cytotoxicity against mouse lymphocytic leukemica cells (L1210) with LD50 values of 2.1, 
71.0, and 2.0 g/Ml for aspergillide A (IV-1), B (IV-2), and C (IV-3) , respectively. The 
structures and absolute configurations of aspergillides were determined by analyses of 
NMR spectra and modified Mosher’s method.  
 
Figure 5. Aspergillides 
 
   Based on the unique molecular architectures and important biological features of 
these natural products, they have attracted interest from synthetic community. To date, 
five total syntheses of IV-1,2 seven of IV-2,3,2e and two of IV-34 have been reported. 
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 Herein I would like to describe our efforts towards total synthesis of aspergillides using 
our de novo methodology.  
 
4.2. Previous Approaches to Aspergillides  
  Most recently, Shishido and coworkers published a total synthesis of aspergillide A 
(IV-1) and B (IV-2) based on transannular oxy-Michael reaction in Angewandte Cheme.2e 
Their retrosynthetic analysis showed that the trisubstituted pyran moiety could be formed 
through a base-mediated transannular oxy-Michael reaction from the 14-membered 
macrolactone IV-4 (Scheme 1). The macrolactone IV-4 could be established by using a 
sequential cross-metathesis and intramolecular Horner–Wadsworth–Emmons reaction of 
IV-5 and IV-6. Compound IV-5 could be prepared from the chiral building block IV-7 
and compound IV-6 was known in the literature (Scheme 1).  
 
Scheme 1. Retrosynthetic analysis of Shishido’s synthesis 
 
   Chiral building block IV-7 was first converted to alcohol IV-8, which then underwent 
five transformations to give hemiacetal IV-9 (Scheme 2). Reduction of IV-9 with LiBH4 
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 provided resulting diol, the secondary alcohol was protected as a TES ether to generate 
alcohol IV-10. Cross-metathesis of IV-10 with the phosphonoacetate IV-6 in the 
presence of the second-generation Grubbs catalyst provided the coupled product as the E 
alkene IV-11 (>20:1) in 98% yield. Oxidation of IV-11 with Dess–Martin periodinane 
and a subsequent intramolecular Horner–Wadsworth–Emmons reaction gave the 
macrolactone. Selective removal of the TES ether provided intermediate IV-4. 
            
Scheme 2. Total synthesis of aspergillide A and B by Shishido 
 
   With the precursor IV-4 in hand, Shishido next investigated the transannular 
oxy-Michael reaction (Scheme 3). They found that the best result was for the treatment of 
IV-4 with DBU and LiCl in acetonitrile at room temperature for 1.5 hours which 
provided a quantitative amount of the syn-adduct IV-12 as a single product (entry 1). The 
best condition for quantitative formation of IV-13 was achieved by using KH and 
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 [18]crown-6 at 0 oC for 0.5 hours. Removal of the TBS group of IV-12 and IV-13 
generated aspergillide A (IV-1) and aspergillide B (IV-2), respectively.  
         
Scheme 3. Transannular oxy-Michael reaction 
In 2007, Kuwahara reported the first total synthesis of aspergillide C.4a They 
envisioned that aspergillide C (IV-3) could be established from a macrolactonization of 
seco acid IV-14, which can be synthesized from compound IV-15. To construct IV-15, 
they took advantage of a Ferrier-type reaction of acetal IV-16, which could be formed by 
Julia olefination of aldehyde IV-18 and sulfone IV-17. The aldehyde IV-18 could be 
prepared via epoxide opening of commercially available epoxide IV-19 and alkyne IV-20 
(Scheme 4).   
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Scheme 4. Retrosynthetic analysis of Kuwahara’s synthesis 
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E-isomer IV-16 was established within 10 steps from starting materials and then 
converted to desired trans-substituted ester IV-21 by Ferrier-type reaction using silyl 
ketene acetal (Scheme 5). Treating IV-21 with aqueous NaOH solution followed by 
KI3/NaHCO3 provided iodolactone which was exposed to DBU in THF to give IV-22. 
With lactone intermediate IV-22 in hand, they proceeded the final construction of 
aspergillide C. After a hydrolysis, protection/deprotection and macrolactonization 
sequence, asptergillide C (IV-3) was finally established.  
 
Scheme 5. Total synthesis of aspergillide C by Kuwahara 
 
4.3. Retrosynthetic Analysis of Aspergillides 
Our strategy proposed to link the Noyori reductions of furyl ketone and alkynyl ketone, 
the alkyne zipper reaction and palladium-catalyzed glycosylation together to construct 
aspergillides. The challenge of our route is using a novel palladium-catalyzed addition of a 
vinyl group to install the key trans-pyran ring system. 
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Scheme 6. Retrosynthetic analysis 
Retrosynthetically, we envisioned that aspergillide C (IV-3) could be prepared from 
the macrolactonization of compound IV-24, which could be synthesized from 
Julie-Kocienski olefination of sulfone precursor IV-25. 5  The key transformation 
Pd-catalyzed C-glycosylation should allow the coupling of pyranone IV-26 and sulfone 
IV-27. Pyranone IV-26 could be established from acetyl-furan by three steps. The other 
coupling partner sulfone IV-27 could be prepared from pivalate protected alkynol IV-29 
by Au-catalyzed alkyne hydration6 and the following transformations. Alkynol IV-29 
could be derived by Noyori reduction and alkyne zipper reaction from non-chiral starting 
material pentyne IV-31 (Scheme 6).  
 
4.4. De Novo Approach to Aspergillides 
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Scheme 7. Synthesis of Boc-pyranone 
 
   Taking advantage of our classic three-step Noyori reduction/Achmatowicz 
reaction/Boc-protection sequence,7 we successfully installed c pyranone in 48% 
yield (3 steps) from furan IV-28, which was derived from acetyl furan IV-30 by 
alkylation with dimethyl carbonate (Scheme 7).8  
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Scheme 8. Synthesis of sulfone precursor  
   With the pyranone building block IV-33 in hand, we next proceeded to establish the 
other coupling partner sulfone intermediate IV-27 (Scheme 8). Treating commercially 
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 available non-chiral starting material 1-pentyne with n-BuLi followed by quenching with 
acetyl aldehyde generated racemic propargyl alcohol. The corresponding propargyl 
alcohol was oxidized with manganese dioxide to provide propargyl ketone IV-35. 
Exposure of the propargyl ketone IV-36 with Noyori (S,S) catalyst generated 
enantioenriched propargyl alcohol IV-36. The propargyl alcohol IV-36 was treated with 
KAPA reagent to give the terminal alkyne, the secondary alcohol was protected as its 
pivalate ether IV-29. With the alkynol IV-29 in hand, we next converted the triple bond 
functional group to a bromo-ketone. Au-catalyzed alkyne hydration6 of pivalate ether 
IV-29 provided ketone IV-37 in 85% yield. Treatment of ketone IV-37 with bromine in 
methanol generated less hindered bromo-ketone IV-38 as the major product (70% 
yield).9 Alternatively, one pot reaction of Au-catalyzed hydration and bromination with 
NBS gave bromo-ketone IV-38 in 85% yield. The bromo-ketone IV-38 was 
converted to a sulfide by SN2 substitution, the resulting sulfide was oxidized by Mo 
catalyst to provide sulfone intermediate IV-27. 
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Scheme 9. Proposed Pd-catalyzed C-glycosylation and Julia olefination 
  With two coupling partners IV-33 and IV-27 prepared, we next investigated 
Pd-catalyzed glycosylation to link the two precursors. As we desired, treatment of IV-33 
and IV-27 with Pd2(dba)3•CHCl3 and PPh3 could give us the C-glycosylation product 
IV-25, which is a mixture of the two diastereomers. NaBH4 reduction of IV-25 could 
reduce two ketones and the resulting alcohol next to sufone would eliminate to give 
E-olefin IV-41 as the major product (Scheme 9).5   
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Scheme 10. Double addition 
  In practice, when we treated c-pyranone IV-33 and sulfone IV-27 with 
Pd2(dba)3•CHCl3 and PPh3, it actually gave us the Michael addition product IV-42 
(Scheme 10). We thought maybe Boc protecting group provided too much basic 
condition in the glycosylation reaction, therefore the double addition occured. Thus, we 
made Piv-pyranone IV-43 to undergo the glycosylation reaction. However, similar 
result was observed from the coupling of Piv-pyranone IV-43 and sulfone IV-27, we 
still received the double addition product IV-42. The mechanism of this double addition 
is shown in scheme 11.  After the coupling of pyranone IV-26 and sulfone IV-27, a 
further 1, 4 addition took place to generate the double addition product IV-42.    
 
 
50
  
 
Scheme 11. Mechanism of double addition  
  With the double addition product IV-42 in hand, we thought if we treat it with some 
base, the glycosylation product IV-25 would be reformed. However, we could not find a 
suitable base to do this transformation. In addition, we planned to reduce the double bond 
of the double addition product IV-42 to provide compound IV-46 which could be 
converted to E olefine IV-47 when treated with some base. Unfortunately, many attempts 
of the hydrogenation of IV-42 failed (Scheme 12).  
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Scheme 12. Attempt to correct double addition product 
  Consequently, we decided to avoid the double addition by diastereoselectivly reducing 
the  unsaturated ketone IV-33 to an equatorial allylic alcohol IV-48 using NaBH4. 
When we utilized our Pd-catalyzed glycosylation reaction followed by one-pot reduction 
with NaBH4 without isolation of the coupling product, we accessed the mixture of 
trans/cis double bond isomers of IV-41 and IV-49. After careful chromatography 
separation, E-olefine IV-41 was collected in 26% yield (Scheme 13).  
 
Scheme 13. Glycosylation of equatorial allylic alcohol with sulfone 
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   We were delighted that the E-olefine IV-41 had been established by our glycosylation 
reaction, but both the yield and selectivity needed to be improved. Thus, we tried many 
different substitutes for the glycosylation reactions. Firstly, we protected the allylic 
alcohol IV-48 as a TBS ether IV-50, however, the Pd-catalyzed glycosylation of the TBS 
ether IV-50 and the sulfone IV-27 failed (Scheme 14), and we could only isolate the 
unknown side products.    
  
Scheme 14. Glycosylation of TBS ether of the equatorial allylic alcohol with sulfone 
        
Scheme 15. Glycosylation of axial allylic alcohol with sulfone 
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Scheme 16. Glycosylation of TBS ether of the axial allylic alcohol with sulfone 
  Secondly, because the stereochemistry of the allylic alcohol IV-48 was opposite with 
the natural product aspergillides, we reversed the stereochemistry by Mitsunobu reaction 
to generate axial allylic alcohol IV-52 (Scheme 15). Unfortunately, no product can be 
isolated from the glycosylation reaction to couple IV-52 and IV-27. Consequently, we 
tried the glycosylation reaction on the TBS protected allylic alcohol IV-54, however, no 
coupling reaction occurred (Scheme 16).  
 
Scheme 17. Glycosylation of pivalate equatorial allylic alcohol with sulfone 
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Scheme 18. Glycosylation of pivalate axial allylic alcohol with sulfone 
   Finally, we prepared pivalate protected allylic alchol IV-56 and IV-58, when we 
treated these two diastereomers with Pd-catalyzed glycosylation condition, IV-56 gave us 
the similar result as IV-48, however, we still could not could IV-58 with the sulfone 
under this condition, only starting materials were recovered.  
4.5. Conclusions 
   In summary, a de novo asymmetric total synthesis of aspergilliges has been 
investigated. To date, intermediate IV-41 which is five steps away from a formal 
synthesis4a (compound IV-23) of aspergillide C (IV-3) has been prepared by Pd-catalyzed 
C-glycosylation and the following Julia olefination.  Noyori reductions of furyl and 
propargyl ketone, alkyne zipper reaction and Au-catalyzed alkyne hydration have been 
utilized.  
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 Experimental Section 
 
Section A: General Information 
 
General Methods and materials:  1H and 13C spectra were recorded on 270 and 600 
spectrometers. Chemical shifts were reported relative to internal tetramethylsilane (δ 0.00 
ppm) or CDCl3 (δ 7.26 ppm) or CD3OD (δ 4.89 ppm) for 1H and CDCl3 (δ 77.1 ppm) or 
CD3OD (δ 49.15 ppm) for 13C. Optical rotations were measured with a digital polarimeter 
in the solvent specified. Infrared (IR) spectra were obtained on a FT-IR spectrometer. 
Flash column chromatography was performed on ICN reagent 60 (60-200 mesh) silica 
gel. Analytical thin-layer chromatography was performed with precoated glass-backed 
plates (K6F 60Å, F254) and visualized by quenching of fluorescence and by charring after 
treatment with p-anisaldehyde or phosphomolybdic acid or potassium permanganate 
stain. Rf values were obtained by elution in the stated solvent ratios (v/v). Ether, THF, 
methylene chloride and triethylamine were dried by passing through activated alumina (8 
x 14 mesh) column with nitrogen gas pressure. Commercial reagents were used without 
purification unless otherwise noted. Air and/or moisture-sensitive reactions were carried 
out under an atmosphere of argon/nitrogen using oven/flamed-dried glassware and 
standard syringe/septa techniques. 
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 Section B: Experimental Procedures 
 
(S)-1-(furan-2-yl)ethanol (I-10)1 
                                                              
 
To a solution of acylfuran I-7 (15 g, 136.4 mmol) in CH2Cl2 (20 mL) was added a 
prepared solution of formic acid/triethylamine (40 mL, 2:1 (mol/mol)) and Noyori 
asymmetric transfer hydrogenation catalyst (R)-Ru(η6-mesitylene)-(S,S)-TsDPEN (0.2 g, 
0.25 mol%). The resulting solution was stirred at room temperature for 24 h. Then it was 
diluted with water (90 mL) and extracted with Et2O (200 mL x 3). The combined organic 
layer was washed with saturated aqueous NaHCO3 (50 mL) saturated brine (50 mL), 
dried over Na2SO4 and then concentrated under reduced pressure to give a residue. Flash 
chromatography on silica gel eluting with hexane/Et2O (1:1, v/v) gave furfuryl alcohol I-
10 (14 g, 92%) as colorless oil: Rf 0.45 (7:3 (v/v) hexane/EtOAc); [α]25D = −20.1 (c 1.0, 
CH2Cl2); 1H NMR (600 MHz CDCl3) δ 7.30 (d, J = 1.8, 1H), 6.26 (dd, J = 3.0, 1.8 Hz, 
1H), 6.15 (d, J = 3.0, 1H), 4.78 (dq, J = 6.6, 6.6 Hz, 1H), 3.11 (s, 1H), 1.46 (d, J = 6.6 Hz, 
3H); 13C NMR (150 MHz, CDCl3) δ 157.7, 141.6, 109.9, 104.9, 63.3, 21.1. 
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 (2S, 6R)-6-hydroxy-2-methyl-2H-pyran-3(6H)-one (I-13)1 
 
 
To a solution of furfuryl alcohol I-10 (14 g, 125 mmol) in THF/H2O (416 mL, 3:1 (v/v)) 
was added NaHCO3 (21 g, 250 mmol), NaOAc•3H2O (17 g, 125 mmol), and NBS (22.3 g, 
125 mmol) at 0 °C. The reaction mixture was kept stirring at this temperature for 1 hour, 
then at 0 °C saturated aqueous NaHCO3 (200 mL) was added to quench the reaction. The 
reaction mixture was directly extracted with Et2O (300 mL × 3) and the combined 
organic layer was washed by saturated brine (100 mL), dried over Na2SO4 and then 
concentrated under reduced pressure to give a residue, which was rapidly subjected to 
flash chromatography on silica gel. Elution with hexane/EtOAc (1:1, v/v) afforded 
diastereomeric mixture of pyranone alcohol I-13 (14.4 g, 90%, α:β=2.8:1): White solid; 
Rf 0.25 (7:3 (v/v) hexane/EtOAc); 1H NMR (600 MHz, CDCl3, α isomer) δ 6.82 (dd, J = 
10.2, 3.0 Hz, 1H), 5.96 (d, J = 10.2, 1H), 5.48 (d, J = 3.0 Hz, 1H), 3.99 (q, J = 7.2 Hz, 
1H), 1.23 (d, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3, α isomer) δ 197.6, 145.3, 
126.6, 87.2, 74.8, 15.1. 
 
 
tert-Butyl (2S,6S)-6-methyl-5-oxo-5,6-dihydro-2H-pyran-2-yl carbonate (I-5))1 
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To a solution of pyranone alcohol I-13 (7.4 g, 57.8 mmol) in CH2Cl2 (80 mL) was added 
DMAP (528 mg, 4.33 mmol) at -78 °C. A pre-cooled solution of (Boc)2O (25.2 g, 115.6 
mmol) in CH2Cl2 (30 mL) was added dropwise to the reaction mixture via a cannula. The 
reaction mixture was stirred at -78 °C for 12 hours. The reaction was quenched by 
saturated aqueous NaHCO3 (100 mL) and then extracted with Et2O (300 mL × 3). The 
combined organic layers was washed by saturated brine (70 mL), dried over Na2SO4 and 
concentrated under reduced pressure to give a residue. Flash chromatography on silica 
gel eluting with hexane/Et2O (100:7, v/v) gave α-Boc-pyranone I-5 (7.8 g, 60%). Elution 
with hexane/Et2O (10:1, v/v) gave β-Boc-pyranone (2.5g, 19%). α-Boc-pyranone 15(α-L): 
Rf = 0.60 (7:3 (v/v) hexane/EtOAc); [α]25D = +98 (c 1.0, CH2Cl2); IR (thin film, cm−1) υ 
2986, 1752, 1703, 1633, 1278, 1258, 1159, 1090, 1058, 1029, 944. 1H NMR (600 MHz, 
CDCl3) δ 6.78 (dd, J = 10.2, 3.6 Hz, 1H), 6.22 (d, J = 3.6 Hz, 1H), 6.09 (d, J = 10.2 Hz, 
1H), 4.53 (q, J = 6.6 Hz, 1H), 1.40 (s, 9H), 1.28 (d,J = 6.6 Hz, 3H); 13C NMR (150.8 
MHz, CDCl3) δ 195.5, 151.7, 140.9, 128.2, 89.1, 83.3, 72.0, 27.5, 15.1; HRMS (CI): 
Calculated for [C11H16O5+Na]+ 251.0890, Found 251.0883. 
 
 
1-(tert-butyldimethylsilyloxy)-pen-4-yne (I-11a): 2 
 
 
                                                        
     
                                                 
2 H. Guo; O’Doherty, G.A.  Org. Lett. 2005; 7(18); 3921-3924. 
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 To a magnetically stirred solution of 4-pentynol I-11 (5.0 g, 59.4 mmol) and imidazole 
(10.1 g, 148.6 mmol) in dry DMF (100 mL), was added dropwise tert-butyldimethylsilyl 
chloride (9.4 g, 62.4 mmol) in DMF (50 mL) over 10 min at 0 oC under an atmosphere of 
nitrogen.  The reaction mixture was warmed to room temperature and stirred overnight. 
Water (300 mL) was added and then the reaction mixture was extracted with Et2O (3 x 
300 mL), dried (Na2SO4), and evaporated under reduced pressure to leave a light yellow 
oil. The crude product was purified using silica gel flash chromatography eluting with 5% 
EtOAc/hexane to give TBS-ether I-11a (11.8 g, 147.1, 99%) as a colorless oil; Rf  = 0.89 
(30% EtOAc/hexane); IR (thin film, cm-1) 3314, 2954, 2930, 2858, 1473, 1256, 1106, 
835, 776; 1H NMR (600 MHz, CDCl3)  δ 3.68 (t, J = 6.6 Hz, 2H), 2.26 (td, J = 7.2, 2.4 
Hz, 2H), 1.90 (t, J = 2.4, 1H), 1.71 (tt, J = 7.2, 6.6 Hz, 2H), 0.89 (s, 9H), 0.05 (s, 6H); 13C 
NMR (150 MHz, CDCl3) δ 84.3, 68.3, 61.5, 31.6, 26.0, 18.4, 14.9, –5.3.   
 
 
(+/-)-7-(tert-butyldimethylsilyloxy)-hept-3-yne-2-ol (I-11b):2 
 
 
 A solution of BuLi in hexane (24.71 mL, 59.3 mmol) was added dropwise to the 
magnetically stirred solution of TBS-ether I-11a (11.8 g, 59.3 mmol) in dry THF (59.3 
mL) at –78  oC under the atmosphere of argon.  After 30 min, acetaldehyde (1.54 g, 35.1 
mmol) was added and stirred for 10 min at 0 oC and then the resulting solution was 
warmed to room temperature for 50 min. 100 mL of CH2Cl2 was added to the reaction 
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 mixture followed by addition of 100 mL of pH = 7.0 phosphate buffer. The aqueous 
phase was separated and extracted with CH2Cl2 (3 x 100 mL). The combined organic 
phase was dried (Na2SO4) and concentrated under reduced pressure. The crude product 
was purified using silica gel flash chromatography eluting with 6% EtOAc/hexane to give 
propargyl alcohol I-11b (8.4 g, 34.6 mmol, 98%): light yellow oil; Rf  = 0.42 (20% 
EtOAc/hexane); IR (thin film, cm-1), 3364, 2953, 2930, 2858, 1740, 1472, 1254, 1103, 
1071, 835, 775; 1H NMR (600 MHz CDCl3) δ 4.65 (qd, J = 6.6, 1.8 Hz, 1H), 3.64 (t, J = 
6.0 Hz, 2H), 2.24 (td, J = 7.2, 1.8 Hz, 2H), 1.66 (tt, J = 7.2, 6.6 Hz, 2H), 1.38 (d, J = 6.6 
Hz, 3H), 0.86 (s, 9H), 0.02 (s, 6H); 13C NMR (150 MHz, CDCl3) δ 84.0, 82.5, 61.6, 58.4, 
31.7, 25.9, 24.7, 18.3, 15.1, –5.0; CIHRMS: Calculated for [C13H26O2SiNa+]: 265.1594, 
found: 265.1630. 
 
 
7-(tert-butyldimethylsilyloxy)-hept-3-yne-2-one (I-8):2 
 
 
 
To a solution of alcohol I-11b (2 g, 8.23 mmol) in THF (82.3 mL), was added activated 
MnO2 (10 g) and left to stir for 30 h, the reaction mixture was filtered and concentrated 
under reduced pressure.  The crude product was purified by silica gel flash 
chromatography eluting with 5% EtOAc/hexane to yield propargyl ketone I-8 (1.96 g, 
8.13 mol, 98%):  Rf  = 0.85 (30% EtOAc/hexane); IR (thin film, cm-1) 2955, 2930, 2858, 
2210, 1678, 1472, 1226, 1103, 966, 8345, 775; 1H NMR (600 MHz, CDCl3) δ 3.64 (t, J = 
6.0 Hz, 2H), 2.40 (t, J = 7.2 Hz, 2H), 2.25 (s, 3H), 1.71 (tt, J = 7.2, 6.0 Hz, 2H), 0.84 (s, 
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 9H), 0.02 (s, J = 0.05 Hz, 6H); 13C NMR (150 MHz, CDCl3) δ 184.5, 93.5, 81.4, 61.1, 
32.6, 30.7, 25.8, 18.2, 15.3, –5.4.  
 
(R)-7-(tert-butyldimethylsilyloxy)-hept-3-yne-2-ol (I-12):2 
 
 
 
 
 To a 20 mL flask was added propargyl ketone I-8 (704 mg, 2.92 mmol), CH2Cl2 (1.48 
mL), formic acid/triethylamine (1:1, 5.38 mL) and Noyori asymmetric transfer 
hydrogenation catalyst (S)-Ru(η6-mesitylene)-(R,R)-TsDPEN (8.9 mg, 0.5 mol%). The 
resulting solution was stirred at room temperature for 24 h.  Water (10 mL) was added to 
dilute and extracted with EtOAc (3 x 20 mL).  The combined organic layers were washed 
with saturated NaHCO3, dried over Na2SO4, and concentrated under reduced pressure to 
afford crude oil.  The crude product was purified by silica gel flash chromatography 
eluting with 6% EtOAc/hexane to give propargyl alcohol I-12 (605 mg, 2.49 mmol, 
86%): colorless oil; Rf  = 0.42 (20% Et2O/hexane); [α]25D = +16 (c = 1.1, CH2Cl2); IR 
(thin film, cm-1) 3346, 2954, 2930, 2858, 1739, 1472, 1253, 1103, 1070, 835, 775; 1H 
NMR (600 MHz CDCl3)  δ 4.43 (qd, J =  6.0, 1.8 Hz, 1H), 3.64 (t, J = 6.0 Hz, 2H), 2.71 
(s, 1H), 2.22 (td, J = 7.2, 1.8 Hz, 2H), 1.63 (tt, J = 7.2, 6.0 Hz, 2H), 1.34 (d, J =  6.0 Hz, 
3H), 0.86 (s, 9H), 0.02 (s, 6H); 13C NMR (150 MHz, CDCl3) δ 83.8, 82.5, 61.5, 58.2, 
31.6, 25.9, 24.7, 18.3, 15.0, –5.3; CI HRMS: Calculated for [C13H26O2SiNa+]: 265.1594, 
found: 265.1630. 
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 (R)-7-(tert-butyldimethylsilyloxy) –heptan-2-ol (I-6):2 
 
H3C
OH
OTBS  
 
 
To a solution of propargyl alcohol I-12 (2 g, 8.23 mmol) in dry EtOAc (33 mL), was 
carefully added Pd/C (20 mg) and the resulting suspension was stirred under H2 (1 atm) 
for 5 min at room temperature.  The catalyst was filtered off through a short pad of celite, 
concentrated under reduced pressure to afford colorless oil.  The crude product was 
purified by silica gel flash chromatography eluting with 6% EtOAc/hexane to give 
alcohol I-6 (1.73 g, 6.75 mmol, 82%): colorless oil; Rf  = 0.40 (20% Et2O/hexane); [α]25D 
= +8 (c = 1.0, CH2Cl2); IR (thin film, cm-1) 3363, 2929, 2857, 1472, 1254, 1096,  835, 
774; 1H NMR (600 MHz, CDCl3)  δ 3.74 (ddq, J = 6.0, 6.0, 6.0, 1H), 3.56 (t, J = 6.6 Hz, 
2H), 1.85(s, 1H), 1.49 (m, 2H), 1.43 (m, 2H), 1.39 (m, 2H), 1.31(m, 2H), 1.14 (d, J = 6.0 
Hz, 3H), 0.86 (s, 9H), 0.02 (s, 6H); 13C NMR (150 MHz, CDCl3) δ 68.0, 63.2, 39.4, 32.8, 
26.0, 25.9, 25.6, 23.5, 18.4, –5.3; CIHRMS: Calculated for [C13H30O2Si+Na]+: 269.1907, 
found: 269.1903. 
 
 
(2S, 6R)-6-((R)-7-(tert-butyldimethylsilyloxyl)heptan-2-yloxy)-2-methyl-2H-pyran-
3(6H)-one (I-14):2 
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O
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To a solution of pyranone I-5 (473 mg, 2.07 mmol) and alcohol I-6 (430 mg, 1.74 mmol) 
in dry CH2Cl2 (1 mL), was added a CH2Cl2 (1 mL) solution of Pd2(DBA)3•CHCl3 (43.9 
mg, 2.5 mol%) and PPh3 (45.6 mg, 10 mol%) at 0 oC under argon atmosphere.  After 
stirring for 3 h at 0 oC to room temperature, the reaction mixture was quenched with 15 
mL of saturated NaHCO3, extracted (3 x 25 mL) with Et2O, dried (Na2SO4), and 
concentrated under reduced pressure.  The crude product was purified using silica gel 
flash chromatography eluting with 4% EtOAc/hexane to give pyranone I-14 (656 mg, 
1.64 mmol, 94%):  Rf  = 0.64 (20% EtOAc/hexane); [α]25D = +13 (c = 1.0, CH2Cl2); IR 
(thin film, cm-1) 2930, 2857, 1701, 1463, 1375, 1254, 1097, 1023, 836; 1H NMR (600 
MHz, CDCl3) δ 6.77 (dd, J = 10.2, 3.6 Hz, 1H), 6.04 (d, J = 10.2 Hz, 1H), 5.25 (d, J = 3.6 
Hz, 1H), 4.56 (q, J = 6.6 Hz, 1H), 3.89 (ddq, J = 6.0, 6.0, 6.0 Hz, 1H), 3.58 (t, J = 6.6 Hz, 
2H), 1.58 (m, 2H) 1.49 (m, 2H), 1.47 (m, 2H), 1.41 (m, 2H), 1.35 (d, J = 6.6 Hz, 3H), 
1.17 (d, J = 6.6 Hz, 3H), 0.87 (s, 9H), 0.02 (s, 6H); 13C NMR (150 MHz, CDCl3) δ 197.2, 
144.2, 127.1, 90.8, 73.8, 70.4, 63.2, 37.3, 32.8, 26.0, 25.8, 25.6, 19.5, 18.3, 15.2, –5.3; 
CIHRMS: Calculated for [C19H36O4SiNa+]: 379.2275, found: 379.2277. 
 
 
 (1S, 3S, 5R, 6R)-5-((R)-7-(tert-butyldimethylsilyloxyl)heptan-2-yloxy)-3-methyl-4,7-
dioxa-bicyclo[4.1.0]heptan-2-one (I-15):2  
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To the solution of pyranone I-14 (440 mg, 1.18 mmol) in methanol (3.93 mL) at 0 oC, 
30% aqueous hydrogen peroxide (0.553 mL, 4.7 mmol) was added dropwise, followed by 
aqueous sodium hydroxide (0.236 mL, 0.5 M). The reaction mixture was warmed to 
room temperature. After stirring for 5 h, the reaction mixture was quenched using 
saturated NaHCO3 (25 mL), extracted with diethyl ether (5 x 20 mL), dried (Na2SO4), 
and concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography eluting with 4% EtOAc/hexane to give 656 mg (1.64 mmol, 94%) 
of epoxy-enone I-15:  Rf  = 0.62 (20% EtOAc/hexane); [α]25D =  –103 (c = 1.0, CH2Cl2); 
IR (thin film, cm-1) 2930, 2858, 1726, 1463, 1380, 1254, 1143, 1094, 1057, 833; 1H 
NMR (600 MHz, CDCl3) δ 5.28 (d, J = 0.6 Hz, 1H), 4.19 (q, J = 7.0 Hz, 1H), 3.86 (ddq, J 
= 6.0, 6.0, 6.0 Hz, 1H), 3.60 ( t, J = 6.6 Hz, 2H), 3.48 (dd, J = 4.2, 0.6 Hz, 1H), 3.42 (d, J 
= 4.2 Hz, 1H), 1.54 (m, 2H), 1.51 (m, 2H), 1.37 (d, J = 6.6 Hz, 3H), 1.32 (m, 2H), 1.24 
(m, 2H), , 1.20 (d, J = 7 Hz, 3H), 0.89 (s, 9H), 0.04 (s, 6H); 13C NMR (150 MHz, CDCl3) 
δ 203.3, 91.3, 73.7, 71.9, 63.1, 54.3, 53.0, 37.1, 32.8, 26.0, 25.8, 25.5, 19.2, 18.4, 16.8, –
5.2; CIHRMS: Calculated for [C19H36O5SiNa+]: 395.2224, found: 379.2228. 
 
 
 (1R, 2S, 3S, 5R, 6R)-5-((R)-7-(tert-butyldimethylsilyl)heptan-2-yloxy)-3-methyl-4, 7-
dioxa-bicyclo[4.1.0]heptan-2-ol  (I-16):2  
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A CH2Cl2 (0.46 mL) solution of epoxy enone I-15 (181 mg, 0.46 mmol) and 
CeCl3/MeOH (0.3 mL, 0.4 M) was cooled to –78 °C.  NaBH4 (38.4 mg, 10.2 mmol) was 
added and the reaction mixture was stirred at –78 to –20 °C for 4 h. The reaction mixture 
was diluted with ether (5 mL) and quenched with 2.5 mL of saturated NaHCO3, extracted 
(3 x 5 mL) with Et2O, dried (Na2SO4), and concentrated under reduced pressure. The 
crude product was purified using silica gel flash chromatography eluting with 20% 
EtOAc/hexane to give 170 mg (0.43 mmol, 93%) of epoxy alcohol I-16: Rf  = 0.34 (40% 
EtOAc/hexane); [α]25D = –54 (c = 1.0, CH2Cl2); IR (thin film, cm-1) 3441, 2930, 2857, 
1463, 1387, 1254,  1097, 1055, 834; 1H NMR (600 MHz, CDCl3) δ 5.02 (s, 1H), 3.84 
(ddq, J = 6.0, 6.0, 6.0 Hz 1H), 3.60 (t, J = 6.6 Hz, 2H), 3.59-3.55 (m, 1H), 3.50 (m, 1H), 
3.26 (d, J = 3.6 Hz, 1H), 3.05 (d, J = 3.6 Hz, 1H), 1.61-1.53 (m, 2H) 1.52 (m, 2H), 1.49-
1.40 (m, 2H), 1.38-1.31 (m, 2H), 1.23 (d, J = 6.6 Hz, 3H), 1.16 (d, J = 6.6 Hz, 3H), 0.89 
(s, 9H), 0.04 (s, 6H); 13C NMR (150 MHz, CDCl3) δ 92.5, 73.1, 68.0, 65.6, 63.3, 56.0, 
50.6, 37.3, 32.8, 26.0, 25.8, 25.5, 19.4, 18.4, 18.3, –5.2; CIHRMS: Calculated for 
[C19H38O5SiNa+]: 397.2380, found: 397.2386. 
 
 
 (2R, 3R, 5R, 6S)-2-((R)-7-(tert-butyldimethylsilyloxyl)heptan-2-yloxy)-tetrahydro-6-
methyl-2H-pyran-3,5-diol (I-4):2 
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To a solution of epoxy ketone I-16 (35 mg, 0.09 mmol) in dry THF (0.15 mL) at  –78 oC, 
was added dropwise the suspension solution of LiAlH4 (6.8 mg, 0.18 mmol) in dry THF 
(0.15 mL) under argon atmosphere.  After stirring 2 h, the resulting solution was warmed 
to the room temperature and LiAlH4 (6.8 mg, 0.18 mmol) in dry THF (0.15 mL) was 
added dropwise again, keeping reaction overnight. Water (1 mL) was added dropwise 
with cooling. Then the mixture was extracted with EtOAc (3 x 3 mL), dried (Na2SO4), 
and concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography eluting with 50% EtOAc/hexane to give 30.5 mg (0.078 mmol, 
86%) of diol I-4: Rf  = 0.21 (50% EtOAc/hexane); [α]25D = –67 (c = 1.0, CH2Cl2); IR 
(thin film, cm-1) 3360, 2929, 2857, 1463, 1378, 1255,  1098, 1028, 984, 835; 1H NMR 
(600 MHz, CD3OD) δ 4.69 (s, 1H), 3.83 (ddq, J = 6.0, 6.0, 6.0 Hz, 1H), 3.76 (m, 1H), 
3.69 (t, J = 6.6 Hz, 2H), 3.66 (m, 1H),  3.56 (ddd, J = 11, 11, 4.2 Hz, 1H), 2.00 (ddd, J 
=13.2, 3.6, 3.6 Hz, 1H), 1.82 (ddd, J = 13.2, 11.4, 3 Hz, 1H), 1.58 (m, 2H) 1.51 (m, 2H), 
1.43 (m, 2H), 1.34 (m, 2H), 1.26 (d, J = 6.6 Hz, 3H), 1.17 (d, J = 6.0 Hz, 3H), 0.95 (s, 
9H), 0.10 (s, 6H); 13C NMR (150 MHz, CD3OD) δ 96.3, 72.5, 71.2, 70.0, 68.8, 63.1, 
38.6, 36.1, 34.0, 27.1, 26.7, 26.6, 19.5, 19.3, 18.3, –4.9; CIHRMS: Calculated for 
[C19H40O5SiNa+]: 399.2537, found: 399.2539. 
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 (2R, 3R, 5R, 6S)-2-((R)-7-(tert-butyldimethylsilyloxyl)heptan-2-yloxy)-tetrahydro-6-
methyl-2H-pyran-3,5-diol (I-17):2 
 
 
To a solution of diol I-4 (752 mg, 2 mmol) in pyridine (2 mL), was added Ac2O (1 mL) 
and DMAP (35 mg). The reaction mixture was stirred for 12 h. Water was added to 
destroy the excess acetic anhydride, extracted (3 x 50 mL) with Et2O washed with 40 mL 
of saturated CuSO4 solution for three times, dried (Na2SO4), and concentrated under 
reduced pressure. The crude product was purified using silica gel flash chromatography 
eluting with 5% ether/hexane to give acetate I-17 (912 mg, 1.98 mmol, 99%); a clean oil; 
Rf = 0.49 (10% EtOAc/hexane); [α]25D = –66 (c = 1.1, CH2Cl2); IR (thin film, cm-1) 2934, 
2958, 1743, 1371, 12309, 1037, 835; 1H NMR (600 MHz, CDCl3) δ 4.74 (m, 1H), 4.70 
(ddd, J = 11.4, 10.2, 4.2 Hz, 1H), 4.65 (s, 1H), 3.85 (dq, J = 9.6, 6.6 Hz, 1H), 3.76 (m, 
1H), 3.60 (t, J = 6.6 Hz, 2H), 2.11 (ddd, J = 13.2, 3.6, 3.6 Hz, 1H), 2.10 (s, 3H), 2.05 (s, 
3H), 1.93 (ddd, J = 13.2, 11.4, 3 Hz, 1H), 1.58 (m, 2H), 1.54 (m, 2H), 1.43 (m, 2H), 1.34 
(m, 2H), 1.17 (d, J = 6.6 Hz, 3H), 1.12 (d, J = 6.0 Hz, 3H), 0.89 (s, 9H), 0.04 (s, 6H); 13C 
NMR (150 MHz, CDCl3) δ 170.4, 170.1, 93.7, 72.4, 70.7, 70.0, 68.8, 63.3, 37.2, 32.9, 
29.5, 26.1, 26.0, 25.9, 25.6, 21.3, 21.2, 19.1, 18.4, 17.7, –5.2; CIHRMS: Calculated for 
[C23H44O7SiNa+]: 483.2754, found: 483.2755. 
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 2-((R)-7-hydroxyheptan-2-yloxy)-tetrahydro-6-methyl-2H-pyran-3, 5-diacetate (I-
18):2  
 
 
To a solution of TBS-ether I-17 (460.6 mg, 1 mmol) in dry MeOH (2 mL), 6 N HCl (2 
mL) was added at room temperature under the argon atmosphere. After 4 h, the reaction 
mixture was diluted with ether (20 mL) and quenched with saturated NaHCO3, extracted 
(3 x 5 mL) with Et2O, dried (Na2SO4), and concentrated under reduced pressure. The 
crude product was purified by passing a silica gel pad eluting with pure ether to give 
alcohol I-18 (350 mg, 0.97 mmol, 97%); a colorless oil, [α]25D = –86 (c = 1.12, CH2Cl2); 
IR (thin film, cm-1) 2975, 2935, 2861, 1739, 1230, 1105, 1032, 983; 1H NMR (600 MHz, 
CDCl3) δ 4.81 (m, 1H), 4.77 (ddd, J = 11.4, 10.2, 4.2 Hz, 1H), 4.72 (s, 1H), 3.84 (dq, J = 
9.6, 6.6 Hz, 1H), 3.74 (m, 1H), 3.62 (t, J = 6.6 Hz, 2H), 2.10 (ddd, J = 13.2, 3.6, 3.6 Hz, 
1H), 2.09 (s, 3H), 2.03 (s, 3H), 1.92 (ddd, J = 13.2, 11.4, 3 Hz, 1H), 1.57 (m, 2H), 1.54 
(m, 2H), 1.43 (m, 2H), 1.36 (m, 2H), 1.15 (d, J = 6.6 Hz, 3H), 1.11 (d, J = 6.0 Hz, 3H);  
13C NMR (150 MHz, CDCl3) δ 170.4, 170.1, 93.7, 72.3, 70.7, 70.0, 66.8, 62.7, 37.1, 32.7, 
29.4, 25.8, 25.5, 21.2, 21.1, 19.1, 17.7; CIHRMS: Calculated for [C17H30O7Na+]: 
369.1889, found: 369.1891. 
 
 
2-methyl-6-((R)-7-oxoheptan-2-yloxy)-tetrahydro-2H-pyran-3, 5-yl diacetate (I-19): 
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A solution of alcohol I-18 (240 mg, 0.693 mmol) and trichloroisocyanuric acid (171.2 
mg, 1.386 mmol) in ethyl ether (30 ml) was stirred at –30 oC, and then 2,2,6,6-
tetramethylpeperidinooxy was added in one portion. The mixture was stirred for 20 min 
and then quenched with 30 ml saturated sodium carbonate. The organic layer was 
separated and the aqueous layer was extracted with ether. Combined the organic layer 
and washed with brine, dried (Na2SO4), filtered and concentrated. Chromatography on 
silica gel (20% EtOAc/Hexane) gave aldehyde I-19 (210 mg, 0.61 mmol, 88%) as 
colorless oil; Rf (40% EtOAc/Hexane) = 0.66; [α]25D = - 41 (c = 1.0, MeOH);  IR (thin 
film, cm-1), 2929, 1741, 1234, 1040;  1H NMR (600 MHz, CD3Cl) δ 9.76 (t, J = 1.8 Hz, 
1H), 4.82 (m, 1H), 4.78 (ddd, J = 11.4, 10.2, 4.8 Hz, 1H), 4.72 (s, 1H), 3.82 (dq, J = 12.6, 
6 Hz, 1H), 3.76 (ddq, J = 6.0, 6.0, 6.0 Hz, 1H), 2.44 (dt,   J = 7.2, 1.8 Hz, 1H), 2.09 (m, 
3H), 2.04 (m, 3H),  1.91 (ddd, J = 13.8, 11.4, 3 Hz, 1H), 1.68-1.46 (m, 8H), 1.33 (d,  J = 
6.6 Hz, 6H);  13C NMR (150 MHz, CD3Cl) δ 202.6, 170.6, 170.3, 93.8, 72.3, 70.8, 70.0, 
67.0, 44.003, 37.01, 29.6, 25.4, 22.3, 21.4, 21.3, 19.19, 17.9. CIHRMS: Calculated for 
[C17H28O7Na+]: 367.1227, Found: 367.1733.  
 
 
(8R,E)-ethyl 8-(3,5-diacetoxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)non-2-enoate 
(I-20): 
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Ylide (396.7 mg, 1.14 mmol) was dissolved in 0.6 ml of CH2Cl2, into which aldehyde I-
19 (190 mg, 0.55 mmol) was added. The reaction was stirred vigorously at room 
temperature for 12 hrs before solvent was removed in vacuum. Chromatography on silica 
gel (30% EtOAc/Hexane) gave ethyl ester I-20 (220 mg, 0.53 mmol, 96.5%) as colorless 
oil.  Rf (40% EtOAc/Hexane) =0.57; [α]25D = - 22 (c = 1.0, MeOH);  IR (thin film, cm-1), 
2936, 1743, 1233, 1038;  1H NMR (600 MHz, CD3Cl) δ 6.96 (dt, J = 13.8, 7.2 Hz, 1H), 
5.82 (dt, J = 15.6, 1.8 Hz, 1H), 4.83 (m, 1H), 4.79 (ddd, J = 10.8, 9.6, 4.2 Hz, 1H), 4.73 
(s, 1H), 4.18 ( q, J = 7.2 Hz, 2H),  3.84 (dq, J = 12, 6 Hz, 1H), 3.76 (ddq, J = 6.0, 6.0, 6.0 
Hz, 1H), 2.22 (dt,   J = 7.2, 1.2 Hz, 1H), 2.11 (m, 3H), 2.06 (m, 3H),  1.93 (ddd, J = 13.8, 
11.4, 3 Hz, 1H), 1.60-1.35 (m, 8H), 1.28 (t,  J = 7.2 Hz, 3H); 1.17 (d,  J = 6.6 Hz, 3H),  
1.13 (d,  J = 6 Hz, 3H);  13C NMR (150 MHz, CD3Cl) δ 170.3, 170.1, 166.7, 148.9, 121.5, 
93.6, 72.2, 70.6, 69.8, 66.8, 60.4, 60.2, 36.8, 32.2, 29.3, 27.9, 25.3, 21.2, 19.0, 17.6, 14.3; 
CIHRMS: Calculated for [C21H34O8Na+]: 437.2146, Found: 437.2151.  
                            
 (8R,E)-methyl 8-(3,5-dihydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)non-2-
enoate (I-21): 
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    To a 20 ml flask was added ethyl ester I-20 (136 mg, 0.328 mmol), MeOH (3 ml), 
Lithium hydroxide (30 mg, 1.25 mmol). The resulting solution was stirred at room 
temperature for 24 hrs. Aqueous HCl (0.5 M, 3 ml) was added before solvent was 
removed in vacuum. Chromatography on silica gel (80% EtOAc/Hexane) gave ethyl ester 
I-21 (103 mg, 0.309 mmol, 99%) as colorless oil. Rf (EtOAc) = 0.58; [α]25D = - 81 (c = 
1.0, MeOH);  IR (thin film, cm-1), 3404, 2934, 2180, 1991, 1723, 1655, 1438, 1273, 
1203, 1101, 1128, 1029, 984, 854;  1H NMR (600 MHz, CD3Cl) δ 6.96 (dt, J = 15.6, 6.6 
Hz, 1H), 5.83 (dt, J = 15.6, 1.2 Hz, 1H), 4.69 (s, 1H), 3.80-3.77 ( m, 1H),  3.72 (s, 3H), 
3.65 (dt, J = 6.6, 3.0 Hz, 1H), 3.59-3.57 (m, 1H), 2.22 (ddd,  J = 9.0, 7.2, 1.8Hz, 1H), 
1.88-1.72 (m, 2H),  1.61(s, 1H), 1.55-1.35 (m, 6H),  1.27 (d,  J = 6. Hz, 3H), 1.22 (d,  J = 
6 Hz, 3H); 13C NMR (150 MHz, CD3Cl) δ  167.3, 149.5, 121.7, 96.1, 71.3, 70.0, 69.3, 
69.1, 51.5, 36.9, 35.2, 32.0, 27.8, 25.0, 20.0, 17.7; CIHRMS: Calculated for 
[C16H28O6Na+]: 339.1778, Found: 339.1784.  
 (8R,E)-8-(3,5-dihydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)non-2-enoic acid 
(I-1) 
 
 
To a 20 ml flask was added methyl ester I-21 (13 mg, 0.04 mmol), THF/H2O (4:1, 0.4 
ml), Lithium hydroxide (1.44 mg, 0.06 mmol). The resulting solution was stirred at room 
temperature for 24 hrs. Aqueous HCl (0.5 M, 0.4ml) was added to make the pH equal to 
7, and then the solvent was removed in vacuum. Chromatography on silica gel (5% 
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 MeOH/EtOAc) gave acid I-1 (12 mg, 0.0397 mmol, 99%) as colorless oil. Rf (EtOAc) = 
0.28; [α]25D = - 62 (c = 1.0, MeOH);  IR (thin film, cm-1), 3703, 3364, 2930, 2357, 2164, 
2084, 2010, 1954, 1696, 1272, 1127, 981, 667; 1H NMR (600 MHz, CD3Cl) δ 6.93 (dt, J 
= 15.6, 7.2 Hz, 1H), 5.79 (dt, J = 15.6, 1.2 Hz, 1H), 4.62 (s, 1H), 3.78-3.75 ( m, 2H),  
3.69 (s, 1H), 3.63-3.58 (m, 1H), 3.49 (ddd,  J = 10.8, 9.6, 4.8Hz, 1H), 2.23-2.21 (m, 2H),  
2.05-1.91 (m, 2H),  1.74 (ddd,  J = 12.6, 11.4, 2.4Hz, 1H), 1.58-1.23 (m, 8H), 1.19 (d,  J 
= 6.6 Hz, 3H), 1.11 (d,  J = 6 Hz, 3H); 13C NMR (150 MHz, CD3OD) δ 169.9, 148.8, 
122.4, 96.4, 71.3, 70.0, 68.8, 67.2, 36.9, 34.8, 31.9, 28.0, 25.2, 18.2, 16.9;  CIHRMS: 
Calculated for [C15H26O6Na+]: 325.1622, Found: 325.1627.  
 
 
(8R,E)-8-(3,5-dihydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-N-(2-(2-(7-
(dimethylamino)-2-oxo-2H-chromen-4-yl)acetamido)ethyl)non-2-enamide (I-23) 
O
O
O
N
O
H
N
N
H
O
O
H3C
OH
OH
CH3
 
 
To a solution of amine (6 mg, 0.015 mmol) in THF (0.125 ml), was added Et3N (3 μL), 
HBTU (4.7 mg, 0.0125 mmol) and acid I-1 (5 mg, 0.0125 mmol). The reaction mixture 
was stirred overnight, concentrated under reduced pressure, purified using silica gel flash 
chromatography eluting with 10% MeOH/EtOAc to give amide I-23 (5 mg, 0.00872 
mmol, 69%); Rf (10% MeOH/EtOAc) = 0.55; [α]25D = - 30 (c = 0.5, MeOH);  IR (thin 
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 film, cm-1), 3781, 3358, 2933, 2252, 2149, 1997, 1699, 1615, 1531, 1453, 1403, 1252, 
1128, 1030, 983, 834; 1H NMR (600 MHz, CD3Cl) δ 7.32 (d , J = 9 Hz, 1H),  6.92 (dt, J 
= 15.6, 7.2 Hz, 1H), 6.77-6.71 (m, 1H), 6.54 (d, J = 3Hz, 1H), 6.03 (s, 1H),  5.81 (dt, J = 
15.6, 1.2 Hz, 1H), 4.63 (s, 1H), 3.79-3.78 (m, 1H),  3.70 (s, 1H), 3.67-3.60 (m, 2H), 
3.41(t, J = 6.0 Hz, 2H), 3.34 (t, J = 6.0 Hz, 2H), 3.06 (s, 6H), 2.26-2.22 (m, 1H), 1.97-
1.88 (m, 2H),  1.78-1.73 (m, 1H), 1.58-1.54 (m, 1H), 1.50-1.45 (m, 2H), 1.43-1.38 (m= 
1H), 1.28 (m, 2H),  1.20 (d,  J = 6.6 Hz, 3H), 1.11 (d,  J = 6 Hz, 3H); 13C NMR (150 
MHz, CD3OD) δ 170.3, 167.9, 163.1, 156.0, 153.6, 151.4, 149.2, 144.6, 125.7, 123.5, 
121.9, 109.5, 108.7, 97.6, 96.4, 71.2, 70.0, 68.8, 67.2, 39.3, 39.0, 38.7, 36.9, 34.8, 31.8, 
28.1, 28.0, 25.2, 18.1, 16.9;  CIHRMS: Calculated for [C30H43O8N3Na+]: 596.2942, 
Found: 596.2948.  
 
 
(2S, 6R)-6-(benzyloxy)-2-methyl-2H-pyran-3(6H)-one (II-20)3 
 
 
To a solution of Boc-protected pyranone II-23 (22.8 g, 100 mmol) and benzyl alcohol 
(21.6 g, 200.0 mmol) in dry CH2Cl2 (100 mL) was added Pd2(DBA)3•CHCl3 (257 mg, 
0.25 mol% Pd) and PPh3 (262 mg, 0.5 mol%) at 0 ºC under argon atmosphere. After 
stirring for 2 h from 0 oC to room temperature, the reaction mixture was quenched with of 
                                                 
3 Guo, H.; O’Doherty, G. A. Angew. Chem. Int. Ed. 2007, 46, 5206-5208. 
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 saturated aqueous NaHCO3 (300 mL), extracted with Et2O (300 mL × 3), dried over 
Na2SO4, and concentrated under reduced pressure. The crude product was purified using 
silica gel flash chromatography eluting with 4% EtOAc/hexane to give Bn-ether II-20 
(19.6 g, 90 mmol, 90%); colorless oil; Rf = 0.71 (30% EtOAc/hexane); [α]25D = +46 (c = 
1.11, CH2Cl2); IR (thin film, cm-1) 2985, 2939, 2873, 1697, 1231, 1022, 953; 1H NMR 
(270 MHz, CDCl3) δ 7.32-7.38 (m, 5H), 6.85 (dd, J = 10.2, 3.6 Hz, 1H), 6.11 (d, J = 10.2 
Hz, 1H), 5.28 (d, J = 3.6 Hz, 1H), 4.86 (d, J = 11.4 Hz, 1H), 4.70 (d, J = 11.4 Hz, 1H), 
4.57 (q, J = 6.7 Hz, 1H), 1.36 (d, J = 6.7 Hz, 3H); 13C NMR (67.5 MHz, CDCl3) δ 197.0, 
143.5, 137.2, 126.6, 128.2, 128.1, 127.5, 92.4, 70.8, 70.5, 15.3; HRMS (CI): Calculated 
for [C13H14O3+Na]+: 241.0835, found: 241.0843. 
 
 
(1R,2R,4S,6S)-2-(benzyloxy)-4-methyl-3,7-dioxabicyclo-[4.1.0]heptan-5-one (II-24). 
O
O
OBn
O
 
 
 To the solution of pyranone II-20 (220 mg, 1.0 mmol) in methanol (3 ml) at 0 °C, 30% 
aqueous hydrogen peroxide (0.26 ml, 2.5 mmol) was added dropwise, followed by 
aqueous sodium hydroxide (0.1 ml, 0.5 M). The reaction mixture was stirred at RT for 4 
h and then the reaction mixture was extracted with diethyl ether. The extracts were 
washed with saturated aqueous NaHCO3, dried over Na2SO4 and concentrated under 
reduced pressure. The crude product was purified using silica gel flash chromatography 
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 to give epoxide II-24 (207 mg, 0.88 mmol, 88%) as colorless oil: Rf (20% 
EtOAc/hexane) 0.47; [α]20D = −59.3 (c 1.0, MeOH); IR (thin film, cm-1) υ 3034, 2937, 
1726, 1455, 1369, 1256, 1146, 1060, 996, 859, 699; 1H NMR (270 MHz, CDCl3) δ 7.36 
(m, 5H), 5.30 (d, J = 1.2 Hz, 1H), 4.80 (d, J = 11.6 Hz, 1H), 4.64 (d, J = 11.6 Hz, 1H), 
4.17 (q, J = 6.9 Hz, 1H), 3.59 (dd, J = 3.9, 1.2 Hz, 1H), 3.46 (d, J = 4.0 Hz, 1H), 1.38 (d, 
J = 6.9 Hz, 3H); 13C NMR (67.5 MHz, CDCl3) δ 203.1, 136.6, 128.7, 128.4, 128.2, 93.3, 
93.2, 72.0, 70.8, 53.8, 53.1; HRMS: Calculated for [C13H14O4+Na]+: 257.0784, Found: 
257.0784. 
 
 
(1R,2R,4S,5S,6R)-2-(benzyloxy)-4-methyl-3,7-dioxabicyclo[4.1.0]heptan-5-ol (II-18).  
OHO
OBn
O  
 
To a solution of epoxide II-20 (672 mg, 2.87 mmol) in CH2Cl2 (3 mL) was added a 
solution of CeCl3/MeOH (3 mL, 0.4 M). The mixture was cooled to −78 °C. NaBH4 (130 
mg, 3.4 mmol) was added and the reaction mixture was stirred at −78 to −20 °C for 4 h. 
The reaction was quenched with saturated aqueous NaHCO3. The mixture was extracted 
with Et2O, and the organic layer was washed with saturated brine, dried over Na2SO4 and 
concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography to give epoxide II-18 (576 mg, 2.44 mmol, 85%) as colorless oil: 
Rf  (80% EtOAc/hexane) 0.47; [α]20D −62.8 (c 1.0, MeOH); IR (thin film, cm-1) υ 3430, 
2911, 1454, 1370, 1241, 1114, 1054, 980, 848, 805, 738, 698; 1H NMR (600 MHz, 
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 CDCl3) δ 7.34 (m, 5H), 5.03 (s, 1H), 4.75 (d, J = 11.4 Hz, 1H), 4.57 (d, J = 11.4 Hz, 1H), 
3.58 (dq, J = 9.0, 6.0 Hz, 1H), 3.45 (d, J = 9.0 Hz, 1H), 3.23 (d, J = 3.6 Hz, 1H), 3.12 (d, 
J = 3.6 Hz, 1H), 1.21 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 137.5, 128.8, 
128.4, 128.3, 94.5, 70.3, 68.0, 65.8, 56.1, 50.5, 18.5; HRMS: Calculated for 
[C13H16O4+H]+: 237.1121, Found: 237.1121. 
 
 
 (2R,3R,4S,5R,6S)-2-(benzyloxy)-6-methyltetrahydro-2H-pyran-3,4,5-triol (II-25).  
OHO
OH
OBn
OH
 
 
To a round bottom flask was added epoxide II-18 (13 mg, 0.055 mmol), HOAc (0.5 ml) 
and Sc(OTf)3 (5 mg, 0.01 mmol). The reaction solution was stirred for 1 h at RT. The 
reaction mixture was diluted with EtOAc and saturated aqueous NaHCO3 was added at 0 
°C. The mixture was extracted with EtOAc, and the EtOAc layer was washed with 
saturated brine, dried over Na2SO4 and concentrated under reduced pressure. The crude 
product was dissolved in THF/H2O (0.4 mL, 3:1) at RT, and lithium hydroxide 
monohydrate (5 mg, 0.13 mmol) was added to the solution. The reaction mixture was 
stirred at RT for 5 h. Then the reaction mixture was directly loaded onto silica gel column 
to give α-6-deoxy-altrose II-25 (9.6 mg, 0.038 mmol, 69%) as colorless oil: Rf (EtOAc) 
0.49; [α]20D −73.3 (c 1.0, MeOH); IR (thin film, cm-1) υ 3384, 2930, 1455, 1375, 1259, 
1127, 1061, 1014, 970, 852, 737, 698; 1H NMR (600 MHz, CDCl3) δ 7.35 (m, 5H), 4.81 
(s, 1H), 4.75 (d, J = 12 Hz, 1H), 4.55 (d, J = 12 Hz, 1H), 3.98 (dd, J = 3.6, 1.8 Hz, 1H), 
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 3.89 (dd, J = 3.6, 3.6 Hz, 1H), 3.79 (dq, J = 9.0, 6.0 Hz, 1H), 3.51 (dd, J = 9.6, 3.6 Hz, 
1H), 1.21 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 136.5, 128.9, 128.6, 128.4, 
99.0, 70.9, 70.1, 69.8, 69.6, 65.8, 17.8; HRMS: Calculated for [C13H18O5+Na]+: 
277.1046, Found: 277.1047. 
 
 
(2R,3S,4S,5S,6S)-2-(benzyloxy)-4-bromo-6-methyltetrahydro-2H-pyran-3,5-diol (II-
27).  
OHO
OBn
O  
 
To a round bottom flask was added epoxide II-18 (96 mg, 0.41 mmol), HOAc (0.5 mL) 
and MgBr2•Et2O (106 mg, 0.41 mmol). The reaction mixture was stirred at RT for 1 h. 
The reaction mixture was diluted with EtOAc and saturated aqueous NaHCO3 was added 
at 0 °C. The mixture was extracted with EtOAc, and the organic layer was washed with 
saturated brine, dried over Na2SO4 and concentrated under reduced pressure. The crude 
product was purified using silica gel flash chromatography to give bromide II-27 (137 
mg, 0.4 mmol, 98%) as colorless oil: Rf (50% EtOAc/hexane) 0.28; [α]25D −57.2 (c 1.0, 
MeOH); IR (thin film, cm-1) υ 3402, 2919, 1718, 1454, 1245, 1055, 994, 739; 1H NMR 
(600 MHz, CDCl3) δ 7.34 (m, 5H), 4.80 (d, J = 12.0 Hz, 1H), 4.72 (d, J = 3.6 Hz, 1H), 
4.54 (d, J = 12.0 Hz, 1H), 4.35 (dd, J = 6.0, 3.6 Hz, 1H), 4.12 (dd, J = 6.0, 3.6 Hz, 1H), 
4.08 (qd, J = 6.6, 6.6 Hz, 1H), 3.67 (dd, J = 6.0, 3.6 Hz, 1H), 1.27 (d, J = 6.6 Hz, 3H); 
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 13C NMR (150 MHz, CDCl3) δ 137.2, 128.4, 127.8, 127.7, 99.0, 71.8, 70.4, 69.8, 68.5, 
56.0, 16.9; HRMS: Calculated for [C13H17BrO4+Na]+: 339.0202, Found: 339.0204. 
 
(2R,3R,5R,6S)-2-(benzyloxy)-6-methyltetrahydro-2H-py-ran-3,5-diol (II-26).  
OHO
OH
OBn
 
 
To a solution of bromide II-27 (17 mg, 0.05 mmol) in dry toluene (0.5 ml), 
tris(trimethylsilyl)silane (TTMSS) (0.033 ml, 0.1 mmol) and AIBN (4 mg, 0.025 mmol) 
was added at 0 °C. At this stage reaction mixture was degassed using freeze-pump-thaw 
technique three times. Then the reaction mixture was stirred at 80 °C for 4 h under Ar. 
The mixture was directly loaded onto silica gel column for purification to give α-
ascarylose II-28 (10 mg, 0.038 mmol, 76%) as colorless oil.     
 
Alternative procedure for (II-26): To a round bottom flask was added epoxide 18 (23 
mg, 0.094 mmol), THF (0.5 ml) and LiAlH4 (7.1 mg, 0.19 mmol) at 0 °C. The reaction 
solution was stirred for 30 min at 0 °C. Water was added dropwise to quench the 
reaction, then the mixture was extracted with EtOAc. The organic layer was washed with 
saturated brine, dried over Na2SO4 and concentrated under reduced pressure. The crude 
product was purified using silica gel flash chromatography to give α-ascarylose 26 (19 
mg, 0.08 mmol, 85%) as colorless oil: Rf (60% EtOAc/hexane) 0.17; [α]20D −90.8 (c 1.0, 
MeOH); IR (thin film, cm-1) υ 3405, 2935, 1718, 1686, 1256, 1123, 1080, 995; 1H NMR 
(600 MHz, CDCl3) δ 7.34 (m, 5H), 4.74 (d, J = 12.0 Hz, 1H), 4.68 (s, 1H), 4.53 (d, J = 
81
 12.0 Hz, 1H), 3.91 (dd, J = 4.8, 3.0 Hz, 1H), 3.70 (dq, J = 9.6, 6.0 Hz, 1H), 3.61 (ddd, J = 
10.8, 9.0, 4.2 Hz, 1H), 2.09 (ddd, J = 13.2, 3.6, 3.6 Hz, 1H), 1.89 (ddd, J = 13.2, 11.4, 3.0 
Hz, 1H), 1.30 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 137.4, 128.5, 127.9, 
127.8, 98.2, 69.8, 69.0, 68.8, 68.1, 35.2, 17.7; HRMS: Calculated for [C13H18O4+H]+: 
239.0202, Found: 239.0204. 
 
 
(+/-) undec-3-yn-2-ol (III-22a) 
OH
 
 
A solution of n-BuLi in hexane (48 mL, 121 mmol) was added dropwise to the solution 
of 1-nonyne III-22 (20 mL, 121 mmol) in dry THF (120 mL) at -78 oC under argon. 
After 30 min, acetaldehyde (6.7 mL, 120 mmol) was added. The reaction was stirred for 
10 min at 0 oC and then the resulting solution was warmed to room temperature for 50 
min. Additional CH2Cl2 (80 ml) was added to the reaction mixture followed by addition 
of 80 ml saturated aqueous NH4Cl (80 ml). The aqueous phase was separated and 
extracted with CH2Cl2. The combined organic layers were washed with brine, dried 
(Na2SO4), filtered and concentrated. Chromatography on silica gel (10% EtOAc/hexane) 
gave alcohol III-22a (16.8 g, 96.8 mmol, 80%) 4  as a colorless oil; Rf (20% 
EtOAc/hexane) = 0.32;  IR (thin film, cm-1), 3345, 2930, 2857, 2227, 1467, 1156, 1078; 
1H NMR (600 MHz, CDCl3) δ 4.48 (qdt, J = 6.6, 4.8, 1.8 Hz 1H), 4.15 (td, J = 7.2, 1.8 
                                                 
4 James, S. A.; Edward, R. D.; Antonio, Z. J. Org. Chem. 1989.54, 5854-5  
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 Hz, 2H), 1.93 (d, J = 4.8 Hz, 1H), 1.46 (tt, J = 7.2, 7.2 Hz, 2H), 1.38 (d, J = 6.6 Hz, 3H), 
1.35-1.25 (m, 8H), 0.85 (t, J = 7.2 Hz, 3H);  13C NMR (150 MHz, CD3Cl) δ 84.9, 82.5, 
58.8, 31.9, 29.0, 28.9, 28.8, 25.0, 22.8, 18.8, 14.2.  
 
 
undec-3-yn-2-one (III-21) 
O
 
    
To a solution of alcohol III-22a (22 g, 131 mmol) in THF (100 mL) at room temperature 
was added activated MnO2 (65 g). The reaction mixture was stirred for 24 h and then 
filtered through celite and concentrated under pressure to give ketone III-21  (18.7 g, 116 
mmol, 86%)5 as a colorless oil. Rf (20% EtOAc/hexane) = 0.70; IR (thin film, cm-1), 
2926, 2213, 1750, 1358, 1228;  1H NMR (600 MHz, CDCl3) δ 2.35 (t, J = 7.2 Hz, 1H), 
2.32 (s, 3H), 1.57 (tt, J = 7.2, 7.2 Hz, 2H), 1.41-1.26 (m, 8H), 0.89 (t, J = 7.2, 3H);  13C 
NMR (150 MHz, CD3Cl) δ 184.9, 94.2, 81.4, 32.7, 31.6, 28.8, 28.7, 27.7, 22.6, 18.9, 
14.0. 
 
 
(R)-undec-3-yn-2-ol (III-23) 
OH
 
                                                 
5 Marshall, J. A.; Robinson, E. D.; Antonio, Z. J. Org. Chem. 1989.54, 5854-5  
83
           
To a flask was added ketone III-21 (0.136 g, 0.82 mmol), CH2Cl2 (0.42 mL), formic 
acid/Et3N (5:4, 1.5 mL) and Noyori asymmetric transfer hydrogenation catalyst (S)-
Ru(η6-mesitylene)-(R,R)-TsDPEN (2.5 mg, 0.0016 mmol, 0.2 mol%). The resulting 
solution was stirred at room temperature for 24 h, water was added to dilute and the 
reaction mixture was extracted with saturated NaHCO3, dried over Na2SO4 and 
concentrated under reduced pressure to afford a crude oil. The crude product was 
purified by silica gel flash chromatography eluting with 10% EtOAc/hexane to give 
alcohol III-23 (0.118 g, 0.71 mmol, 86%)6 as a colorless oil. Rf (20% Et2O/hexane) = 
0.32; [α]25D = +18 (MeOH); IR (thin film, cm-1), 3303, 2926, 2856, 2253, 1458, 1376, 
1076, 889; 1H NMR (600 MHz, CDCl3) δ 4.48 (qdt, J = 6.6, 4.8, 1.8 Hz 1H), 4.15 (td, J 
= 7.2, 1.8 Hz, 2H), 1.93 (d, J = 4.8 Hz, 1H), 1.46 (tt, J = 7.2, 7.2 Hz, 2H), 1.38 (d, J = 
6.6 Hz, 3H), 1.35-1.25 (m, 8H), 0.85 (t, J = 7.2 Hz, 3H);  13C NMR (150 MHz, CD3Cl) δ 
84.9, 82.5, 58.8, 31.9, 29.0, 28.9, 28.8, 25.0, 22.8, 18.8, 14.2.  
 
 
(R)-undec-10-yn-2-ol (III-23a) 
OH
 
            
A 30% suspension of KH in mineral oil (171 mg, 4.28 mmol) was washed three times 
under Argon with dry ether and then the excess solvent was removed under vacuum, Dry 
1,3-diaminopropane (1.14 mL) was added with cooling (15 oC). After the mixture was 
                                                 
6 Marshall, J. A.; Wang, X.; J. Org. Chem. 1990.55, 2995-6 
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 stirred for 1 h, the alkynol III-23 (172 mg, 1.02 mmol) was added dropwise (10 min) at 
(10-15 oC) to the mixture and the resulting slurry was stirred further under argon for 2 
hrs. With cooling (0 oC), water (11 mL) was added dropwise and the mixture was 
extracted with ether, the combined extracts were washed with 1 N HCl, saturated aqueous 
sodium bicarbonate and brine, and then dried with anhydrous sodium sulfate. Flash 
chromatography gave (R)-undec-10-yn-2-ol III-23a (143 mg, 85%) as a colorless oil: 
[α]25D =  - 4 (CH2Cl2); Rf (30% EtOAc/Hexane)= 0.32; IR (thin film, cm-1) 3296, 2931, 
2856, 2116, 1611, 1512, 1244, 1034, 821; 1H NMR (600 MHz, CDCl3) δ 3.79 (t, J = 5.4 
Hz, 1H), 2.18 (td, J = 7.2, 2.4 Hz, 2H), 1.93 (t, J = 2.4 Hz, 1H), 1.57~1.25 (m, 12H), 1.18 
(d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 84.7, 68.2, 68.1, 39.3, 29.5, 29.0, 
28.7, 28.4, 25.7, 23.5, 18.4; ESI HRMS Calcd for [C11H20O+H]+: 169.1587, Found: 
169.1586. 
 
 
(R)-tert-butyldimethyl(undec-10-yn-2-yloxy)silane (III-24) 
OTBS
 
                                   
To a magnetically stirred solution of alcohol III-23a (300 mg, 1.79 mmol) and imidazole 
(304 mg, 4.48 mmol) in dry CH2Cl2 (3 mL) was added dropwise TBSCl (281 mg, 1.87 
mmol) at 0 oC. The reaction mixture was warmed to room temperature and stirred 
overnight. Water was added and then the reaction mixture was extracted with Et2O, dried 
with Na2SO4 and evaporated under reduced pressure to leave the crude product which 
was then purified using silica gel flash chromatography to give alkyne III-24 (490 mg, 
85
 1.74 mmol, 97%) as a colorless oil. Rf (5% Et2O/hexane) = 0.68; [α]25D = - 13 (CH2Cl2); 
IR (thin film, cm-1), 3314, 2929, 2857, 2253, 1463, 1374, 1254, 1134, 1069, 1005, 834, 
807, 773; 1H NMR (600 MHz, CDCl3) δ 3.76 (qdd, J = 6.0, 6.0, 6.0 Hz, 1H), 2.16 (td, J = 
6.6, 2.4 Hz, 2H), 1.92 (t, J = 2.4 Hz, 1H), 1.58-1.26 (m, 12H), 1.11 (d, J = 6.0 Hz, 3H), 
0.88 (s, 9H), 0.04 (s, 6H);  13C NMR (150 MHz, CD3Cl) δ 84.8, 68.6, 68.0, 39.7, 29.5, 
29.2, 29.0, 28.7, 28.5, 26.0, 25.7, 23.8, 18.4, 18.2, - 4.37, - 4.69 ; ESI HRMS Calcd for 
[C17H34OSi+H]+: 283.2452, Found: 283.2453. 
 
 
(R)-ethyl 11-(tert-butyldimethylsilyloxy)dodec-2-ynoate (III-24a) 
OTBS
O
OEt
 
              
To a solution of alkyne III-24 (358 mg, 1.27 mmol) in THF (2.5 mL) at -78 oC was 
added n-BuLi (0.5 mL, 1.4 mmol) dropwise and the reaction mixture was stirred for 1h. 
Ethylchloroformate (0.15 mL, 1.55 mmol) was added at -78 oC and the reaction mixture 
was stirred for another 1h. The reaction mixture was then warmed to 0 oC and stirred for 
15 min. The reaction was quenched with saturated aqueous NH4Cl (10 mL) and then 
extracted with Et2O, washed with brine and dried with Na2SO4. Evaporated under 
reduced pressure gave the crude product which was then purified using silica gel flash 
chromatography to give ester III-24a (373 mg, 1.05 mmol, 83%) as a colorless oil. Rf 
(10% Et2O/hexane) = 0.65; [α]25D = - 7 (CH2Cl2); IR (thin film, cm-1), 2930, 2857, 2235, 
1713, 1366, 1246, 1134, 1070, 1005, 834, 807, 773, 752; 1H NMR (600 MHz, CDCl3) δ 
86
 4.20 (q, J = 7.2 Hz, 2H), 3.75 (qdd, J = 6.0, 6.0, 6.0 Hz, 1H), 2.31 (t, J = 7.2 Hz, 2H), 
1.57 (tt, J = 7.2, 7.2 Hz, 2H), 1.44-1.22 (m, 10H), 1.30 (t, J = 7.2 Hz, 3H), 1.10 (d, J = 
6.0 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 3H), 0.03 (s, 3H);  13C NMR (150 MHz, CD3Cl) δ 
153.9, 89.4, 73.2, 68.6, 61.7, 39.7, 29.4, 29.0, 28.8, 27.5, 25.9, 25.7, 23.8, 18.6, 18.1, 
14.0, - 4.20, - 4.51; ESI HRMS Calcd for [C20H38O3Si+H]+: 355.2663, Found: 355.2665. 
 
 
 (R, 2E, 4E)-ethyl 11-(tert-butyldimethylsilyloxy)dodeca-2, 4-dienoate (III-25) 
OTBS
OEt
O
 
          
In to a round bottom flask were added ester III-24a (276 mg, 0.78 mmol), PPh3 (204 mg, 
0.78 mmol), phenol (73 mg, 0.78 mmol) and benzene (1.5 mL). The mixture was stirred 
at 50 oC for 12 h. The solution was diluted with ether (1 mL) and 1 N NaOH (1 mL). The 
layer was separated and the aqueous layer was extracted with ether. The combined 
organic layers were washed (water, brine), dried (Na2SO4) and concentrated. The residue 
was dissolved in ether (3 mL) and MeI (0.06 mL) was added to the solution. The reaction 
mixture was refluxed for 12 hrs. Then the solution was filtered, concentrated and purified 
by flash chromatography on silica gel to give diene III-25 (249 mg, 0.70 mmol) as a light 
yellow oil. Rf (10% Et2O/hexane) = 0.64; [α]25D = - 14 (CH2Cl2); IR (thin film, cm-1), 
2930, 2857, 2200, 1717, 1643, 1368, 1255, 1138, 1047, 1001, 836, 774; 1H NMR (600 
MHz, CDCl3) δ 7.25 (dd, J = 15.6, 10.2 Hz, 1H), 6.16 (dd, J = 15.0, 10.2 Hz, 1H), 6.11 
(dt, J = 15.0, 6.6 Hz, 1H), 5.77 (d, J = 15.6 Hz, 1H), 4.19 (q, J = 7.2 Hz, 2H), 3.76 (qdd, J 
= 6.0, 6.0, 6.0 Hz, 1H), 2.16 (dt, J = 6.6, 6.6 Hz, 2H), 1.44-1.26 (m, 8H), 1.29 (t, J = 7.2 
87
 Hz, 3H), 1.10 (d, J = 6.0 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 6H);  13C NMR (150 MHz, 
CD3Cl) δ 167.3, 145.1, 144.6, 128.4, 119.2, 68.6, 60.1, 39.6, 32.9, 29.2, 28.7, 26.0, 23.8, 
18.2, 14.3, - 4.40, - 4.69; ESI HRMS Calcd for [C20H38O3Si+H]+: 355.2663, Found: 
355.2664. 
 
 
(4R,5R,11R,E)-ethyl11-(tert-butyldimethylsilyloxy)-4,5-dihydroxydodec-2-enoate 
(III-19) 
OTBS OH
OH
O
OEt
 
                                    
In a round bottom flask were added t-BuOH (40 mL), water (40 mL), K3Fe(CN)6  (8.29 g, 
25.31 mmol), K2CO3 (3.49 g, 35.31 mmol), MeSO2NH2 (806 mg, 8.48 mmol), (DHQD)2-
PHAL (130 mg), and OSO4 (3 mg.). The reaction mixture was stirred at room temperature 
for about 15 min. and then cooled to 0 oC. To this solution was added diene III-25 (3.00 
g, 8.48 mmol) and the reaction was stirred at 0 oC overnight. The reaction was quenched 
with saturated aqueous sodium sulfite (30 mL) at room temperature and then extracted 
with ethyl acetate, washed with 2 N NaOH and brine to remove methanesulfonamide. 
After removal of solvents in vacuum, flash chromatography on silica gel gave diol III-19 
(2.70 g, 6.95 mmol, 82%) as a colorless oil. Rf (30% Et2O/hexane) = 0.40; [α]25D = - 14 
(CH2Cl2); IR (thin film, cm-1), 3406, 2932, 2859, 1720, 1463, 1370, 1256, 1177, 1047, 
836, 774; 1H NMR (600 MHz, CDCl3) δ 6.93 (dd, J = 15.6, 5.4 Hz, 1H), 6.14 (dd, J = 
15.6, 1.8 Hz, 1H), 4.21 (q, J = 7.2 Hz, 2H), 4.12 (ddd, J = 5.4, 5.4, 1.8 Hz, 1H), 3.76 
88
 (qdd, J = 6.0, 6.0, 6.0 Hz, 1H), 3.55 (ddd, J = 5.4, 4.2, 3.6 Hz, 1H), 1.54-1.25 (m, 10H), 
1.30 (t, J = 7.2 Hz, 3H), 1.11 (d, J = 6.0 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 6H); 13C NMR 
(150 MHz, CD3Cl) δ 166.2, 146.6, 122.6, 74.1, 74.0, 68.9, 60.6, 39.6, 33.1, 29.6, 25.9, 
25.7, 25.6, 23.8, 18.1, 14.2, - 4.42, - 4.75; ESI HRMS Calcd for [C20H40O5Si+H]+: 
389.2718, Found: 389.2719. 
 
 
(4S,5S,11R,E)-ethyl 11-(tert-butyldimethylsilyloxy)-4,5-dihydroxydodec-2-enoate 
(III-20) 
OTBS OH
OH
O
OEt
 
           
In a round bottom flask were added t-BuOH (2 mL), water (2 mL), K3Fe(CN)6  (649 mg, 
1.97 mmol), K2CO3 (272 mg, 1.97 mmol), MeSO2NH2 (71.8 mg, 0.65 mmol), (DHQ)2-
PHAL (10 mg), and OSO4 (4 mg.). The reaction mixture was stirred at room temperature 
for about 15 min. and then cooled to 0 oC. To this solution was added diene III-25 (233 
mg, 0.65 mmol) and the reaction was stirred at 0 oC overnight. The reaction was 
quenched with saturated aqueous sodium sulfite (3 mL) at room temperature and then 
extracted with ethyl acetate, washed with 2 N NaOH, and brine to remove 
methanesulfonamide. After removal of solvents in vacuum, flash chromatography on 
silica gel gave diol III-20 (202 mg, 0.52 mmol, 80%) as a colorless oil. Rf (30% 
Et2O/hexane) = 0.40; [α]25D = - 31 (CH2Cl2); IR (thin film, cm-1), 3402, 2930, 2857, 
1721, 1658, 1370, 1254, 1133, 1040, 835, 774;  1H NMR (600 MHz, CDCl3) δ 6.91 (dd, J 
89
 = 15.6, 4.8 Hz, 1H), 6.14 (dd, J = 15.6, 1.2 Hz, 1H), 4.17 (q, J = 7.2 Hz, 2H), 4.11 (ddd, J 
= 5.4, 5.4, 1.2 Hz, 1H), 3.76 (qdd, J = 6.0, 6.0, 6.0 Hz, 1H), 3.53 (ddd, J = 4.8, 4.8, 4.8 
Hz, 1H), 1.54-1.25 (m, 10H), 1.28 (t, J = 7.2 Hz, 3H), 1.11 (d, J = 6.0 Hz, 3H), 0.87 (s, 
9H), 0.03 (s, 3H), 0.02 (s, 3H); 13C NMR (150 MHz, CD3Cl) δ 166.4, 146.9, 122.4, 74.1, 
74.0, 68.6, 60.6, 39.6, 33.1, 29.6, 25.9, 25.7, 25.6, 23.8, 18.1, 14.2, - 4.43, - 4.74; ESI 
HRMS Calcd for [C20H40O5Si+H]+: 389.2718, Found: 389.2720. 
 
 
 (E)-ethyl-3-((4R,5R)-5-((R)-6-hydroxyheptyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-
acrylate (III-19a) 
O
OEt
OH O O
 
                               
The monohydrate of p-toluenesulfonic acid (100 mg, 5.27 mmol) was added to a solution 
of diol III-19 (2.05 g, 5.27 mmol), 2,2-dimethyoxypropane (1.5 mL, 10.54 mmol) and 
CH2CH2 (4 mL). The solution was stirred for 5 h. The reaction mixture was diluted with 
CH2CH2 and washed with 1 N NaOH. The organic layer was dried over Na2SO4, filtered 
and concentrated to give the crude product. The crude product was further purified by 
column chromatography to give alcohol III-19a (1.33 g, 4.25 mmol, 81%) as a colorless 
oil. Rf (30% Et2O/hexane) = 0.40; [α]25D = + 24 (CH2Cl2); IR (thin film, cm-1), 3473, 
2934, 2861, 1722, 1661, 1371, 1259, 1174, 1036, 979;  1H NMR (600 MHz, CDCl3) δ 
6.85 (dd, J = 15.6, 6.0 Hz, 1H), 6.10 (dd, J = 15.6, 1.2 Hz, 1H), 4.20 (q, J = 7.2 Hz, 2H), 
4.11 (ddd, J = 6.6, 6.0, 1.2 Hz, 1H), 3.78 (qdd, J = 6.0, 6.0, 6.0 Hz, 1H), 3.72 (ddd, J = 
90
 6.6, 5.4, 3.0 Hz, 1H), 1.61-1.24 (m, 10H), 1.43 (s, 3H), 1.40 (s, 3H), 1.29 (t, J = 7.2 Hz, 
3H), 1.17 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CD3Cl) δ 166.0, 144.1, 122.8, 109.4, 
80.6, 80.2, 68.0, 60.6, 39.2, 31.9, 29.5, 27.2, 26.7, 25.9, 25.5, 23.5, 14.2; ESI HRMS 
Calcd for [C17H30O5+Na]+: 337.1986, Found: 337.1987. 
 
 
(E)-ethyl-3-((4S,5S)-5-((R)-6-hydroxyheptyl)-2,2-dimethyl-1,3-dioxolan-4-yl)acrylate 
(III-20a) 
O
OEt
OH O O
 
           
The monohydrate of p-toluenesulfonic acid (2.3 mg, 0.012 mmol) was added to a solution 
of diol III-20 (95.5 mg, 0.246 mmol), 2,2-dimethyoxypropane (0.06 mL, 0.492 mmol) 
and CH2CH2 (0.2 mL). The solution was stirred for 5 h. The reaction mixture was diluted 
with CH2CH2 and washed with 1 N NaOH. The organic layer was dried over Na2SO4, 
filtered and concentrated to give the crude product. The crude product was further 
purified by column chromatography to give alcohol III-20a (60 mg, 0.19 mmol, 78%) as 
a colorless oil. Rf (30% Et2O/hexane) = 0.40; [α]25D = - 20 (CH2Cl2); IR (thin film, cm-1), 
3443, 2934, 2860, 1722, 1662, 1460, 1371, 1261, 1173, 1036, 979, 877;  1H NMR (600 
MHz, CDCl3) δ 6.84 (dd, J = 15.6, 6.0 Hz, 1H), 6.10 (dd, J = 15.6, 1.2 Hz, 1H), 4.20 (q, J 
= 7.2 Hz, 2H), 4.13 (ddd, J = 8.4, 6.0, 1.2 Hz, 1H), 3.78 (qdd, J = 6.0, 6.0, 6.0 Hz, 1H), 
3.72 (ddd, J = 8.4, 6.0, 6.0 Hz, 1H), 1.61-1.27 (m, 10H), 1.42 (s, 3H), 1.40 (s, 3H), 1.29 
(t, J = 7.2 Hz, 3H), 1.17 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CD3Cl) δ 166.0, 144.1, 
91
 122.7, 109.3, 80.5, 80.2, 68.0, 60.6, 39.1, 31.9, 29.5, 27.2, 26.6, 25.9, 25.5, 23.5, 14.2; 
ESI HRMS Calcd for [C17H30O5+Na]+: 337.1986, Found: 337.1987. 
 
 
(E)-3-((4R,5R)-5-((R)-6-hydroxyheptyl)-2,2-dimethyl-1,3-dioxolan-4-yl)acrylic acid 
(III-19b) 
O
OH
OH O O
 
              
LiOH (452 mg, 10.78 mmol) was added to a solution of alcohol III-19a (1.35 g, 4.31 
mmol), THF (4 mL) and H2O (1 mL). The reaction mixture was stirred for 5 h, then 
diluted with CH2CH2 and washed with 1 N HCl and brine. The organic layer was dried 
over Na2SO4, filtered and concentrated to give the crude product. The crude product was 
further purified by column chromatography to give acid III-19b (1.12 g, 3.92 mmol, 
91%) as a colorless oil. Rf (50% Et2O/hexane) = 0.26; [α]25D = + 22 (CH2Cl2); IR (thin 
film, cm-1), 3450, 2933, 2862, 1701, 1380, 1261, 1238, 1111, 1054, 980;  1H NMR (600 
MHz, CDCl3) δ 6.96 (dd, J = 15.6, 5.4 Hz, 1H), 6.13 (dd, J = 15.6, 1.2 Hz, 1H), 4.17 
(ddd, J = 8.4, 5.4, 1.2 Hz, 1H), 3.80 (qdd, J = 6.0, 6.0, 6.0 Hz, 1H), 3.72 (ddd, J = 8.4, 
6.0, 6.0 Hz, 1H), 1.63-1.32 (m, 10H), 1.44 (s, 3H), 1.41 (s, 3H), 1.18 (d, J = 6.0 Hz, 3H); 
13C NMR (150 MHz, CD3Cl) δ 170.3, 146.6, 121.8, 109.5, 80.5, 80.1, 68.2, 39.0, 31.9, 
29.5, 27.2, 26.6, 25.9, 25.5, 23.4; ESI HRMS Calcd for [C15H25O5+H]+: 287.1853, 
Found: 287.1854. 
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(E)-3-((4S,5S)-5-((R)-6-hydroxyheptyl)-2,2-dimethyl-1,3-dioxolan-4-yl)acrylic acid 
(III-20b) 
O
OH
OH O O
 
               
LiOH (19.4 mg, 0.463 mmol) was added to a solution of alcohol III-20a (58 mg, 0.185 
mmol), THF (1.7 mL) and H2O (0.3 mL). The reaction mixture was stirred for 5 h, then 
diluted with CH2CH2 and washed with 1 N HCl and brine. The organic layer was dried 
over Na2SO4, filtered and concentrated to give the crude product. The crude product was 
further purified by column chromatography to give acid III-20b (48 mg, 0.167 mmol, 
90%) as a colorless oil. Rf (50% Et2O/hexane) = 0.26; [α]25D = - 22 (CH2Cl2); IR (thin 
film, cm-1), 3311, 2934, 2860, 1702, 1373, 1240, 1169, 1052, 980, 863;  1H NMR (600 
MHz, CDCl3) δ 6.95 (dd, J = 15.6, 5.4 Hz, 1H), 6.13 (dd, J = 15.6, 1.2 Hz, 1H), 4.17 
(ddd, J = 8.4, 5.4, 1.2 Hz, 1H), 3.80 (qdd, J = 6.0, 6.0, 6.0 Hz, 1H), 3.73 (ddd, J = 8.4, 
6.0, 6.0 Hz, 1H), 1.63-1.32 (m, 10H), 1.44 (s, 3H), 1.41 (s, 3H), 1.18 (d, J = 6.0 Hz, 3H); 
13C NMR (150 MHz, CD3Cl) δ 170.3, 146.6, 121.8, 109.5, 80.5, 80.1, 68.2, 39.0, 32.0, 
29.5, 27.2, 26.6, 25.9, 25.5, 23.4; ESI HRMS Calcd for [C15H26O5+H]+: 287.1853, 
Found: 287.1854. 
 
 
 (3aR,8R,13aR,E)-2,2,8-trimethyl-9,10,11,12,13,13a-hexahydro-3aH-[1,3]dioxolo[4,5-
e][1]oxacyclododecin-6(8H)-one (III-19c) 
93
 O
O
O
O  
                             
 
(3aR,8R,13aR,Z)-2,2,8-trimethyl-9,10,11,12,13,13a-hexahydro-3aH-[1,3]dioxolo[4,5-
e][1]oxacyclododecin-6(8H)-one (III-19d) 
O
O
O
O
 
                                 
To a solution of acid III-19b (47.5 mg, 0.17 mmol) and Et3N (0.028 mL, 0.2 mmol) in 
THF (0.83 mL) was added 2,4,6-trichlorobenzoyl chloride (0.029 mL, 0.18 mmol) 
dropwise. The reaction mixture was stirred at room temperature for 2 h, followed by 
dilution with dry toluene (20 mL) and added dropwise to a refluxing solution of DMAP 
(646 mg, 5.3 mmol) in dry toluene (50 mL). After addition, the mixture was refluxed for 
10 h and then concentrated in vacuum. The residue was dissolved in EtOAc (30 mL) and 
washed with 1 N HCl (20 mL), saturated NaHCO3, brine, dried over Na2SO4, filtered and 
evaporated. The residue was purified by flash chromatography on silica gel to give the 
macrolactone III-19c (28.5 mg, 0.10 mmol, 60%)7 and macrolactone III-19d (4.74 mg, 
0.017 mmol, 10%).  
                                                 
7 These known compounds were characterized based on the comparison of 1H and 13C NMR data with 
the published ones: Chou, C.-Y. Hou, D.-R. J. Org. Chem. 2006, 71, 9887. 
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 III-19c: colorless oil; Rf (10% Et2O/hexane) = 0.33; [α]25D = + 6 (MeOH); IR (thin film, 
cm-1), 2982, 2934, 2866, 1718, 1463, 1371, 1252, 1163, 1050, 988, 857;  1H NMR (600 
MHz, CDCl3) δ 6.77 (dd, J = 15.6, 9.6 Hz, 1H), 6.22 (d, J = 15.6 Hz, 1H), 4.98 (dqd, J = 
9.6, 6.0, 4.2 Hz, 1H), 4.04 (dd, J = 9.6, 8.4 Hz, 1H), 3.91 (ddd, J = 11.4, 8.4, 4.2 Hz, 1H), 
1.96 (ddt, J = 13.8, 13.8, 4.2 Hz, 1H), 1.68 (dddd, J = 15.6, 9.0, 4.2, 1.8 Hz, 1H), 1.61-
1.35 (m, 8H), 1.44 (s, 3H), 1.42 (s, 3H), 1.30 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, 
CD3Cl) δ 166.6, 143.8, 125.9, 109.3, 80.4, 80.1, 75.4, 35.4, 29.5, 27.8, 27.1, 26.8, 25.1, 
24.9, 20.6; ESI HRMS Calcd for [C15H24O4 + Na]+: 291.1567, Found: 291.1568. 
 
III-19d: colorless oil; Rf (10% Et2O/hexane) = 0.41; [α]25D = + 53 (MeOH); IR (thin film, 
cm-1), 2982, 2939, 2866, 1718, 1380, 1206, 1047, 861;  1H NMR (600 MHz, CDCl3) δ 
5.97 (d, J = 12.0 Hz, 1H), 6.22 (dd, J = 12.0, 8.4 Hz, 1H), 5.08 (qdd, J = 6.0, 4.2, 3.0 Hz, 
1H), 4.87 (dd, J = 9.0, 9.0 Hz, 1H), 3.87 (ddd, J = 9.0, 5.4, 1.8 Hz, 1H), 1.85-1.41 (m, 
8H), 1.42 (s, 3H), 1.41 (s, 3H), 1.25 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CD3Cl) δ 
166.3, 139.1, 125.3, 109.3, 79.9, 75.1, 72.9, 30.8, 27.4, 27.2, 26.4, 25.4, 18.3, 18.2, 17.9; 
ESI HRMS Calcd for [C15H24O4+H]+: 269.1747, Found: 269.1748. 
 
 
(3aS,8R,13aS,E)-2,2,8-trimethyl-9,10,11,12,13,13a-hexahydro-3aH-[1,3]dioxolo[4,5-
e][1]oxacyclododecin-6(8H)-one (III-20c) 
O
O
O
O
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(3aS,8R,13aS,Z)-2,2,8-trimethyl-9,10,11,12,13,13a-hexahydro-3aH-[1,3]dioxolo[4,5-
e][1]oxacyclododecin-6(8H)-one (III-20d) 
O
O
O
O
 
                                
To a solution of acid III-20b (180 mg, 0.63 mmol) and Et3N (0.1 mL) in THF (3.1 mL) 
was added 2,4,6-trichlorobenzoyl chloride (0.11 mL, 0.65 mmol) dropwise. The reaction 
mixture was stirred at room temperature for 2h, followed by dilution with dry toluene (76 
mL) and added dropwise to a refluxing solution of DMAP (169 mg, 20.16 mmol) in dry 
toluene (190 mL). After addition, the mixture was refluxed for 10 h and then 
concentrated in vacuum. The residue was dissolved in EtOAc (100 mL) and washed with 
1 N HCl, saturated NaHCO3, brine, dried over Na2SO4, filtered and evaporated. The 
residue was purified by flash chromatography on silica gel to give the macrolactone III-
20c (108 mg, 0.39 mmol, 62%) and macrolactone III-20d (17 mg, 0.06 mmol, 10%)8  
III-20c: colorless oil. Rf (10% Et2O/hexane) = 0.56; [α]25D = + 30 (MeOH); IR (thin film, 
cm-1), 2983, 2937, 2870, 1717, 1465, 1230, 1163, 1057, 993, 848;  1H NMR (600 MHz, 
CDCl3) δ 6.86 (dd, J = 16.2, 6.6 Hz, 1H), 6.20 (dd, J = 16.2, 1.2 Hz, 1H), 5.02 (qdd, J = 
6.0, 5.4, 5.4 Hz, 1H), 4.11 (ddd, J = 7.8, 7.2, 1.2 Hz, 1H), 3.63 (ddd, J = 10.8, 8.4, 3.6 
Hz, 1H), 1.99-1.44 (m, 8H), 1.44 (s, 3H), 1.43 (s, 3H), 1.28 (d, J = 6.0 Hz, 3H); 13C NMR 
(150 MHz, CD3Cl) δ 166.8, 143.9, 123.7, 109.5, 83.0, 81.2, 73.1, 33.3, 29.0, 27.4, 27.3, 
                                                 
8 Sharma, G. V. M.; Reddy, J. J.; Reddy, K. L. Tetrahedron Lett. 2006, 47, 6531-6535. 
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 26.9, 25.3, 24.2, 20.2; ESI HRMS Calcd for [C15H24O4+Na]+: 291.1567, Found: 
291.1568. 
 
III-20d: colorless oil. Rf (10% Et2O/hexane) = 0.38; [α]25D = - 50 (MeOH); IR (thin film, 
cm-1), 2941, 2937, 1710, 1460, 1379, 1298, 1211, 1074, 1045, 993, 833;  1H NMR (600 
MHz, CDCl3) δ 6.14 (dd, J = 12.0, 8.4 Hz, 1H), 6.22 (dd, J = 12.0, 1.2 Hz, 1H), 5.31 
(ddd, J = 9.0, 8.4, 1.2 Hz, 1H), 4.89 (dqd, J = 12.0, 6.0, 3.6. Hz, 1H), 3.87 (dd, J = 8.4, 
6.0, Hz, 1H), 1.75-1.31 (m, 16H), 1.45 (s, 3H), 1.42 (s, 3H), 1.27 (d, J = 6.0 Hz, 3H); 13C 
NMR (150 MHz, CD3Cl) δ 165.8, 144.7, 123.7, 109.3, 79.5, 74.2, 74.0, 32.5, 27.3, 27.0, 
26.5, 24.4, 20.8, 20.1, 17.1; ESI HRMS Calcd for [C15H24O4+Na]+: 291.1567, Found: 
291.1568. 
 
 
(5R,6R,12R,E)-5,6-dihydroxy-12-methyloxacyclododec-3-en-2-one (Cladospolide C) 
O
OH
OH
O  
                                 
To a solution of lactone III-19c (140 mg, 0.50 mmol) and acetonitrile/water (2:1, v/v, 5 
mL) was added trifluoroacetic acid (3.75 mL) at 0 °C. Then the reaction was stirred at 
room temperature for another 2 h, diluted with ether acetate, washed with sat. 
NaHCO3(aq), dried over Na2SO4, filtered, and concentrated. The residue was purified by 
flash chromatography on silica gel to give the Cladospolide C (91 mg, 0.40 mmol, 80%) 
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 as a colorless solid.9 Rf (50% Et2O/hexane) = 0.27; Mp 91-92 °C; [α]25D = - 90 (MeOH); 
IR (thin film, cm-1), 3415, 2940, 2864, 1705, 1650, 1460, 1258, 1035; 1H NMR (600 
MHz, CDCl3) δ 6.81 (dd, J = 15.6, 9.0 Hz, 1H), 6.05 (d, J = 15.6 Hz, 1H), 4.98 (dqd, J = 
8.4, 6.0, 1.8 Hz, 1H), 3.98 (dd, J = 8.4, 7.8 Hz, 1H), 3.57 (ddd, J = 7.8, 7.8, 1.8 Hz, 1H), 
1.30 (d, J = 6.0 Hz, 3H) 1.69-1.11 (m, 10H); 13C NMR (150 MHz, CD3Cl) δ 166.7, 
145.3, 124.5, 77.5, 76.5, 74.3, 33.9, 32.1, 27.3, 24.5, 24.1, 20.8; ESI HRMS Calcd for 
[C12H20O4+H]+: 229.1434, Found: 229.1435. 
 
 
(5R, 6R, 12R, Z)-5,6-dihydroxy-12-methyloxacyclododec-3-en-2-one (III-17) 
O
O
OH
HO
 
                                   
To a solution of lactone III-19d (58 mg, 0.21 mmol) and acetonitrile/water (2:1, v/v, 2 
mL) was added trifluoroacetic acid (1.58 mL) at 0 °C. Then the reaction was stirred at 
room temperature for another 2 h, diluted with ether acetate, washed with sat. 
NaHCO3(aq), dried over Na2SO4, filtered, and concentrated. The residue was purified by 
flash chromatography on silica gel to give the lactone III-17 (48 mg, 0.17 mmol, 81%) as 
a colorless oil; Rf (50% Et2O/hexane) = 0.33; [α]25D = + 1 (MeOH); IR (thin film, cm-1), 
3272, 2943, 2862, 1710, 1461, 1278, 1050; 1H NMR (600 MHz, CDCl3) δ 6.12 (dd, J = 
12.0, 8.4 Hz, 1H), 6.05 (dd, J = 12.0, 1.2 Hz, 1H), 5.10 (qdd, J = 6.0, 5.4, 3.0 Hz, 1H), 
                                                 
9 These known compounds were characterized based on the comparison of 1H and 13C NMR data with 
the published ones: Chou, C.-Y. Hou, D.-R. J. Org. Chem. 2006, 71, 9887. 
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 4.97 (ddd, J = 8.4, 4.8, 1.2 Hz, 1H), 3.87 (ddd, J = 9.0, 4.8, 3.0 Hz, 1H), 2.04-1.35 (m, 
10H), 1.25 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CD3Cl) δ 166.7, 145.3, 124.5, 77.5, 
76.5, 74.3, 33.9, 32.1, 27.3, 24.5, 24.1, 20.8; ESI HRMS Calcd for [C12H20O4+H]+: 
229.1434, Found: 229.1435. 
 
(5S, 6S, 12R, E)-5, 6-dihydroxy-12-methyloxacyclododec-3-en-2-one (III-18) 
O
O
OH
OH
 
                                
To a solution of lactone III-20c (68 mg, 0.24 mmol) and acetonitrile/water (2:1, v/v, 2.5 
mL) was added trifluoroacetic acid (1.83 mL) at 0 °C. Then the reaction was stirred at 
room temperature for another 2 h, diluted with ether acetate, washed with sat. 
NaHCO3(aq), dried over Na2SO4, filtered, and concentrated. The residue was purified by 
flash chromatography on silica gel to give the lactone III-18 (45 mg, 0.20 mmol, 83%) as 
a colorless oil; Rf (50% Et2O/hexane) = 0.41; [α]25D = - 10 (MeOH); IR (thin film, cm-1), 
3396, 2937, 2870, 1711, 1464, 1247, 1028; 1H NMR (600 MHz, CDCl3) δ 6.94 (dd, J = 
15.6, 6.0 Hz, 1H), 6.12 (dd, J = 15.6, 1.2 Hz, 1H), 4.96 (dqd, J = 6.6, 6.0, 3.0 Hz, 1H), 
4.12 (ddd, J = 7.2, 6.0, 1.2 Hz, 1H), 3.32 (ddd, J = 9.6, 7.8, 1.8 Hz, 1H), 1.74-1.20 (m, 
10H), 1.28 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CD3Cl) δ 167.2, 146.9, 122.5, 78.0, 
77.8, 73.1, 33.2, 32.6, 28.3, 25.0, 22.8, 19.0; ESI HRMS Calcd for [C12H20O4+Na]+: 
251.1254, Found: 251.1254. 
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(5S,6S,12R,Z)-5,6-dihydroxy-12-methyloxacyclododec-3-en-2-one (Cladospolide B) 
O
O
OH
HO
 
                                  
To a solution of lactone III-20d (34 mg, 0.12 mmol) and acetonitrile/water (2:1, v/v, 1.2 
mL) was added trifluoroacetic acid (0.90 mL) at 0 °C. Then the reaction was stirred at 
room temperature for another 2 h, diluted with ether acetate, washed with sat. 
NaHCO3(aq), dried over Na2SO4, filtered, and concentrated. The residue was purified by 
flash chromatography on silica gel to give the Cladospolide B (27 mg, 0.10 mmol, 81%) 
as a white solid;10 Rf (50% Et2O/hexane) = 0.57; Mp 108-109 °C; [α]25D = + 5 (MeOH); 
IR (thin film, cm-1), 3345, 2934, 2865, 1707, 1461, 1280, 1046`; 1H NMR (600 MHz, 
CDCl3) δ 6.23 (dd, J = 12.0, 8.4 Hz, 1H), 5.77 (dd, J = 12.0, 1.2 Hz, 1H), 5.26 (ddd, J 
=8.4, 4.2, 1.2 Hz, 1H), 4.88 (dqd, J = 10.2, 6.0, 1.8 Hz, 1H), 3.77 (ddd, J = 9.0, 4.2, 2.4 
Hz, 1H), 1.84-1.35 (m, 10H), 1.28 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CD3Cl) 
δ165.8, 148.5, 121.9, 74.4, 73.9, 67.5, 32.0, 30.6, 25.7, 24.1, 21.3, 19.7; ESI HRMS 
Calcd for [C12H20O4+H]+: 229.1434, Found: 229.1435. 
 
 
 
                                                 
10 These known compounds were characterized based on the comparison of 1H and 13C NMR data with 
the published ones: Austin, K. A. B.; Banwell, M. G.; Loong, D. T. J.; Rae, A. D.; Willis, A. C. Org. 
Biomol. Chem. 2005, 3, 1081. 
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 (5R,6R,12R,E)-6-(tert-butyldimethylsilyloxy)-5-hydroxy-12-methyloxacyclododec-3-
en-2-one (III-3a) 
O
OTBS
OH
O  
                                
(5R,6R,12R,E)-5-(tert-butyldimethylsilyloxy)-6-hydroxy-12-methyloxacyclododec-3-
en-2-one (III-3a1) 
.       
O
OH
OTBS
O  
                               
To a magnetically stirred solution of Cladospolide C (10 mg, 0.044 mmol) and 
imidazole (7.5 mg, 0.11 mmol) in dry CH2Cl2 (0.5 mL) was added dropwise TBSCl (19 
mg, 0.13 mmol) at 0 oC. The reaction mixture was warmed to room temperature and 
stirred overnight. Water was added and then the reaction mixture was extracted with 
Et2O, dried with Na2SO4 and evaporated under reduced pressure to leave the crude 
product which was then purified using silica gel flash chromatography to give alcohol 
III-3a (4.5 mg, 0.013 mmol, 30%) and alcohol III-3a1 (9 mg, 0.026 mmol, 60%). 
 
III-3a: colorless oil; Rf (10% Et2O/hexane) = 0.20; [α]25D = 50 (CH2Cl2); IR (thin film, 
cm-1), 3457, 2930, 2858, 1722, 1463, 1255, 1048, 998, 776 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 6.84 (dd, J = 15.6, 9.0 Hz, 1H), 6.07 (d, J = 15.6 Hz, 1H), 5.02 (dqd, J = 9.0, 
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 6.0, 3.0 Hz, 1H), 4.04 (dd, J = 9.0, 7.2 Hz, 1H), 3.64 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 1.70-
1.10 (m, 10H), 1.28 (d, J = 6.0 Hz, 3H), 0.90 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H); 13C NMR 
(150 MHz, CD3Cl) δ 167.2, 145.4, 123.7, 77.2, 76.8, 73.7, 33.5, 32.1, 27.6, 25.8, 24.4, 
23.4, 20.3, 18.0, - 4.49, - 4.78; ESI HRMS Calcd for [C18H34O4Si+H]+: 343.2299, Found: 
343.2300. 
 
III-3a1: colorless oil; Rf (10% Et2O/hexane) = 0.08; [α]25D = + 34 (CH2Cl2); IR (thin 
film, cm-1), 3482, 2931, 2859, 1721, 1463, 1254, 1039, 997, 778; 1H NMR (600 MHz, 
CDCl3) δ 6.77 (dd, J = 16.2, 9.0 Hz, 1H), 6.01 (dd, J = 16.2, 0.6 Hz, 1H), 4.99 (dqd, J = 
10.2, 6.0, 2.4 Hz, 1H), 3.93 (ddd, J = 9.0, 7.2, 0.6 Hz, 1H), 3.54 (ddd, J = 7.2, 7.2, 2.4 
Hz, 1H), 1.70-1.11 (m, 10H), 1.30 (d, J = 6.0 Hz, 3H), 0.91 (s, 9H), 0.10 (s, 3H), 0.06 (s, 
3H); 13C NMR (150 MHz, CD3Cl) δ 167.0, 146.6, 123.8, 78.3, 76.6, 74.2, 33.8, 30.4, 
27.5, 25.8, 24.4, 24.0, 20.7, 18.1, - 4.50, - 4.82; ESI HRMS Calcd for [C18H34O4Si+H]+: 
343.2299, Found: 343.2300. 
 
 
 (6R,12R,E)-6-(tert-butyldimethylsilyloxy)-12-methyloxacyclododec-3-ene-2,5-dione 
(III-3b) 
O
O
OTBS
O
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 To a magnetically stirred solution of alcohol III-3a (5 mg, 0.015 mmol) in dry CH2Cl2 
(0.2 mL) was added Dess-Martin periodinane (16 mg, 0.038 mmol) at room temperature. 
The reaction mixture was stirred for 1 h. CH2Cl2 was added to dilute the reaction solution 
and then the reaction mixture was washed with NaHCO3, extracted with ether acetate, 
dried with Na2SO4 and evaporated under reduced pressure to leave the crude product 
which was then purified using silica gel flash chromatography to give ketone III-3b (4.6 
mg, 0.014 mmol, 95%) as a colorless oil; Rf (10% Et2O/hexane) = 0.33; [α]25D = - 12 
(CH2Cl2); IR (thin film, cm-1), 2931, 2858, 1721, 1463, 1251, 1078, 838, 779; 1H NMR 
(600 MHz, CDCl3) δ 7.21 (d, J = 16.8 Hz, 1H), 6.90 (d, J = 16.8 Hz, 1H), 4.89 (dqd, J = 
7.8., 6.0, 4.8 Hz, 1H), 4.41 (dd, J = 6.0, 4.2 Hz, 1H), 1.78-1.15 (m, 10H), 1.34 (d, J = 6.0 
Hz, 3H), 0.91 (s, 9H), 0.10 (s, 3H), 0.07 (s, 3H); 13C NMR (150 MHz, CD3Cl) δ 200.8, 
166.8, 138.2, 131.3, 79.2, 75.3, 35.1, 34.1, 27.7, 25.8, 23.9, 20.6, 18.1, - 4.79, - 5.25; ESI 
HRMS Calcd for [C18H32O4Si+Na]+: 363.1962, Found: 363.1964. 
 
 
(6R,12R,E)-6-hydroxy-12-methyloxacyclododec-3-ene-2,5-dione (III-28) 
O
O
OH
O
 
                               
To a plastic flask were added III-3b (4 mg, 0.012 mmol) and 5% HF in CH3CN (15 μL) 
at room temperature. The reaction mixture was stirred for 2 h and then ether acetate was 
added to dilute the reaction solution. The reaction mixture was washed with NaHCO3, 
103
 extracted with ether acetate, dried with Na2SO4 and evaporated under reduced pressure to 
leave the crude product which was then purified using silica gel flash chromatography to 
give ketone III-28 (2.3 mg, 0.102 mmol, 85%) as a colorless oil; Rf (50% Et2O/hexane) = 
0.33; [α]25D = - 23 (CH2Cl2); IR (thin film, cm-1), 3501, 2931, 1719, 1249, 1156; 1H NMR 
(600 MHz, CDCl3) δ 7.37 (d, J = 16.2 Hz, 1H), 6.67 (d, J = 16.2 Hz, 1H), 4.94 (dqd, J = 
9.6, 6.0, 3.0 Hz, 1H), 4.34 (dd, J = 9.6, 3.0 Hz, 1H), 2.01 (m, 1H), 1.67-1.17 (m, 9H), 
1.42 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CD3Cl) δ 201.5, 165.6, 137.5, 131.2, 77.3, 
75.2, 35.1, 33.5, 27.8, 24.5, 23.3, 20.8; ESI HRMS Calcd for [C12H18O4+H]+: 227.1278, 
Found: 227.1278. 
 
(5S,6S,12R,E)-6-(tert-butyldimethylsilyloxy)-5-hydroxy-12-methyloxacyclododec-3-
en-2-one (III-18a) 
O
OTBS
OH
O  
     
(5S,6S,12R,E)-5-(tert-butyldimethylsilyloxy)-6-hydroxy-12-methyloxacyclododec-3-
en-2-one (III-18a1) 
O
OH
OTBS
O  
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 To a magnetically stirred solution of diol III-18 (20 mg, 0.088 mmol) and imidazole (15 
mg, 0.22 mmol) in dry CH2Cl2 (1 mL) was added dropwise TBSCl (38 mg, 0.26 mmol) at 
0 oC. The reaction mixture was warmed to room temperature and stirred overnight. Water 
was added and then the reaction mixture was extracted with Et2O, dried with Na2SO4 and 
evaporated under reduced pressure to leave the crude product which was then purified 
using silica gel flash chromatography to give alcohol III-18a (18 mg, 0.053 mmol, 60%) 
and alcohol III-18a1 (9 mg, 0.027 mmol, 30%). 
 
III-18a: colorless oil; Rf (10% Et2O/hexane) = 0.17; [α]25D = + 7 (CH2Cl2); IR (thin film, 
cm-1), 3484, 2931, 2858, 1716, 1464, 1252, 1004, 837, 776; 1H NMR (600 MHz, CDCl3) 
δ 6.95 (dd, J = 15.6, 5.4 Hz, 1H), 6.10 (dd, J = 15.6, 1.8 Hz, 1H), 5.08 (qdd, J = 6.0, 6.0, 
2.4 Hz, 1H), 4.04 (ddd, J = 7.2, 5.4, 1.8 Hz, 1H), 3.30 (dd, J = 7.2, 7.2, Hz, 1H), 1.60-
1.20 (m, 10H), 1.28 (d, J = 6.0 Hz, 3H), 0.90 (s, 9H), 0.10 (s, 6H); 13C NMR (150 MHz, 
CD3Cl) δ166.9, 146.8, 121.9, 78.9, 77.3, 72.6, 33.7, 32.4, 28.0, 25.8, 24.5, 22.9, 19.0, 
18.0, - 4.20, - 4.19; ESI HRMS Calcd for [C18H34O4Si+Na]+: 365.2189, Found: 
365.2120. 
 
III-18a1: colorless oil; Rf (10% Et2O/hexane) = 0.20; [α]25D = + 30 (CH2Cl2); IR (thin 
film, cm-1), 3508, 2932, 2858, 1716, 1464, 1251, 1229, 1004, 837, 778; 1H NMR (600 
MHz, CDCl3) δ 6.94 (dd, J = 16.2, 6.0 Hz, 1H), 6.05 (dd, J = 16.2, 1.2 Hz, 1H), 5.11 
(dqd, J = 6.6, 6.0, 3.0 Hz, 1H), 4.03 (ddd, J = 7.2, 6.0, 1.2 Hz, 1H), 3.29 (ddd, J = 8.4, 
7.2, 1.2 Hz, 1H), 1.75-1.20 (m, 10H), 1.28 (d, J = 6.0 Hz, 3H), 0.93 (s, 9H), 0.10 (s, 3H), 
0.07 (s, 3H); 13C NMR (150 MHz, CD3Cl) δ166.9, 147.9, 122.4, 78.7, 77.9, 72.7, 32.3, 
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 31.6, 28.0, 25.8, 24.8, 22.6, 18.8, 18.1, -5.35, -5.36; ESI HRMS Calcd for [C18H34O4Si 
+H]+: 343.2119, Found: 343.2301. 
 
 
(6S,12R,E)-6-(tert-butyldimethylsilyloxy)-12-methyloxacyclododec-3-ene-2,5-dione 
(III-18b) 
O
OTBS
O
O  
   
To a magnetically stirred solution of alcohol III-18a (10 mg, 0.03 mmol) in dry CH2Cl2 
(0.4 mL) was added Dess-Martin periodinane (32 mg, 0.076 mmol) at room temperature. 
The reaction mixture was stirred for 1 h. CH2Cl2 was added to dilute the reaction solution 
and then the reaction mixture was washed with NaHCO3, extracted with ether acetate, 
dried with Na2SO4 and evaporated under reduced pressure to leave the crude product 
which was then purified using silica gel flash chromatography to give ketone III-18b (9.2 
mg, 0.028 mmol, 95%) as a colorless oil; Rf (10% Et2O/hexane) = 0.64; [α]25D = + 31 
(CH2Cl2); IR (thin film, cm-1), 2932, 2858, 1723, 1464, 1254, 1095, 847, 779; 1H NMR 
(600 MHz, CDCl3) δ 7.41 (d, J = 16.8 Hz, 1H), 6.93 (d, J = 16.8 Hz, 1H), 4.63 (qdd, J = 
6.0, 6.0, 6.0 Hz, 1H), 4.34 (dd, J = 6.0, 1.6 Hz, 1H), 1.90-1.06 (m, 10H), 1.34 (d, J = 6.0 
Hz, 3H), 0.92 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H); 13C NMR (150 MHz, CD3Cl) δ 201.3, 
167.5, 134.2, 132.0, 77.2, 74.9, 34.8, 34.2, 27.9, 25.7, 24.1, 21.4, 20.6, 18.1, - 4.91, - 
4.90; ESI HRMS Calcd for [C18H32O4Si+H]+: 341.2143, Found: 341.2144. 
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 (6S,12R,E)-6-hydroxy-12-methyloxacyclododec-3-ene-2,5-dione (III-29) 
O
OH
O
O  
  
To a plastic flask was added III-18b (8 mg, 0.024 mmol) and 5% HF in CH3CN (30 μL) 
at room temperature. The reaction mixture was stirred for 2 hrs and then ether acetate was 
added to dilute the reaction solution. The reaction mixture was washed with NaHCO3, 
extracted with ether acetate, dried with Na2SO4 and evaporated under reduced pressure to 
leave the crude product which was then purified using silica gel flash chromatography to 
give ketone III-29 (4.6 mg, 0.2 mmol, 85%) as a colorless oil; Rf (50% Et2O/hexane) = 
0.56; [α]25D = -10 (CH2Cl2); IR (thin film, cm-1), 3508, 2936, 1714, 1256, 1194, cm-1; 1H 
NMR (600 MHz, CDCl3) δ 7.12 (d, J = 16.2 Hz, 1H), 6.82 (d, J = 16.2 Hz, 1H), 4.92 
(qdd, J = 6.0, 6.0, 6.0 Hz, 1H), 4.52 (dd, J = 8.4, 4.2 Hz, 1H), 1.90 (m, 1H), 1.72-1.18 (m, 
9H), 1.36 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CD3Cl) δ 203.0, 166.3, 138.0, 130.9, 
75.1, 74.6, 35.0, 34.8, 26.7, 24.0, 23.3, 20.7; ESI HRMS Calcd for [C12H18O4+H]+: 
227.1278, Found: 227.1278. 
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 (6S,12R,Z)-6-(tert-butyldimethylsilyloxy)-12-methyloxacyclododec-3-ene-2,5-dione 
(III-2a) 
O
O
OTBS
O
 
      
(A) To a magnetically stirred solution of Cladospolide B (5 mg, 0.022 mmol) and 
imidazole (4 mg, 0.05 mmol) in dry CH2Cl2 (0.2 mL) was added dropwise TBSCl (9 mg, 
0.06 mmol) at 0 oC. The reaction mixture was warmed to room temperature and stirred 
overnight. Water was added and then the reaction mixture was extracted with Et2O, dried 
with Na2SO4 and evaporated under reduced pressure to leave the inseparable 1:2 mixture 
of alcohol (6.8 mg, 0.02 mmol). To a magnetically stirred solution of mixture of  (2 mg, 
0.006 mmol) in dry CH2Cl2 (0.06 mL) was added Dess-Martin periodinane (6 mg, 0.015 
mmol) at room temperature. The reaction mixture was stirred for 1 h. CH2Cl2 was added 
to dilute the reaction solution and then the reaction mixture was washed with NaHCO3, 
extracted with ether acetate, dried with Na2SO4 and evaporated under reduced pressure to 
leave the crude product which was then purified using silica gel flash chromatography to 
give ketone III-2a (0.6 mg, 0.0018 mmol, 27% in 2 steps) 
 
(B) To a plastic flask was added III-18b (8 mg, 0.024 mmol) and 5% HF/Py. (2:1) in 
CH3CN (30 μL) at room temperature. The reaction mixture was stirred for 2 h and then 
ether acetate was added to dilute the reaction solution. The reaction mixture was washed 
with NaHCO3, extracted with ether acetate, dried with Na2SO4 and evaporated under 
reduced pressure to leave the crude product which was then purified using silica gel flash 
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 chromatography to give ketone III-2a (7.4 mg, 0.22 mmol, 90%) as a colorless oil; Rf 
(10% Et2O/hexane) = 0.37; [α]25D = - 80 (CH2Cl2); IR (thin film, cm-1), 2931, 2860, 1726, 
1464, 1251, 1164, 1119, 839, 778; 1H NMR (600 MHz, CDCl3) δ 6.73 (d, J = 12.6 Hz, 
1H), 6.23 (d, J = 12.6 Hz, 1H), 4.91 (dqd, J = 9.6, 6.0, 3.0 Hz, 1H), 4.32 (dd, J = 7.8, 4.2 
Hz, 1H), 1.93-1.26 (m, 10H), 1.27 (d, J = 6.0 Hz, 3H), 0.93 (s, 9H), 0.11 (s, 3H), 0.09 (s, 
3H); 13C NMR (150 MHz, CD3Cl) δ 203.2, 166.3, 133.6, 130.6, 76.4, 73.9, 33.3, 330.5, 
26.3, 25.8, 22.1, 21.2, 20.0, 18.1, -4.91, -5.07; ESI HRMS Calcd for [C18H32O4Si+H]+: 
341.2143, Found: 341.2144. 
 
 
(6S,12R,Z)-6-hydroxy-12-methyloxacyclododec-3-ene-2,5-dione ((ent)-Cladospolide 
D III-31) 
                                                           
O
O
OH
O
 
   
To a plastic flask was added III-2a (5 mg, 0.015 mmol) and 5% HF in CH3CN (17 μL) at 
room temperature. The reaction mixture was stirred for 2 h and then ether acetate was 
added to dilute the reaction solution. The reaction mixture was washed with NaHCO3, 
extracted with ether acetate, dried with Na2SO4 and evaporated under reduced pressure to 
leave the crude product which was then purified using silica gel flash chromatography to 
give (ent)-Cladospolide D III-31 (3 mg, 0.013 mmol, 87%) as a colorless oil;11 Rf (30% 
                                                 
11 Zhang, H.; Tomoda, H.; Tabata, N.; Miura, H.; Namikoshi, M.; Yamaguchi, Y.; Masuma, R.; Omura, S. 
J. O. Anti. 54, 635-641 
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 Et2O/hexane) = 0.36; [α]25D = - 28 (CH2Cl2); IR (thin film, cm-1), 3467, 2936, 1720, 
1224, 1167, 1083; 1H NMR (600 MHz, CDCl3) δ 6.40 (d, J = 13.2 Hz, 1H), 6.31 (d, J = 
13.2 Hz, 1H), 5.22 (dqd, J = 9.0, 6.0, 6.0 Hz, 1H), 4.66 (ddd, J = 8.4, 6.0, 5.4 Hz, 1H), 
3.16 (d, J = 6.0 Hz, 1H), 1.95 (m, 1H), 1.72-1.18 (m, 9H), 1.30 (d, J = 6.0 Hz, 3H); 13C 
NMR (150 MHz, CD3Cl) δ 203.5, 165.4, 133.3, 130.9, 73.5, 71.5, 33.2, 31.1, 23.0, 21.6, 
21.5, 20.6; ESI HRMS Calcd for [C12H18O4+H]+: 227.1278, Found: 227.1278. 
 
 
(5R,6R,12R,Z)-6-(tert-butyldimethylsilyloxy)-5-hydroxy-12-methyloxacyclododec-3-
en-2-one (III-17a) 
O
O
OTBS
HO
 
       
(5R,6R,12R,Z)-5-(tert-butyldimethylsilyloxy)-6-hydroxy-12-methyloxacyclododec-3-
en-2-one (III-17a1) 
O
O
OH
TBSO
 
       
To a magnetically stirred solution of diol III-17 (15 mg, 0.066 mmol) and imidazole 
(11.2 mg, 0.16 mmol) in dry CH2Cl2 (0.7 mL) was added dropwise TBSCl (30 mg, 0.2 
mmol) at 0 oC. The reaction mixture was warmed to room temperature and stirred over 
night. Water was added and then the reaction mixture was extracted with Et2O, dried with 
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 Na2SO4 and evaporated under reduced pressure to leave the crude product which was 
then purified using silica gel flash chromatography to give alcohol III-17a (6.7 mg, 0.02 
mmol, 30%) and alcohol III-17a1 (13.4 mg, 0.04 mmol, 60%). 
 
III-17a: colorless oil; Rf (20% Et2O/hexane) = 0.39; [α]25D = -56 (CH2Cl2); IR (thin film, 
cm-1), 3482, 2931, 2858, 1713, 1463, 1217, 1075, 835, 778; 1H NMR (600 MHz, CDCl3) 
δ 6.14 (dd, J = 12.0, 7.2 Hz, 1H), 6.93 (dd, J = 12.0, 1.2 Hz, 1H), 5.14 (qdd, J = 6.0, 6.0, 
3.0 Hz, 1H), 4.94 (dd, J = 7.2, 1.2 Hz, 1H), 3.98 (ddd, J = 10.2, 3.0, 1.2 Hz, 1H), 2.06-
1.26 (m, 10H), 1.39 (d, J = 6.0 Hz, 3H), 0.90 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H); 13C NMR 
(150 MHz, CD3Cl) δ 165.8, 148.7, 121.0, 74.3, 72.5, 67.4, 31.9, 29.3, 25.8, 24.4, 21.5, 
21.2, 18.0, 16.8, - 4.70, - 5.09; ESI HRMS Calcd for [C18H34O4Si +H]+: 343.2299, 
Found: 343.2300. 
 
III-17a1: colorless oil; Rf (20% Et2O/hexane) = 0.6; [α]25D = + 40 (CH2Cl2); IR (thin 
film, cm-1), 3570, 2931, 2857, 1713, 1464, 1199, 1073, 836, 779; 1H NMR (600 MHz, 
CDCl3) δ 6.14 (d, J = 12.0, 8.4 Hz, 1H), 6.93 (dd, J = 12.0, 1.2 Hz, 1H), 5.13 (qdd, J = 
6.0, 4.8, 3.6 Hz, 1H), 5.02 (ddd, J = 9.0, 3.6, 1.2 Hz, 1H), 3.75 (ddd, J = 9.6, 7.2, 3.6, Hz, 
1H), 2.03-1.25 (m, 10H), 1.27 (d, J = 6.0 Hz, 3H), 0.91 (s, 9H), 0.11 (s, 3H), 0.07 (s, 3H); 
13C NMR (150 MHz, CD3Cl) δ 166.1, 146.9, 121.6, 73.6, 72.6, 69.0, 31.5, 29.9, 26.0, 
24.9, 20.9, 20.7, 18.3, 17.3, - 4.66, - 4.68; ESI HRMS Calcd for [C18H34O4Si +H]+: 
343.2299, Found: 343.2301. 
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 (6R,12R,Z)-6-(tert-butyldimethylsilyloxy)-12-methyloxacyclododec-3-ene-2,5-dione 
(III-17b) 
O
O
OTBSO
 
       
To a magnetically stirred solution of alcohol III-17a (8 mg, 0.023 mmol) in dry CH2Cl2 
(0.3 mL) was added Dess-Martin periodinane (24 mg, 0.058 mmol) at room temperature. 
The reaction mixture was stirred for 1 h. CH2Cl2 was added to dilute the reaction solution 
and then the reaction mixture was washed with NaHCO3, extracted with ether acetate, 
dried with Na2SO4 and evaporated under reduced pressure to leave the crude product 
which was then purified using silica gel flash chromatography to give ketone III-17b (7.4 
mg, 0.022 mmol, 95%) as a colorless oil; Rf (10% Et2O/hexane) = 0.50; [α]25D = + 18 
(CH2Cl2); IR (thin film, cm-1), 2932, 2857, 1717, 1464, 1285, 1098, 838, 778; 1H NMR 
(600 MHz, CDCl3) δ 6.78 (d, J = 12.6 Hz, 1H), 5.95 (d, J = 12.6 Hz, 1H), 4.87 (dqd, J = 
9.0, 6.0, 3.0 Hz, 1H), 4.14 (dd, J = 9.6, 3.0 Hz, 1H), 1.84-1.24 (m, 10H), 1.25 (d, J = 6.0 
Hz, 3H), 0.91 (s, 9H), 0.09 (s, 6H); 13C NMR (150 MHz, CD3Cl) δ 204.3, 164.5, 140.4, 
125.9, 78.8, 73.9, 31.9, 31.3, 27.1, 25.7, 20.7, 19.5, 19.3, 18.0, - 4.80, - 5.13; ESI HRMS 
Calcd for [C18H32O4Si+Na]+: 363.1962, Found: 363.1964. 
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 (6R,12R,Z)-6-hydroxy-12-methyloxacyclododec-3-ene-2,5-dione (III-30) 
O
O
OHO
 
        
To a plastic flask was added III-17b (6 mg, 0.018 mmol) and 5% HF in CH3CN (20 μL) 
at room temperature. The reaction mixture was stirred for 2 h and then ether acetate was 
added to dilute the reaction solution. The reaction mixture was washed with NaHCO3, 
extracted with ether acetate, dried with Na2SO4 and evaporated under reduced pressure to 
leave the crude product which was then purified using silica gel flash chromatography to 
give alcohol III-30 (3.4 mg, 0.015 mmol, 86%) as a colorless oil; Rf (30% Et2O/hexane) 
= 0.32; [α]25D = + 4 (CH2Cl2); IR (thin film, cm-1), 3453, 2934, 1712, 1284, 1083; 1H 
NMR (600 MHz, CDCl3) δ 6.56 (d, J = 13.2 Hz, 1H), 6.20 (d, J = 13.2 Hz, 1H), 4.96 
(dqd, J = 9.6, 6.0, 3.6 Hz, 1H), 4.44 (m 1H), 2.01 (m, 1H), 1.82-1.18 (m, 9H), 1.27 (d, J = 
6.0 Hz, 3H); 13C NMR (150 MHz, CD3Cl) δ 203.2, 165.3, 134.8, 130.3, 76.0, 74.0, 31.2, 
31.0, 27.3, 25.6, 21.5, 18.7; ESI HRMS Calcd for [C12H18O4+H]+: 227.1278, Found: 
227.1278. 
 
 
(R,E)-12-methyloxacyclododec-3-ene-2,5,6-trione (III-26) 
O
O
O
O  
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A solution of diol III-3 (6 mg, 0.026 mmol) and trichloroisocyanuric acid (6.1 mg, 0.026 
mmol) in ethyl ether (0.3 ml) was stirred at –30 oC, then 2,2,6,6-
tetramethylpeperidinooxy was added in one portion. The mixture was stirred for 60 min 
and then quenched with saturated sodium carbonate. The organic layer was separated and 
the aqueous layer was extracted with ether. Combined the organic layer, washed with 
brine, dried (Na2SO4), filtered and concentrated. Chromatography on silica gel gave III-
26 (3.8 mg, 0.017 mmol, 67%) as colorless oil. 
 
A solution of diol III-18 (12 mg, 0.052 mmol) and trichloroisocyanuric acid (12.3 mg, 
0.053 mmol) in ethyl ether (0.5 ml) was stirred at –30 oC, then 2,2,6,6-
tetramethylpeperidinooxy was added in one portion. The mixture was stirred for 60 min 
and then quenched with saturated sodium carbonate. The organic layer was separated and 
the aqueous layer was extracted with ether. Combined the organic layer, washed with 
brine, dried (Na2SO4), filtered and concentrated. Chromatography on silica gel gave III-
26 (7.6 mg, 0.034 mmol, 65%) as colorless oil. 
 
III-16: Rf = 0.67 (7:3 (v/v) hexane/EtOAc); [α]D20 = – 2 (c = 0.1, MeOH); IR (thin film, 
cm-1)  3373, 2934, 1715, 1134, 1040, 987, 706; 1H NMR (600 MHz, CDCl3) 1H spectra 
shows a mixture of diketone 16 and it’s hydrate, peaks associated with the diketone: δ 
6.87 (d, J = 15.6 Hz, 1H), 6.36 (d, J = 15.6 Hz, 1H), 5.05 (m, 1H),  3.05 (ddd, J = 13.2, 
7.8, 3.0 Hz, 1H), 2.36 (ddd, J = 13.2, 12.0, 3.0 Hz, 1H), 1.41 (d, J = 7.8 Hz, 3H), peaks 
associated with the hydride: 7.00 (s, 2H), 4.60 (m,1H), 4.14 (s, 1H), 3.73 (s, 1H), 2.69 
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 (m,1H), 2.54 (m,1H), 1.41 (d, J = 6.6 Hz, 3H), peaks associated with the mixture: 1.67-
1.54 (m);  13C NMR (150 MHz, CD3Cl) diketone 16: δ 204.2, 195.6, 164.9, 136.6, 136.0, 
75.5, 39.5, 34.8, 24.8, 23.4, 21.8, 20.8;  ESI HRMS Calcd for [C12H16O4 +H]+: 225.1121, 
Found: 225.1122.  
 
 
(R,Z)-12-methyloxacyclododec-3-ene-2,5,6-trione (III-27) 
 
 
A solution of diol III-17 (6 mg, 0.026 mmol) and trichloroisocyanuric acid (6.0 mg, 
0.026 mmol) in ethyl ether (0.3 ml) was stirred at –30 oC, then 2,2,6,6-
tetramethylpeperidinooxy was added in one portion. The mixture was stirred for 40 min 
and then quenched with saturated sodium carbonate. The organic layer was separated and 
the aqueous layer was extracted with ether. Combined the organic layer, washed with 
brine, dried (Na2SO4), filtered and concentrated. Chromatography on silica gel gave III-
27 (5.0 mg, 0.022 mmol, 86%) as colorless oil. 
 
A solution of diol III-2 (15 mg, 0.066 mmol) and trichloroisocyanuric acid (15.3 mg, 
0.066 mmol) in ethyl ether (0.6 ml) was stirred at –30 oC, then 2,2,6,6-
tetramethylpeperidinooxy was added in one portion. The mixture was stirred for 40 min 
and then quenched with saturated sodium carbonate. The organic layer was separated and 
the aqueous layer was extracted with ether. Combined the organic layer, washed with 
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 brine, dried (Na2SO4), filtered and concentrated. Chromatography on silica gel gave III-
27 (12 mg, 0.056 mmol, 85%) as colorless oil. 
 
III-27: Rf = 0.34 (9:1 (v/v) hexane/EtOAc); [α]25D = + 2 (c = 0.5, CH2Cl2); IR (thin film, 
cm-1), 2931, 1710, 1377, 1284, 995; 1H NMR (600 MHz, CDCl3) δ 6.49 (d, J = 12.6 Hz, 
1H), 6.29 (d, J = 12.6 Hz, 1H), 5.02 (dqd, J = 6.0, 6.0, 2.4 Hz, 1H), 3.13 (ddd, J = 15.6, 
10.2, 2.4 Hz, 1H), 2.44 (ddd, J = 15.6, 9.6, 2.4 Hz, 1H), 1.98 (m, 1H), 1.83 (m, 1H), 1.59-
1.61 (m, 6H), 1.18 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CD3Cl) δ 199.1, 190.4, 
163.8, 135.7, 129.6, 73.2, 34.6, 31.6, 26.5, 21.4, 21.0, 19.0; ESI HRMS Calcd for 
[C12H16O4 +H]+: 225.1121, Found: 225.1122. 
 
(6S,12R,Z)-6-hydroxy-12-methyloxacyclododec-3-ene-2,5-dione (III-31) 
 
To a solution of III-34 (1.0 mg) in 3.0 ml D6-benzene, 0.1 mg I2 was added,  the solution 
was irradiated with 300 nm UV light through a Pyrex filter for 20 min, the 
chromatography gave double bond isomer III-35 (0.95 mg, 95%) was formed. To a 
plastic flask was added III-35 (5 mg, 0.015 mmol) 0.1 mL CH3CN and 5% HF in CH3CN 
(17 μL) at room temperature. The reaction mixture was stirred for 2 h and then ether 
acetate was added to dilute the reaction solution. The reaction mixture was washed with 
NaHCO3, extracted with EtOAc, dried with Na2SO4 and evaporated under reduced 
pressure to leave the crude product which was then purified using silica gel flash 
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 chromatography to give (ent)-cladospolide D III-31 (3 mg, 0.013 mmol, 87%) as a 
colorless oil; 
 
III-31: Rf (30% Et2O/hexane) = 0.36; [α]25D = – 57 (c = 0.1, CH2Cl2); IR (thin film, cm-
1), 3467, 2936, 1720, 1224, 1167, 1083; 1H NMR (600 MHz, CDCl3) δ 6.40 (d, J = 13.2 
Hz, 1H), 6.31 (d, J = 13.2 Hz, 1H), 5.22 (dqd, J = 9.0, 6.0, 6.0 Hz, 1H), 4.66 (ddd, J = 
8.4, 6.0, 5.4 Hz, 1H), 3.16 (d, J = 6.0 Hz, 1H), 1.95 (m, 1H), 1.72-1.18 (m, 9H), 1.30 (d, J 
= 6.0 Hz, 3H); 13C NMR (150 MHz, CD3Cl) δ 203.5, 165.4, 133.3, 130.9, 73.5, 71.5, 
33.2, 31.1, 23.0, 21.6, 21.5, 20.6; ESI HRMS Calcd for [C12H18O4+H]+: 227.1278, 
Found: 227.1278. 
 
 
Photo equilibration of TBS-protected (E)-5-bis-cladospolide D (III-32) and TBS-
protected (Z)-5-bis-cladospolide D (III-33) 
 
 
A solution of III-32 (1.5 mg) in 3.5 ml D6-benzene was irradiated with 300 nm UV light 
through a Pyrex filter. After 24 h, a photo equilibrium (1.3:1, III-33/ III-32) was 
established with the Z-isomer III-33 being slightly favored, III-32 and III-33 could be 
separated by chromatography.  
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 Pure III-33 (1.0 mg) was irradiated in 3.0 ml D6-benzene solution with 300 nm UV light 
through a Pyrex filter, the same photo equilibrium (1.3:1, III-33/ III-32) was established 
with the Z-isomer III-33 being slightly favored, III-32 and III-33 could be separated by 
chromatography.  
 
III-32: Rf (10% Et2O/hexane) = 0.33; [α]25D = – 12 (c = 0.5, CH2Cl2);  IR (thin film, cm-
1), 2931, 2858, 1721, 1463, 1251, 1078, 838, 779;  1H NMR (600 MHz, CDCl3) δ 7.21 (d, 
J = 16.8 Hz, 1H), 6.90 (d, J = 16.8 Hz, 1H), 4.89 (dqd, J = 7.8., 6.0, 4.8 Hz, 1H), 4.41 
(dd, J = 6.0, 4.2 Hz, 1H), 1.78-1.15 (m, 10H), 1.34 (d, J = 6.0 Hz, 3H), 0.91 (s, 9H), 0.10 
(s, 3H), 0.07 (s, 3H);  13C NMR (150 MHz, CD3Cl) δ 200.8, 166.8, 138.2, 131.3, 79.2, 
75.3, 35.1, 34.1, 27.7, 25.8, 23.9, 20.6, 18.1, - 4.79, - 5.25; ESI HRMS Calcd for 
[C18H32O4Si +Na]+: 363.1962, Found: 363.1964. 
 
III-33: Rf (10% Et2O/hexane) = 0.50; [α]25D = + 18 (c = 0.4, CH2Cl2); IR (thin film, cm-
1), 2932, 2857, 1717, 1464, 1285, 1098, 838, 778; 1H NMR (600 MHz, CDCl3) δ 6.78 (d, 
J = 12.6 Hz, 1H), 5.95 (d, J = 12.6 Hz, 1H), 4.87 (dqd, J = 9.0, 6.0, 3.0 Hz, 1H), 4.14 (dd, 
J = 9.6, 3.0 Hz, 1H), 1.84-1.24 (m, 10H), 1.25 (d, J = 6.0 Hz, 3H), 0.91 (s, 9H), 0.09 (s, 
6H); 13C NMR (150 MHz, CD3Cl) δ 204.3, 164.5, 140.4, 125.9, 78.8, 73.9, 31.9, 31.3, 
27.1, 25.7, 20.7, 19.5, 19.3, 18.0, - 4.80, - 5.13; ESI HRMS Calcd for [C18H32O4Si +Na]+: 
363.1962, Found: 363.1964. 
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 Iodine promoted photochemical equilibration of TBS-protected (E)-5-bis-
cladospolide D (III-32) and TBS-protected (Z)-5-bis-cladospolide D (III-33) 
 
 
To a solution of III-32 (1.5 mg) in 3.5 ml D6-benzene, 0.1 mg I2 was added, the solution 
was irradiated with 300 nm UV light through a Pyrex filter. After 50 min, a 
photochemical equilibrium (Keq = 4, III-33/ III-32) was established with the Z-isomer 
III-33 being favored, III-32 and III-33 could be separated by chromatography.  
 
To a solution of III-33 (1.0 mg) in 3.0 ml D6-benzene, 0.1 mg I2 was added, the solution 
was irradiated with 300 nm UV light through a Pyrex filter. After 50 min, the same 
photochemical equilibrium (Keq = 4, III-33/ III-32) was established with the Z-isomer 
III-33 being favored, III-32 and III-33 could be separated by chromatography. 
 
Photo equilibration of TBS-protected (E)-cladospolide D (III-34) and TBS-protected 
(Z)-cladospolide D (III-35) 
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 A solution of III-34 (1.0 mg) in 3.0 ml D6-benzene was irradiated with 300 nm UV light 
through a Pyrex filter. After 24 h, a photo equilibrium (1:2, III-34/III-35) was 
established with the Z-isomer III-35 being slightly favored, III-34 and III-35 could be 
separated by chromatography.  
 
When pure III-35 (1.0 mg) was irradiated in 3.0 ml D6-benzene solution with 300 nm UV 
light through a Pyrex filter, the same photo equilibrium (1:2, III-34/III-35) was 
established with the Z-isomer III-35 being slightly favored, III-34 and III-35 could be 
separated by chromatography.  
 
III-34: Rf (10% Et2O/hexane) = 0.64; [α]25D = + 31 (c = 0.4, CH2Cl2); IR (thin film, cm-
1), 2932, 2858, 1723, 1464, 1254, 1095, 847, 779; 1H NMR (600 MHz, CDCl3) δ 7.41 (d, 
J = 16.8 Hz, 1H), 6.93 (d, J = 16.8 Hz, 1H), 4.63 (qdd, J = 6.0, 6.0, 6.0 Hz, 1H), 4.34 (dd, 
J = 6.0, 1.6 Hz, 1H), 1.90-1.06 (m, 10H), 1.34 (d, J = 6.0 Hz, 3H), 0.92 (s, 9H), 0.08 (s, 
3H), 0.07 (s, 3H); 13C NMR (150 MHz, CD3Cl) δ 201.3, 167.5, 134.2, 132.0, 77.2, 74.9, 
34.8, 34.2, 27.9, 25.7, 24.1, 21.4, 20.6, 18.1, - 4.91, - 4.90; ESI HRMS Calcd for 
[C18H32O4Si+H]+: 341.2143, Found: 341.2144. 
 
III-35: Rf (10% Et2O/hexane) = 0.37; [α]25D = – 80 (c = 0.5, CH2Cl2); IR (thin film, cm-
1), 2931, 2860, 1726, 1464, 1251, 1164, 1119, 839, 778; 1H NMR (600 MHz, CDCl3) δ 
6.73 (d, J = 12.6 Hz, 1H), 6.23 (d, J = 12.6 Hz, 1H), 4.91 (dqd, J = 9.6, 6.0, 3.0 Hz, 1H), 
4.32 (dd, J = 7.8, 4.2 Hz, 1H), 1.93-1.26 (m, 10H), 1.27 (d, J = 6.0 Hz, 3H), 0.93 (s, 9H), 
0.11 (s, 3H), 0.09 (s, 3H); 13C NMR (150 MHz, CD3Cl) δ 203.2, 166.3, 133.6, 130.6, 
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 76.4, 73.9, 33.3, 330.5, 26.3, 25.8, 22.1, 21.2, 20.0, 18.1, -4.91, -5.07; ESI HRMS Calcd 
for [C18H32O4Si +H]+: 341.2143, Found: 341.2144. 
 
 
Iodine promoted photochemical equilibration of TBS-protected (E)-cladospolide D 
(III-34) and TBS-protected (Z)-cladospolide D (III-35) 
 
 
To a solution of III-34 (1.0 mg) in 3.0 ml D6-benzene, 0.1 mg I2 was added, the solution 
was irradiated with 300 nm UV light through a Pyrex filter. After 20 min, a 
photochemical equilibrium (Keq > 20, III-35/III-34) was established with the Z-isomer 
III-35 being favored.  
 
To the other solution of III-35 (1.0 mg) in 3.0 ml D6-benzene, 0.1 mg I2 was added, the 
solution was irradiated with 300 nm UV light through a Pyrex filter. After 20 min, the 
same photochemical equilibrium (Keq > 20, III-35/III-34) was established with the Z-
isomer III-35 being favored. 
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 Iodine promoted photochemical equilibration of cladospolide C (III-3) and 4,5-bis-
epi-cladospolide B (III-7) 
O
O
OH
OH O
O
HO
OH
pyrex filter
300 nm hv, I2
Keq = 1
 
To a solution of III-3 (1.0 mg) in 3.0 ml D6-benzene, 0.1 mg I2 was added,  the solution 
was irradiated with 300 nm UV light through a Pyrex filter. After 24 h, a photochemical 
equilibrium (Keq = 1, III-3/III-7) was established, III-3 and III-7 were separated by 
chromatography (SiO2, 50% Et2O/hexane).  
 
To the other solution of III-7 (1.0 mg) in 3.0 ml D6-benzene, 0.1 mg I2 was added, the 
solution was irradiated with 300 nm UV light through a Pyrex filter. After 24 h, the same 
photochemical equilibrium (Keq = 1, III-3/ III-7) was established, III-3 and III-7 were 
separated by chromatography (SiO2, 50% Et2O/hexane). 
 
III-3: Rf (50% Et2O/hexane) = 0.27; Mp 91-92 °C; [α]25D = +53  (c = 0.4, MeOH); IR 
(thin film, cm-1), 3415, 2940, 2864, 1705, 1650, 1460, 1258, 1035; 1H NMR (600 MHz, 
CDCl3) δ 6.81 (dd, J = 15.6, 9.0 Hz, 1H), 6.05 (d, J = 15.6 Hz, 1H), 4.98 (dqd, J = 8.4, 
6.0, 1.8 Hz, 1H), 3.98 (dd, J = 8.4, 7.8 Hz, 1H), 3.57 (ddd, J = 7.8, 7.8, 1.8 Hz, 1H), 1.30 
(d, J = 6.0 Hz, 3H) 1.69-1.11 (m, 10H);  13C NMR (150 MHz, CD3Cl) δ 166.7, 145.3, 
124.5, 77.5, 76.5, 74.3, 33.9, 32.1, 27.3, 24.5, 24.1, 20.8;  ESI HRMS Calcd for 
[C12H20O4 +H]+: 229.1434, Found: 229.1435. 
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 III-7: Rf (50% Et2O/hexane) = 0.33; [α]25D = - 1 (c = 0.2, MeOH); IR (thin film, cm-1), 
3272, 2943, 2862, 1710, 1461, 1278, 1050; 1H NMR (600 MHz, CDCl3) δ 6.12 (dd, J = 
12.0, 8.4 Hz, 1H), 6.05 (dd, J = 12.0, 1.2 Hz, 1H), 5.10 (qdd, J = 6.0, 5.4, 3.0 Hz, 1H), 
4.97 (ddd, J = 8.4, 4.8, 1.2 Hz, 1H), 3.87 (ddd, J = 9.0, 4.8, 3.0 Hz, 1H), 2.04-1.35 (m, 
10H), 1.25 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CD3Cl) δ 166.7, 145.3, 124.5, 77.5, 
76.5, 74.3, 33.9, 32.1, 27.3, 24.5, 24.1, 20.8; ESI HRMS Calcd for [C12H20O4+H]+: 
229.1434, Found: 229.1435. 
 
 
Isomerization of cladospolide B (III-2) and 4,5-bis-epi-cladospolide C (III-8) 
 
 
To a solution of III-8 (1.0 mg) in 3.0 ml D6-benzene, 0.1 mg I2 was added, the solution 
was irradiated with 300 nm UV light through a Pyrex filter. After 24 h, a photochemical 
equilibrium (Keq = 0.3, III-2/III-8) was established, III-8 and III-2 were separated by 
chromatography (SiO2, 50% Et2O/hexane).  
 
To the other solution of III-2 (1.0 mg) in 3.0 ml D6-benzene, 0.1 mg I2 was added, the 
solution was irradiated with 300 nm UV light through a Pyrex filter. After 24 h, a 
photochemical equilibrium (Keq = 6, III-2/ III-8) was established, III-8 and III-2 were 
separated by chromatography (SiO2, 50% Et2O/hexane). 
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III-8: Rf (50% Et2O/hexane) = 0.41; [α]25D = – 13 (c = 0.1, MeOH); IR (thin film, cm-1), 
3396, 2937, 2870, 1711, 1464, 1247, 1028; 1H NMR (600 MHz, CDCl3) δ 6.94 (dd, J = 
15.6, 6.0 Hz, 1H), 6.12 (dd, J = 15.6, 1.2 Hz, 1H), 4.96 (dqd, J = 6.6, 6.0, 3.0 Hz, 1H), 
4.12 (ddd, J = 7.2, 6.0, 1.2 Hz, 1H), 3.32 (ddd, J = 9.6, 7.8, 1.8 Hz, 1H), 1.74-1.20 (m, 
10H), 1.28 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CD3Cl) δ 167.2, 146.9, 122.5, 78.0, 
77.8, 73.1, 33.2, 32.6, 28.3, 25.0, 22.8, 19.0; ESI HRMS Calcd for [C12H20O4 +Na]+: 
251.1254, Found: 251.1254. 
 
III-2: Rf (50% Et2O/hexane) = 0.57; Mp 108-109 °C; [α]25D = +24 (c = 0.1, MeOH);  
IR (thin film, cm-1), 3345, 2934, 2865, 1707, 1461, 1280, 1046; 1H NMR (600 MHz, 
CDCl3) δ 6.23 (dd, J = 12.0, 8.4 Hz, 1H), 5.77 (dd, J = 12.0, 1.2 Hz, 1H), 5.26 (ddd, J 
=8.4, 4.2, 1.2 Hz, 1H), 4.88 (dqd, J = 10.2, 6.0, 1.8 Hz, 1H), 3.77 (ddd, J = 9.0, 4.2, 2.4 
Hz, 1H), 1.84-1.35 (m, 10H), 1.28 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CD3Cl) 
δ165.8, 148.5, 121.9, 74.4, 73.9, 67.5, 32.0, 30.6, 25.7, 24.1, 21.3, 19.7; ESI HRMS 
Calcd for [C12H20O4 +H]+: 229.1434, Found: 229.1435. 
 
 
Methyl 3-(furan-2-yl)-3-oxopropanoate (IV-28) 
OMe
OO
O
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 Sodium hydride (5.71 g, 0.24 mol) was placed in a flask and washed with dry hexane 
three times, dimethyl carbonate (15.9 g, 0.177 mol) and 60 mL THF was added to this 
flask. The mixture was heated to 50 oC, a solution of 2-acetyl furan IV-30 (6.54g, 0.059 
mol) in 60 mL THF was added dropwise. The mixture was stirred for 1 h at 50 oC and 
then cooled to 0 oC. After addition of glacial acetic acid followed by cold water, the 
mixture was extracted with ether acetate. The extracts were washed with cold water, 
dried (Na2SO4) and concentrated under reduced pressure. The crude product was purified 
using silica gel flash chromatography to give furan ketone IV-28 (7.23 g, 0.043 mol, 
73%) as colorless oil: Rf (10% EtOAc/hexane) = 0.15; IR (thin film, cm-1) 3135, 2956, 
1740, 1674, 1571, 1467, 1328, 1153, 1017, 883, 768; 1H NMR (600 MHz, CDCl3) δ 7.61 
(dd, J = 1.8, 0.6 Hz, 1H), 7.27 (dd, J = 3.6, 0.6 Hz, 1H), 6.57 (dd, J = 3.6, 1.8 Hz, 1H), 
3.86 (s, 2H), 3.75 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 180.8, 167.4, 152.0, 147.0, 
118.3, 112.7, 52.5, 45.2 
 
 
(S)-Methyl 3-(furan-2-yl)-3-hydroxypropanoate (IV-28a) 
OMe
OOH
O
 
To a flask was added furan ketone IV-28 (173 mg, 1.03 mmol), 2 M NaCOOH in water 
(10 mL), cetyl trimethylammonium bromide (37.5 mg, 0.10 mmol). The mixture was 
stirred at RT. for 5 min, then Noyori catalyst (S, S) (1.3 mg, 0.002 mmol) was added. The 
reaction mixture was allowed to stir for 24 hr. Water was added to dilute and the mixture 
was extracted with Et2O, dried (Na2SO4) and concentrated under reduced pressure. The 
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 crude product was purified using silica gel flash chromatography to give 148 mg (0.88 
mmol, 85%) of furan alcohol IV-28a as colorless oil: Rf  (30% EtOAc/hexane) = 0.18; 
[α]25
 
D  = - 24 (c = 1.0, MeOH); IR (thin film, cm-1) 3450, 2956, 1733, 1439, 1362, 1284, 
1163, 1011, 884, 805, 741; 1H NMR (600 MHz, CDCl3) δ 7.37 (dd, J = 1.8, 0.6 Hz, 1H), 
6.33 (dd, J = 3.0, 1.8 Hz, 1H), 6.277 (ddd, J = 3.0, 0.6, 0.6 Hz, 1H), 5.14 (ddd, J = 9.0, 
4.2, 0.6Hz, 1H), 3.75 (s, 3H), δ 2.91 (dd, J = 16.8, 9.0 Hz, 1H), 2.83 (dd, J = 16.8, 4.2 
Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 172.2, 154.7, 142.2, 110.2, 106.3, 64.1, 51.9, 
39.6 
 
 
(S)-Methyl 2-(6-hydroxy-3-oxo-3,6-dihydro-2H-pyran-2-yl)acetate (IV-32) 
 
 
To a solution of furan alcohol IV-28a (100 mg, 0.59 mmol) in 4 mL THF-H2O (3:1) was 
added NaHCO3 (98.8 mg, 1.18 mmol), NaOAc.3H2O (80 mg, 0.59 mmol) and NBS (105 
mg, 0.59 mmol) at 0 oC. The reaction mixture was kept stirring at this temperature for 1h, 
then saturated NaHCO3 was added to quench the reaction. The reaction mixture was 
extracted with EtOAc, dried (Na2SO4) and concentrated under reduced pressure. The 
crude product was purified using silica gel flash chromatography to give 87 mg (0.47 
mmol, 80%) of pyranone alcohol IV-32 as colorless oil: Rf  (30% EtOAc/hexane) = 0.14 
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 Methyl-2-((2S,6S)-6-(tert-butoxycarbonyloxy)-3-oxo-3,6-dihydro-2H-pyran-2-
yl)acetate (IV-33) 
 
 
To a solution of pyranone alcohol IV-32 (70 mg, 0.376 mmol) in 3 mL CH2Cl2 was 
added DMAP (4.6 mg, 0.0376 mmol) at -78 oC, a pre-cooled solution of (Boc)2O (164 
mg, 0.75mmol) in 2 mL CH2Cl2 was added dropwise. The reaction mixture was stirred at 
-78 oC for 12 hr. The reaction mixture was diluted with EtOAc and quenched with 
saturated NaHCO3, extracted with EtOAc, washed (NaCl), dried (Na2SO4) and 
concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography to give Boc-pyranone IV-33 76 mg (0.27 mmol, 71%) as light 
yellow oil: Rf (35% EtOAc/hexane) = 0.71; [α]25
 
D = + 34.2 (c = 1.0, MeOH); IR (thin 
film, cm-1) 2919, 1744, 1702, 1371, 1275, 1159, 946, 849; 1H NMR (600 MHz, CDCl3) δ 
6.87 (dd, J = 10.2, 3.6 Hz, 1H), 6.33 (d, J = 3.6 Hz, 1H), 6.25 (d, J = 10.2 Hz, 1H), 4.91 
(dd, J = 6.0, 4.2 Hz, 1H), 3.68 (s, 3H), 2.95 (dd, J = 16.8, 4.8 Hz, 1H), 2.85 (dd, J = 16.8, 
6.0 Hz, 1H), 1.52 (s, J = 9H); 13C NMR (150 MHz, CDCl3) δ193.8, 170.3, 151.7, 140.8, 
128.5, 88.9, 83.7, 72.4, 51.9, 35.1, 27.6; CIHRMS: Calculated for [C13H18O7 +Na+]: 
309.0945, Found: 309.0946 
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 Methyl-2-((2S,6R)-6-(tert-butoxycarbonyloxy)-3-oxo-3,6-dihydro-2H-pyran-2-
yl)acetate (IV-34) 
                                                         
 
To a solution of pyranone alcohol IV-32 (70 mg, 0.376 mmol) in 3 mL CH2Cl2 was 
added DMAP (4.6 mg, 0.0376 mmol) at -78 oC, a pre-cooled solution of (Boc)2O (164 
mg, 0.75mmol) in 2 mL CH2Cl2 was added dropwise. The reaction mixture was stirred at 
-78 oC for 12 hr. The reaction mixture was diluted with EtOAc and quenched with 
saturated NaHCO3, extracted with EtOAc, washed (NaCl), dried (Na2SO4) and 
concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography to give Boc-pyranone IV-34 9 mg (0.03 mmol, 8%) as light yellow 
oil: Rf (35% EtOAc/hexane) = 0.66; [α]25
 
D = - 64.8 (c = 1.0, MeOH); IR (thin film, cm-1) 
2919, 1748, 1700, 1371, 1275, 1164, 1064, 945, 851; 1H NMR (600 MHz, CDCl3) δ 6.91 
(dd, J = 10.2, 2.4 Hz, 1H), 6.40 (dd, J = 1.8, 1.8 Hz, 1H), 6.26 (dd, J = 10.2, 1.2 Hz, 1H), 
4.73 (dd, J = 7.8, 5.4 Hz, 1H), 3.71 (s, 3H), 2.91 (dd, J = 16.8, 4.8 Hz, 1H), 2.88 (dd, J = 
16.8, 7.8 Hz, 1H), 1.52 (s, J = 9H); 13C NMR (150 MHz, CDCl3) δ193.6, 170.1, 151.4, 
143.5, 128.8, 90.0, 83.9, 75.8, 52.0, 37.4, 27.6; CIHRMS: Calculated for [C13H18O7 
+Na+]: 309.0945, Found: 309.0943 
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 Methyl-2-((2S,3R,6S)-6-(tert-butoxycarbonyloxy)-3-hydroxy-3,6-dihydro-2H-pyran-
2-yl)acetate (IV-48) 
 
 
To a solution of pyranone IV-32 (62 mg, 0.22 mmol) in 0.5 mL CH2Cl2 was added 0.5 
mL CeCl3 in MeOH (0.4 M) and NaBH4 (16 mg, 0.43 mmol) at -78 oC. The reaction 
mixture was stirred at -78 oC for 3 hr. The reaction mixture was diluted with EtOAc and 
quenched with saturated NaHCO3, extracted with EtOAc, washed (NaCl), dried (Na2SO4) 
and concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography to give allylic alcohol IV-48 57 mg (0.20 mmol, 90%) as colorless 
oil: Rf (30% EtOAc/hexane) = 0.28; [α]25
 
D = - 73.0 (c = 1.0, CH2Cl2); IR (thin film, cm-1) 
3483, 2981, 1744, 1438, 1371, 1275, 1164, 1057, 938, 847; 1H NMR (600 MHz, CDCl3) 
δ 6.07 (ddd, J = 10.2, 1.2, 1.2 Hz, 1H), 6.03 (ddd, J = 2.4, 1.2, 1.2 Hz, 1H), 5.78 (ddd, J = 
10.2, 3.0, 2.4 Hz, 1H), 4.13-4.09 (m, 2H), 3.69 (s, 3H), 2.83 (dd, J = 16.2, 4.2 Hz, 1H), 
2.63 (dd, J = 16.2, 7.2 Hz, 1H), 1.51 (s, J = 9H); 13C NMR (150 MHz, CDCl3) δ171.7, 
152.2, 134.8, 124.2, 90.3, 82.8, 70.3, 67.2, 51.9, 37.6, 27.7; CIHRMS: Calculated for 
[C13H20O7 +Na+]: 311.1101, Found: 311.1092 
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 Methyl-2-((2S,3R,6S)-6-(tert-butoxycarbonyloxy)-3-(tert-butyldimethylsilyloxy)-3,6-
dihydro-2H-pyran-2-yl)acetate (IV-50) 
 
 
To a solution of alcohol IV-48 (50 mg, 0.17 mmol) in 1 mL CH2Cl2 was added imidazol 
(24 mg, 0.35 mmol) and TBSCl (53 mg, 0.35 mmol) at 0 oC. The reaction mixture was 
stirred at RT overnight. The reaction mixture was diluted with EtOAc and quenched with 
saturated NaHCO3, extracted with EtOAc, washed (NaCl), dried (Na2SO4) and 
concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography to give TBS-alcohol IV-50 63 mg (0.16 mmol, 92%) as colorless 
oil: Rf (10% EtOAc/hexane) = 0.5; [α]25
 
D = - 83.5 (c = 1.3, CH2Cl2); IR (thin film, cm-1) 
2960, 2932, 2859, 1748, 1370, 1254, 1139, 1096, 838; 1H NMR (600 MHz, CDCl3) δ 
6.01 (dd, J = 1.8, 1.2 Hz, 1H), 5.96 (ddd, J = 10.2, 1.2, 1.2 Hz, 1H), 5.70 (ddd, J = 10.2, 
3.0, 1.8 Hz, 1H), 4.18 (ddd, J = 9.6, 9.0, 2.4 Hz, 1H), 4.08 (ddd, J = 9.0, 3.0, 1.2 Hz, 1H), 
3.67 (s, 3H), 2.77 (dd, J = 15.6, 2.4 Hz, 1H), 2.43 (dd, J = 15.6, 9.6 Hz, 1H), 1.51 (s, J = 
9H), 0.87 (s, J = 9H), 0.10 (s, J = 6H), 0.07 (s, J = 6H); 13C NMR (150 MHz, CDCl3) 
δ171.0, 152.3, 135.9, 123.4, 90.5, 82.6, 70.4, 67.0, 51.6, 36.6, 27.7, 25.6, 17.8, -4.29, -
4.88; CIHRMS: Calculated for [C19H34O7Si+Na+]: 425.1966, Found: 425.1970 
  
 
 
130
 (2S,3S,6S)-6-(tert-butoxycarbonyloxy)-2-(2-methoxy-2-oxoethyl)-3,6-dihydro-2H-
pyran-3-yl 4-nitrobenzoate (IV-48a) 
 
 
To a solution of alcohol IV-48 (100 mg, 0.35 mmol) in 5 mL THF was added PPh3 (182 
mg, 0.69 mmol), p-Nitrobenzoic acid (116 mg, 0.69 mmol) and DIAD (0.14 mL, 0.69 
mmol) at 0 oC. The reaction mixture was stirred at RT overnight. The reaction mixture 
was diluted with EtOAc and quenched with saturated NaHCO3, extracted with EtOAc, 
washed (NaCl), dried (Na2SO4) and concentrated under reduced pressure. The crude 
product was purified using silica gel flash chromatography to give IV-48a 125 mg (0.29 
mmol, 82%) as colorless oil: Rf (10% EtOAc/hexane) = 0.25; [α]25
 
D = 148.4 (c = 1.0, 
CH2Cl2); IR (thin film, cm-1) 2990, 2957, 1747, 1530, 1263, 1167, 942, 847; 1H NMR 
(600 MHz, CDCl3) δ 8.29 (d, J = 9.0, 2H), δ 8.21 (d, J = 9.0, 2H), 6.36 (ddd, J = 10.2, 
6.0, 1.2 Hz, 1H), 6.21 (dd, J = 3.0, 0.6 Hz, 1H), 6.13 (ddd, J = 10.2, 3.0, 0.6 Hz, 1H), 
5.32 (dd, J = 6.0, 2.4 Hz, 1H), 4.75 (ddd, J = 8.4, 6.0, 2.4 Hz, 1H), 3.66 (s, 3H), 2.77 (dd, 
J = 16.2, 8.4 Hz, 1H), 2.66 (dd, J = 16.2, 6.0 Hz, 1H), 1.53 (s, J = 9H); 13C NMR (150 
MHz, CDCl3) 170.1, 164.0, 152.0, 150.8, 134.8, 130.9, 129.1, 126.4, 123.7, 90.0, 83.1, 
67.4, 64.8, 51.9, 35.5, 27.7; CIHRMS: Calculated for [C20H23NO10 +Na+]: 460.1214, 
Found: 460.1169 
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 Methyl-2-((2S,3S,6S)-6-(tert-butoxycarbonyloxy)-3-hydroxy-3,6-dihydro-2H-pyran-
2-yl)acetate (IV-52) 
 
 
To a solution of nitrobenzoate IV-48a (34 mg, 0.08 mmol) in 0.8 mL MeOH was added 
K2CO3 (1 mg, 10% mmol) at 0 oC. The reaction mixture was stirred at RT for 15 min. 
The reaction mixture was diluted with EtOAc and quenched with H2O, extracted with 
EtOAc, washed (NaCl), dried (Na2SO4) and concentrated under reduced pressure. The 
crude product was purified using silica gel flash chromatography to give allylic alcohol 
IV-52 12 mg (0.04 mmol, 50%) as colorless oil: Rf (30% EtOAc/hexane) = 0.26; [α]25
 
D = 
2.4 (c = 1.0, MeOH); IR (thin film, cm-1) 3472, 2934, 1744, 1279, 1259, 1030, 938, 848; 
1H NMR (600 MHz, CDCl3) δ 6.30 (ddd, J = 9.6, 6.0, 0.6 Hz, 1H), 6.11 (dd, J = 3.0, 0.6 
Hz, 1H), 5.94 (ddd, J = 9.6, 3.0, 1.2 Hz, 1H), 4.48 (ddd, J = 7.2, 6.0, 1.2 Hz, 1H), 3.87 
(m, 1H), 3.70 (s, 3H), 2.76 (d, J = 7.2, 2H), 1.51 (s, J = 9H); 13C NMR (150 MHz, 
CDCl3) δ171.1, 152.1, 131.0, 126.2, 90.4, 82.9, 69.4, 63.0, 51.8, 35.3, 27.7; CIHRMS: 
Calculated for [C13H20O7 +Na+]: 311.1101, Found: 311.1092 
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 Methyl-2-((2S,3S,6S)-6-(tert-butoxycarbonyloxy)-3-(tert-butyldimethylsilyloxy)-3,6-
dihydro-2H-pyran-2-yl)acetate (IV-54) 
 
To a solution of alcohol IV-52 (4 mg, 0.014 mmol) in 0.1 mL CH2Cl2 was added 
imidazol (2 mg, 0.028 mmol) and TBSCl (4 mg, 0.028 mmol) at 0 oC. The reaction 
mixture was stirred at RT overnight. The reaction mixture was diluted with EtOAc and 
quenched with saturated NaHCO3, extracted with EtOAc, washed (NaCl), dried (Na2SO4) 
and concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography to give TBS-alcohol IV-54 5 mg (0.013 mmol, 90%) as colorless 
oil: Rf (10% EtOAc/hexane) = 0.52; [α]25
 
D = 12.4 (c = 0.8, CH2Cl2); IR (thin film, cm-1) 
2960, 2932, 2859, 1748, 1368, 1256, 1139, 1096, 941, 838; 1H NMR (600 MHz, CDCl3) 
δ 6.13 (dd, J = 10.2, 5.4 Hz, 1H), 6.12 (d, J = 3.0 Hz, 1H), 5.89 (dd, J = 10.2, 3.0, Hz, 
1H), 4.43 (ddd, J = 7.2, 6.6, 2.4 Hz, 1H), 3.96 (dd, J = 5.4, 2.4 Hz, 1H), 3.67 (s, 3H), 2.71 
(dd, J = 16.8, 7.2 Hz, 1H), 2.68 (dd, J = 16.8, 6.6 Hz, 1H), 1.51 (s, J = 9H), 0.88 (s, J = 
9H), 0.07 (s, J = 6H), 0.05 (s, J = 6H); 13C NMR (150 MHz, CDCl3) δ171.3, 152.2, 
131.0, 125.4, 90.7, 82.6, 69.6, 62.3, 51.6, 35.4, 27.8, 25.7, 18.1, -4.27, -4.89; CIHRMS: 
Calculated for [C19H34O7Si+Na+]: 425.1966, Found: 425.1970 
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 (2S,6S)-6-(2-methoxy-2-oxoethyl)-5-oxo-5,6-dihydro-2H-pyran-2-yl pivalate (IV-43) 
 
 
To a solution of pyranone alcohol (IV-32) (55 mg, 0.3 mmol) in 3 mL CH2Cl2 was added 
PivCl (0.07 mL, 0.6 mmol), pyridine (0.07 mL, 0.9 mmol) at -78 oC. The reaction 
mixture was stirred at -78 oC for 12 hr. The reaction mixture was diluted with EtOAc and 
quenched with saturated NaHCO3, extracted with EtOAc, washed (NaCl), dried (Na2SO4) 
and concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography to give Piv-pyranone IV-43 61 mg (0.23 mmol, 75%) as light 
yellow oil: Rf (10% EtOAc/hexane) = 0.25; [α]25
 
D = + 52.8 (c = 0.5, CH2Cl2); IR (thin 
film, cm-1) 2976, 1742, 1702, 1370, 1174, 1127, 1094, 936; 1H NMR (600 MHz, CDCl3) 
δ 6.89 (dd, J = 10.2, 3.6 Hz, 1H), 6.48 (d, J = 3.6 Hz, 1H), 6.26 (d, J = 10.2 Hz, 1H), 4.89 
(dd, J = 7.2, 4.2 Hz, 1H), 3.69 (s, 3H), 3.00 (dd, J = 16.8, 4.2 Hz, 1H), 2.89 (dd, J = 16.8, 
7.2 Hz, 1H), 1.25 (s, J = 9H); 13C NMR (150 MHz, CDCl3) δ194.0, 176.9, 170.5, 141.8, 
128.3, 86.6, 72.5, 52.0, 39.3, 35.0, 27.0; CIHRMS: Calculated for [C13H18O6 +Na+]: 
293.0996, Found: 309.0996 
 
 
 
134
 (2R,6S)-6-(2-methoxy-2-oxoethyl)-5-oxo-5,6-dihydro-2H-pyran-2-yl pivalate (IV-
44)12 
 
 
To a solution of pyranone alcohol (IV-32) (55 mg, 0.3 mmol) in 3 mL CH2Cl2 was added 
PivCl (0.07 mL, 0.6 mmol), pyridine (0.07 mL, 0.9 mmol) at -78 oC. The reaction 
mixture was stirred at -78 oC for 12 hr. The reaction mixture was diluted with EtOAc and 
quenched with saturated NaHCO3, extracted with EtOAc, washed (NaCl), dried (Na2SO4) 
and concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography to give Piv-pyranone IV-44 5 mg (0.02 mmol, 6%) as light yellow 
oil. 
 
(2S,5R,6S)-5-hydroxy-6-(2-methoxy-2-oxoethyl)-5,6-dihydro-2H-pyran-2-yl pivalate 
(IV-56) 
 
 
To a solution of pyranone IV-43 (56 mg, 0.21 mmol) in 0.5 mL CH2Cl2 was added 0.5 
mL CeCl3 in MeOH (0.4 M) and NaBH4 (24 mg, 0.63 mmol) at -78 oC. The reaction 
mixture was stirred at -78 oC for 3 hr. The reaction mixture was diluted with EtOAc and 
                                                 
12 This compound is not characterized.  
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 quenched with saturated NaHCO3, extracted with EtOAc, washed (NaCl), dried (Na2SO4) 
and concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography to give allylic alcohol IV-56 50 mg (0.18 mmol, 88%) as colorless 
oil: Rf (30% EtOAc/hexane) = 0.25; [α]25
 
D = - 45.5 (c = 0.29, MeOH); IR (thin film, cm-1) 
3480, 2974, 1741, 1439, 1280, 1122, 1035, 926; 1H NMR (600 MHz, CDCl3) δ 6.21 (d, J 
= 2.4 Hz, 1H), 6.06 (dd, J = 10.8, 1.2 Hz, 1H), 5.78 (ddd, J = 10.2, 1.8, 1.2 Hz, 1H), 4.09-
4.08 (m, 2H), 3.70 (s, 3H), 2.84 (dd, J = 15.6, 4.2 Hz, 1H), 2.60 (dd, J = 15.6, 7.8 Hz, 
1H), 1.23 (s, J = 9H); 13C NMR (150 MHz, CDCl3) δ177.3, 171.7, 134.2, 124.9, 89.3, 
87.7, 70.6, 67.2, 39.0, 37.6, 27.0; CIHRMS: Calculated for [C13H20O6 +Na+]: 295.1152, 
Found: 295.1166 
 
 
(2S,3S,6S)-2-(2-methoxy-2-oxoethyl)-6-(pivaloyloxy)-3,6-dihydro-2H-pyran-3-yl 4-
nitrobenzoate (IV-56a) 
 
 
To a solution of alcohol IV-56 (46 mg, 0.17 mmol) in 1 mL THF was added PPh3 (262 
mg, 0.25 mmol), p-Nitrobenzoic acid (167 mg, 0.25 mmol) and DIAD (0.05 mL, 0.25 
mmol) at 0 oC. The reaction mixture was stirred at RT overnight. The reaction mixture 
was diluted with EtOAc and quenched with saturated NaHCO3, extracted with EtOAc, 
washed (NaCl), dried (Na2SO4) and concentrated under reduced pressure. The crude 
product was purified using silica gel flash chromatography to give IV-56a 57 mg (0.14 
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 mmol, 80%) as colorless oil: Rf (10% EtOAc/hexane) = 0.29; [α]25
 
D = 147.0 (c = 1.0, 
MeOH); IR (thin film, cm-1) 2981, 2879, 1728, 1530, 1270, 1113, 932, 718; 1H NMR 
(600 MHz, CDCl3) δ 8.29 (d, J = 9.0, 2H), δ 8.21 (d, J = 9.0, 2H), 6.38 (dd, J = 3.0, 1.2 
Hz, 1H), 6.35 (ddd, J = 10.2, 6.0, 1.2 Hz, 1H), 6.11 (ddd, J = 10.2, 3.0, 0.6 Hz, 1H), 5.33 
(dd, J = 6.0, 2.4 Hz, 1H), 4.71 (ddd, J = 8.4, 4.8, 2.4 Hz, 1H), 3.67 (s, 3H), 2.75 (dd, J = 
16.2, 9.0 Hz, 1H), 2.62 (dd, J = 16.2, 4.8 Hz, 1H), 1.25 (s, J = 9H); 13C NMR (150 MHz, 
CDCl3) 177.1, 170.3, 164.1, 150.8, 134.8, 130.9, 129.7, 125.9, 123.7, 87.5, 67.7, 65.1, 
52.0, 39.1, 35.7, 27.0; CIHRMS: Calculated for [C20H23NO9 +Na+]: 444.1265, Found: 
444.1248 
 
 
(2S,5S,6S)-5-hydroxy-6-(2-methoxy-2-oxoethyl)-5,6-dihydro-2H-pyran-2-yl pivalate 
(IV-58) 
 
 
To a solution of nitrobenzoate IV-56a (18 mg, 0.043 mmol) in 0.5 mL MeOH was added 
NEt3 (3 L) at 0 oC. The reaction mixture was stirred at RT for 3 hr. The reaction mixture 
was diluted with EtOAc and quenched with H2O, extracted with EtOAc, washed (NaCl), 
dried (Na2SO4) and concentrated under reduced pressure. The crude product was purified 
using silica gel flash chromatography to give allylic alcohol IV-58 6 mg (0.024 mmol, 
60%) as colorless oil: Rf (30% EtOAc/hexane) = 0.25; [α]25
 
D = 37 (c = 1.0, MeOH); IR 
(thin film, cm-1) 3467, 2976, 2812, 1737, 1439, 1280, 1070, 919; 1H NMR (600 MHz, 
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 CDCl3) δ 6.30 (ddd, J = 10.2, 6.0, 1.2 Hz, 1H), 6.28 (d, J = 3.6 Hz, 1H), 5.92 (ddd, J = 
10.2, 3.6, 0.6 Hz, 1H), 4.46 (ddd, J = 7.8, 6.0, 2.4 Hz, 1H), 3.85 (m, 1H), 3.69 (s, 3H), 
2.75 (dd, J = 16.2, 7.8 Hz, 1H), 2.71 (dd, J = 16.2, 6.0 Hz, 1H), 1.23 (s, J = 9H); 13C 
NMR (150 MHz, CDCl3) 177.2, 171.3, 130.7, 126.8, 87.9, 69.6, 62.3, 51.8, 39.0, 35.6, 
27.0; CIHRMS: Calculated for [C13H20O6 +Na+]: 295.1152, Found: 295.1143 
 
 
Hept-3-yn-2-ol (IV-31a) 
 
 
A solution of n-BuLi in hexane (11.1 mL, 26.5 mmol) was added dropwise to the solution 
of 1-heptyn IV-31 (1.5 g, 22.1 mmol) in dry THF (44 mL) at -78 oC under argon. After 
30 min, acetaldehyde (1.2 mL, 22.1 mmol) was added. The reaction was stirred for 10 
min at 0 oC and then the resulting solution was warmed to room temperature for 50 min. 
Additional CH2Cl2 (10 mL) was added to the reaction mixture followed by addition of 
saturated aqueous NH4Cl (20 mL). The aqueous phase was separated and extracted with 
CH2Cl2. The combined organic layers were washed with brine, dried (Na2SO4), filtered 
and concentrated. Chromatography on silica gel gave alcohol IV-31a (2.03 g, 18.1 mmol, 
82%) as a colorless oil; Rf (10% EtOAc/hexane) = 0.28;  IR (thin film, cm-1), 3340, 2958, 
2869, 2244, 1458, 1291, 1155, 1074, 893; 1H NMR (600 MHz, CDCl3) δ 4.45 (qt, J = 
6.6, 1.8 Hz, 1H), 2.10 (td, J = 6.6, 1.8 Hz, 2H), 1.45 (qt, J = 7.2, 6.6 Hz, 2H), 1.35 (d, J = 
138
 6.6 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H);  13C NMR (150 MHz, CD3Cl) δ 84.1, 82.4, 58.2, 
24.5, 21.9, 20.5, 13.2 
 
 
Hept-3-yn-2-one (IV-35) 
 
To a solution of alcohol (IV-31a) (4.0 g, 35.7 mmol) in THF (100 mL) at room 
temperature was added activated MnO2 (20 g). The reaction mixture was stirred for 24 h 
and then filtered through celite and concentrated under pressure to give ketone IV-35 
(3.73 g, 33.9 mmol, 95%) as a colorless oil. Rf (10% EtOAc/hexane) = 0.40; IR (thin 
film, cm-1), 2960, 2871, 2210, 1675, 1358, 1226; 1H NMR (600 MHz, CDCl3) δ 2.30 (t, J 
= 7.2 Hz, 2H), 2.28 (s, 3H), 1.57 (qt, J = 7.2, 7.2 Hz, 2H), 0.98 (t, J = 7.2, 3H);  13C NMR 
(150 MHz, CD3Cl) δ 184.8, 93.8, 81.4, 32.6, 21.1, 20.7, 13.3 
 
 
(S)-Hept-3-yn-2-ol (IV-36) 
 
 
To a flask was added ketone IV-35 (10.8 g, 86.9 mmol), 2 M NaCOOH in water (400 
mL), cetyl trimethylammonium bromide (3.17 g, 8.69 mmol). The mixture was stirred at 
RT. for 5 min, then Noyori catalyst (S, S) (105 mg, 0.174 mmol) was added. The reaction 
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 mixture was allowed to stir for 24 hr. Water was added to dilute and extracted with Et2O, 
dried (Na2SO4) and concentrated under reduced pressure. The crude product was purified 
using silica gel flash chromatography to give 9.5 g (84.8 mmol, 97%) of alcohol IV-36 as 
colorless oil: Rf (10% EtOAc/hexane) = 0.28;  [α]25
 
D = - 10.3 (c = 0.29, MeOH); IR (thin 
film, cm-1), 3340, 2958, 2869, 2244, 1458, 1291, 1155, 1074, 893; 1H NMR (600 MHz, 
CDCl3) δ 4.45 (qt, J = 6.6, 1.8 Hz, 1H), 2.10 (td, J = 6.6, 1.8 Hz, 2H), 1.45 (qt, J = 7.2, 
6.6 Hz, 2H), 1.35 (d, J = 6.6 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H);  13C NMR (150 MHz, 
CD3Cl) δ 84.1, 82.4, 58.2, 24.5, 21.9, 20.5, 13.2 
 
 
(S)-Hept-6-yn-2-ol (IV-36a) 
 
 
A 30% suspension of KH in mineral oil (5.62 g, 140 mmol) was washed three times 
under Argon with dry ether and then the excess solvent was removed under vacuum, dry 
1,3-diaminopropane (28 mL) was added with cooling (15 oC). After the mixture was 
stirred for 1 h, the alkynol  IV-36 (3.15 g, 28.1 mmol) was added dropwise (20 min) at 
(10-15 oC) to the mixture and the resulting slurry was stirred further under argon for 2 
hrs. With cooling (0 oC), water was added dropwise and the mixture was extracted with 
ether, the combined extracts were washed with 1 N HCl, saturated aqueous sodium 
bicarbonate and brine, and then dried with anhydrous sodium sulfate. Flash 
chromatography gave alkynol IV-36a (2.71 g, 24.2 mmol, 85%) as a colorless oil: [α]25D 
=  8 (c = 1.0, CHCl3); Rf (20% EtOAc/Hexane)= 0.28; IR (thin film, cm-1) 3309, 2934, 
140
 2862, 2117, 1460, 1432, 1374, 1128, 1093, 937, 821; 1H NMR (600 MHz, CDCl3) δ 3.83 
(qt, J = 6.0, 6.0 Hz, 1H), 2.23 (td, J = 7.2, 3.0 Hz, 2H), 1.95 (t, J = 3.0 Hz, 1H), 
1.67~1.56 (m, 4H), 1.20 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 84.3, 68.5, 
67.6, 38.2, 24.7, 23.6, 18.4 
 
 
(S)-Hept-6-yn-2-yl pivalate (IV-29) 
 
 
To a flask was added alkynol IV-36a (1.55 g, 13.8 mmol), PivCl (2.06 mL, 16.6 mmol), 
pyridine (5.6 mL, 6.9 mmol) at 0 oC. The mixture was then stirred at RT. for 3 hr. 
NaHCO3 was added and the mixture was extracted with Et2O, dried (Na2SO4) and 
concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography to give 2.57 g (13.1 mmol, 95%) of pivalate alcohol IV-29 as 
colorless oil: Rf (10% EtOAc/hexane) = 0.5;  [α]25
 
D = 27.8 (c = 1.0, CH2Cl2); IR (thin 
film, cm-1) 3300, 2976, 2874, 2244, 1725, 1288, 1166, 1088; 1H NMR (600 MHz, 
CDCl3) δ 4.90 (qt, J = 6.6, 6.0 Hz, 1H), 2.20 (td, J = 7.2, 2.4 Hz, 2H), 1.95 (t, J = 2.4 Hz, 
1H), 1.70~1.51 (m, 4H), 1.20 (d, J = 6.6 Hz, 3H), 1.19 (s, 9H);  13C NMR (150 MHz, 
CD3Cl) δ 178.1, 84.0, 70.0, 68.6, 38.7, 34.9, 27.1, 24.4, 19.9, 18.3; CIHRMS: Calculated 
for [C12H20O2 +Na+]: 219.1356, Found: 219.1355 
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 (S)-6-Oxoheptan-2-yl pivalate (IV-37) 
 
 
To a flask was added [(i-Pr)AuCl] (21.9 mg, 0.035 mmol) and small amount of AgSbF6 
(covering the tip of a spatula) in 3 mL MeOH, the mixture was stirred at RT for 1 min. 
Alkyne IV-29 (135 mg, 0.69 mmol) was added followed by addition of 1 mL water. The 
reaction mixture was heated at 65 oC for 12 hr. The solvent was removed by vacuum, the 
crude product was purified using silica gel flash chromatography to give ketone IV-37 
126 mg (0.59 mmol, 85%) as colorless oil: Rf (10% EtOAc/hexane) = 0.35;  [α]25
 
D = 34.7 
(c = 0.8, CH2Cl2); IR (thin film, cm-1) 2976, 1721, 1481, 1367, 1284, 1166, 1088; 1H 
NMR (600 MHz, CDCl3) δ 4.90 (qt, J = 6.0, 6.0 Hz, 1H), 2.42 (t, J = 7.2 Hz, 2H), 2.11 
(s, 3H), 1.65~1.48 (m, 4H), 1.18 (d, J = 6.0 Hz, 3H), 1.17 (s, 9H);  13C NMR (150 MHz, 
CD3Cl) δ 208.7, 178.4, 70.2, 43.4, 38.9, 35.4, 30.1, 27.3, 20.0, 19.7; CIHRMS: 
Calculated for [C12H22O3 +Na+]: 237.1461, Found: 237.1460 
 
 
(S)-7-Bromo-6-oxoheptan-2-yl pivalate (IV-38) 
 
 
Bromine (0.035 mL, 0.67 mmol) was added to a solution of ketone IV-37 (120 mg, 0.56 
mmol) in 3 mL MeOH at RT. for 10 min under N2. After the addition was completed, the 
reaction mixture was stirred for 2 hr. Then the MeOH was removed from the reaction 
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 mixture under reduced pressure. The residue was partitioned between ether and water. 
The PH of the resulting solution was adjusted to 8.0 by adding NaHCO3. The ether layer 
was washed with NaHCO3 and brine, dried over Na2SO4, filtered and concentrated to 
yield crude product, the crude product was purified using silica gel flash chromatography 
to give bromo-ketone IV-38 114 mg (0.39 mmol, 70%) as colorless oil. 
 
To a flask was added [(i-Pr)AuCl] (50 mg) and small amount of AgSbF6 (covering the tip 
of a spatula) in 3 mL anhydrous MeOH, the mixture was stirred at RT for 1 min. Alkyne 
IV-29 (494 mg, 4.4 mmol) was added. The reaction mixture was heated at 65 oC for 5 hr. 
NBS (801mg, 4.5 mmol) was added to the reaction solution. After another 5 hr, the 
solvent was removed by vacuum, the crude product was purified using silica gel flash 
chromatography to give ketone IV-38 1.1 g (0.59 mmol, 85%) as colorless oil.  
 
IV-38: Rf (10% EtOAc/hexane) = 0.53;  [α]25
 
D = 0.60 (c = 1.0, CH2Cl2); IR (thin film, 
cm-1) 2974, 1716, 1460, 1397, 1284, 1166, 1127; 1H NMR (600 MHz, CDCl3) δ 4.89 (qt, 
J = 6.0, 6.0 Hz, 1H), 3.86 (s, 2H), 2.67 (t, J = 7.2 Hz, 2H), 1.65~1.48 (m, 4H), 1.19 (d, J 
= 6.0 Hz, 3H), 1.19 (s, 9H);  13C NMR (150 MHz, CD3Cl) δ 201.7, 178.1, 69.8, 39.3, 
38.7, 35.0, 34.1, 27.2, 19.8, 19.6; CIHRMS: Calculated for [C12H21BrO3 +Na+]: 
317.0566, Found: 317.0544 
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 (S)-6-oxo-7-(1-phenyl-1H-tetrazol-5-ylthio)heptan-2-yl pivalate (IV-38a) 
 
 
To the solution of ketone IV-38 (113 mg, 0.39 mmol) in MeOH (2 mL), PT-SH (68 mg, 
0.39 mmol) and KOH (21 mg, 0.39 mmol) was added at RT The mixture was then stirred 
at RT for 3 hr. 1 M HCl was added and extracted with Et2O, dried (Na2SO4) and 
concentrated under reduced pressure. The crude product was purified using silica gel 
flash chromatography to give 129 mg (0.33 mmol, 85%) of sulfide IV-38a as colorless 
oil: Rf (20% EtOAc/hexane) = 0.24;  [α]25
 
D = 42.3 (c = 0.65, CH2Cl2); IR (thin film, cm-
1) 2976, 2939, 2874, 1718, 1500, 1169, 698; 1H NMR (600 MHz, CDCl3) δ 7.62~7.55 
(m, 5H), 4.89 (qt, J = 6.0, 6.0 Hz, 1H), 4.32 (s, 2H), 2.69 (t, J = 6.6 Hz, 2H), 1.65~1.48 
(m, 4H), 1.19 (d, J = 6.0 Hz, 3H), 1.19 (s, 9H);  13C NMR (150 MHz, CD3Cl) δ 209.2, 
178.1, 133.0, 131.0, 130.1, 124.4, 121.2, 69.7, 68.1, 38.7, 37.8, 35.2, 27.1, 19.8, 19.4; 
CIHRMS: Calculated for [C19H26 N4O3S+Na+]: 413.1678, Found: 413.1618 
 
 
(S)-6-oxo-7-(1-phenyl-1H-tetrazol-5-ylsulfonyl)heptan-2-yl pivalate (IV-27) 
 
 
A solution of sulfide IV-38a (66 mg, 0.17 mmol ) in ethanol (1 mL) at 0 oC was treated 
with ammonium heptamolybdate tetrahydrate (31mg, 0.025 mmol) and 30% aqueous 
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 hydrogen peroxide solution (0.17 ml, 1.7 mmol), The reaction mixture was warmed to 
ambient temperature over 5 hr, stirred for additional 7 hr and then brine was added. The 
mixture was extracted with Et2O, dried (Na2SO4) and concentrated under reduced 
pressure. The crude product was purified using silica gel flash chromatography to give 
sulfone IV-27 50 mg (0.12 mmol, 70%) as colorless oil: Rf (30% EtOAc/hexane) = 0.54;  
[α]25
 
D = 3.5 (c = 1.2, CH2Cl2); IR (thin film, cm-1) 2974, 2941, 2876, 1720, 1450, 1356, 
1164, 764; 1H NMR (600 MHz, CDCl3) δ 7.67~7.58 (m, 5H), 4.85 (qt, J = 6.0, 6.0 Hz, 
1H), 4.71 (s, 2H), 2.67 (t, J = 6.6 Hz, 2H), 1.65~1.48 (m, 4H), 1.19 (d, J = 6.0 Hz, 3H), 
1.19 (s, 9H);  13C NMR (150 MHz, CD3Cl) δ 196.0, 178.2, 153.4, 132.9, 131.6, 129.6, 
125.5, 69.6, 64.8, 43.7, 38.7, 34.7, 27.1, 19.7, 19.7; CIHRMS: Calculated for [C19H26 
N4O5S+Na+]: 445.1516, Found: 445.1517 
 
 
(2S)-5-((5S,7aS)-3-(sulfonyl)-5-(2-methoxy-2-oxoethyl)-6-oxo-5,6 
7,7a-tetrahydro-3aH-furo[3,2-b]pyran-2-yl)pentan-2-yl-pivalate (IV-42) 
 
 
To a solution of Boc-pyranone IV-33 (10 mg, 0.024 mmol) and sulfone IV-27 (7 mg, 
0.024 mmol) in dry CH2Cl2 (0.3 mL), was added Pd2(DBA)3•CHCl3 (2.5 mg, 10 mol%) 
and PPh3 (2.5 mg, 40 mol%) at 0 oC under argon atmosphere.  After stirring for 3 h at 0 
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 oC, the reaction mixture was quenched with saturated NaHCO3, extracted with Et2O, 
dried (Na2SO4), and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography to give 12 mg IV-42 (0.02 mmol, 85%) as 
colorless oil. 
 
To a solution of Piv-pyranone IV-43 (11 mg, 0.026 mmol) and sulfone IV-27 (7 mg, 
0.026 mmol) in dry CH2Cl2 (0.3 mL), was added Pd2(DBA)3•CHCl3 (2.5 mg, 10 mol%) 
and PPh3 (2.5 mg, 40 mol%) at 0 oC under argon atmosphere.  After stirring for 3 h at 0 
oC, the reaction mixture was quenched with saturated NaHCO3, extracted with Et2O, 
dried (Na2SO4), and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography to give 14 mg IV-42 (0.02 mmol, 85%) as 
colorless oil. 
 
 IV-42: Rf (20% EtOAc/hexane) = 0.44;  [α]25
 
D = -172.1 (c = 1.0, CH2Cl2); IR (thin film, 
cm-1) 2975, 2957, 2873, 1739, 1596, 1369, 1172, 1083, 764, 632; 1H NMR (600 MHz, 
CDCl3) δ 7.71 (m, 2H), 7.61 (m, 3H), 5.57 (d, J = 7.2 Hz, 1H), 5.31 (dt, J = 7.2, 3.6 Hz, 
1H), 4.85 (qt, J = 6.0, 6.0 Hz, 1H), 4.29 (t, J = 4.2 Hz, 1H), 3.61 (s, 3H), 3.26 (dd, J = 
16.2, 3.0 Hz, 1H), 3.04 (dd, J = 16.2, 3.0 Hz, 1H), 3.02 (dd, J = 17.4, 4.2 Hz, 1H), 2.78 (t, 
J = 7.2 Hz, 2H), 2.54 (dd, J = 17.4, 4.2 Hz, 1H), 1.71~1.50 (m, 4H), 1.17 (d, J = 6.0 Hz, 
3H), 1.16 (s, 9H);  13C NMR (150 MHz, CD3Cl) δ 206.2, 182.0, 178.0, 170.3, 156.0, 
133.3, 131.3, 129.6, 125.4, 106.9, 82.1, 76.6, 73.3, 69.6, 51.9, 38.7, 38.6, 35.7, 35.2, 27.8, 
27.1, 22.6, 19.7; CIHRMS: Calculated for [C27H34 N4O9S+Na+]: 613.1939, Found: 
613.1940 
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 (S,E)-7-((2S,5R,6S)-5-hydroxy-6-(2-methoxy-2-oxoethyl)-5,6-dihydro-2H-pyran-2-
yl)hept-6-en-2-yl pivalate (IV-41) 
 
 
To a solution of allylic alcohol IV-48 (15 mg, 0.052 mmol) and sulfone IV-27 (22 mg, 
0.052 mmol) in dry CH2Cl2 (0.3 mL), was added Pd2(DBA)3•CHCl3 (2.5 mg, 5 mol%) 
and PPh3 (2.5 mg, 20 mol%) at 0 oC under argon atmosphere.  After stirring for 3 h at 0 
oC, the reaction mixture was cooled to -78 oC and MeOH was added to the solution. Then 
NaBH4 was added to the reaction solution, the reaction mixture was allowed to stir at -78 
oC for 5 hr. The reaction was then quenched with saturated NaHCO3, extracted with 
Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography to give 5 mg IV-41 (0.013 mmol, 26%) as 
colorless oil: Rf (30% EtOAc/hexane) = 0.50;  [α]25
 
D = 57.0 (c = 0.75, CH2Cl2); IR (thin 
film, cm-1) 3485, 2978, 2936, 1723, 1456, 1167, 1070, 1132; 1H NMR (600 MHz, 
CDCl3) δ 5.85 (ddd, J = 10.8, 1.8, 1.8 Hz, 1H), 5.79 (ddd, J = 10.8, 3.0, 1.8 Hz, 1H), 5.63 
(dtd, J = 15.6, 7.2, 1.2 Hz, 1H), 5.53 (dd, J = 15.6, 5.4 Hz, 1H), 4.85 (qt, J = 6.0, 6.0 Hz, 
1H), 4.63 (dddd, J = 5.4, 3.0, 1.8, 1.2 Hz, 1H), 3.94 (ddd, J = 7.2, 1.8, 1.8 Hz, 1H), 3.89 
(ddd, J = 7.8, 7.2, 4.8 Hz, 1H), 3.71 (s, 3H), 2.81 (dd, J = 15.6, 4.8 Hz, 1H), 2.57 (dd, J = 
15.6, 7.8 Hz, 1H), 2.08 (dt, J = 7.2, 7.2 Hz, 2H), 1.64~1.38 (m, 4H), 1.19 (d, J = 6.0 Hz, 
3H), 1.18 (s, 9H);  13C NMR (150 MHz, CD3Cl) δ 178.3, 172.1, 133.9, 129.5, 128.6, 
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 127.9, 72.5, 70.5, 67.2, 57.0, 51.8, 38.7, 37.9, 35.0, 32.1, 27.1, 24.5, 19.7; CIHRMS: 
Calculated for [C20H32O6 +Na+]: 391.2091, Found: 391.2079 
 
 
(S,Z)-7-((2S,5R,6S)-5-hydroxy-6-(2-methoxy-2-oxoethyl)-5,6-dihydro-2H-pyran-2-
yl)hept-6-en-2-yl pivalate (IV-49)13 
 
To a solution of allylic alcohol IV-48 (15 mg, 0.052 mmol) and sulfone IV-27 (22 mg, 
0.052 mmol) in dry CH2Cl2 (0.3 mL), was added Pd2(DBA)3•CHCl3 (2.5 mg, 5 mol%) 
and PPh3 (2.5 mg, 20 mol%) at 0 oC under argon atmosphere.  After stirring for 3 h at 0 
oC, the reaction mixture was cooled to -78 oC and MeOH was added to the solution. Then 
NaBH4 was added to the reaction solution, the reaction mixture was allowed to stir at -78 
oC for 5 hr. The reaction was then quenched with saturated NaHCO3, extracted with 
Et2O, dried (Na2SO4), and concentrated under reduced pressure.  The crude product was 
purified using silica gel flash chromatography to give 2 mg IV-49 (0.006 mmol, 13%) as 
colorless oil. 1H NMR (600 MHz, CDCl3) δ 5.84 (ddd, J = 10.2, 2.4, 2.4 Hz, 1H), 5.71 
(ddd, J = 10.8, 3.0, 1.8 Hz, 1H), 5.55 (m, 2H), 4.92 (ddd, J = 4.8, 2.4, 1.8, Hz, 1H), 4.86 
(qt, J = 6.0, 6.0 Hz, 1H), 3.97 (ddd, J = 7.8, 6.6, 4.8 Hz, 1H), 3.92 (ddd, J = 6.6, 3.0, 2.4 
Hz, 1H), 3.71 (s, 3H), 2.77 (dd, J = 15.6, 4.8 Hz, 1H), 2.59 (dd, J = 15.6, 7.8 Hz, 1H), 
                                                 
13 This compound is not fully characterized.  
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 2.33 (ddd, J = 6.0, 4.8, 1.8 Hz, 2H), 1.64~1.38 (m, 4H), 1.19 (d, J = 6.0 Hz, 3H), 1.18 (s, 
9H); 
 
 
 
(2R,7R)-7-(sulfonyl)-7-((2R,6S)-6-(2-methoxy-2-oxoethyl)-5-oxo-5,6-dihydro-2H-
pyran-2-yl)-6-oxoheptan-2-yl pivalate (IV-25)14 
 
To three round bottle flasks, IV-42 in THF (0.5 M) was added. NaOMe, KOt-Bu and 
NaH (catalytic to 5 equivalent) was added to the three bottles respectively. The reaction 
solutions were allowed to stir for 24 hr at R.T. No desired product IV-25 can be isolated.  
 
(2S)-5-((3S,3aR,5S,7aS)-3-(sulfonyl)-5-(2-methoxy-2-oxoethyl)-6-oxohexahydro-2H-
furo[3,2-b]pyran-2-yl)pentan-2-yl pivalate (IV-46)14 
 
 
 
To a solution of IV-42 in dry CH2Cl2 was carefully added Pd/C (3 equivalents) and the 
resulting suspension was stirred under H2 (1 atm) for 24 hr at room temperature.   TLC 
                                                 
14 This compound was not obtained.  
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 showed there was still starting materials. The reaction solution was allowed to stir under 
H2 (3 atm) for 24 hr, starting materials was fully recovered.   
To a solution of IV-42 in dry CH2Cl2 was carefully added Wilkinson’s catalyst (20 mol 
%) and the resulting suspension was stirred under H2 (1 atm) for 24 hr at room 
temperature.   TLC showed there was still starting materials. The reaction solution was 
allowed to stir under H2 (3 atm) for 24 hr, starting materials was fully recovered.   
 
 
(2R,7R)-7-(sulfonyl)-7-((2R,5R,6S)-5-(tert-butyldimethylsilyloxy)-6-(2-methoxy-2-
oxoethyl)-5,6-dihydro-2H-pyran-2-yl)-6-oxoheptan-2-yl pivalate (IV-51)14 
 
To a solution of IV-50 and sulfone IV-27 in dry CH2Cl2 (0.5 M), was added 
Pd2(DBA)3•CHCl3 (5 mol%) and PPh3 (20 mol%) at 0 oC under argon atmosphere.  After 
stirring for 3 h at 0 oC, the reaction mixture was warmed up to R.T. and allowed to stir for 
5 hr, desired product IV-51 was not observed.  
 
 
(2R,7R)-7-(sulfonyl)-7-((2R,5S,6S)-5-hydroxy-6-(2-methoxy-2-oxoethyl)-5,6-dihydro-
2H-pyran-2-yl)-6-oxoheptan-2-yl pivalate (IV-53)14 
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To a solution of IV-52 and sulfone IV-27 in dry CH2Cl2 (0.5 M), was added 
Pd2(DBA)3•CHCl3 (5 mol%) and PPh3 (20 mol%) at 0 oC under argon atmosphere.  After 
stirring for 3 h at 0 oC, the reaction mixture was warmed up to R.T. and allowed to stir for 
5 hr, desired product IV-53 was not observed.  
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To a solution of IV-58 and sulfone IV-27 in dry CH2Cl2 (0.5 M), was added 
Pd2(DBA)3•CHCl3 (5 mol%) and PPh3 (20 mol%) at 0 oC under argon atmosphere.  After 
stirring for 3 h at 0 oC, the reaction mixture was warmed up to R.T. and allowed to stir for 
5 hr, desired product IV-53 was not observed.  
 
(2R,7R)-7-(sulfonyl)-7-((2R,5S,6S)-5-(tert-butyldimethylsilyloxy)-6-(2-methoxy-2-
oxoethyl)-5,6-dihydro-2H-pyran-2-yl)-6-oxoheptan-2-yl pivalate (IV-55)14 
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To a solution of IV-54 and sulfone IV-27 in dry CH2Cl2 (0.5 M), was added 
Pd2(DBA)3•CHCl3 (5 mol%) and PPh3 (20 mol%) at 0 oC under argon atmosphere.  After 
stirring for 3 h at 0 oC, the reaction mixture was warmed up to R.T. and allowed to stir for 
5 hr, desired product IV-55 was not observed.  
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